

BRAIN & BEHAVIOR RESEARCH FOUNDATION

2024 ANNUAL REPORT

Awarding research grants to develop improved treatments, cures, and methods of prevention for mental illness.

**ADDICTION, ADHD,
ANXIETY, AUTISM,
BIPOLAR DISORDER,
BORDERLINE
PERSONALITY
DISORDER,
DEPRESSION, EATING
DISORDERS, OCD,
PSYCHOSIS, PTSD,
SCHIZOPHRENIA,
SUICIDE PREVENTION.**

MISSION:

**THE BRAIN & BEHAVIOR RESEARCH
FOUNDATION IS COMMITTED TO
ALLEVIATING THE SUFFERING CAUSED
BY MENTAL ILLNESS BY AWARDING
GRANTS THAT WILL LEAD TO
ADVANCES AND BREAKTHROUGHS IN
SCIENTIFIC RESEARCH.**

100% OF EVERY DOLLAR DONATED FOR RESEARCH GOES TO RESEARCH



Jeffrey Borenstein, M.D.
President & CEO



Judith M. Ford, Ph.D.
President, Scientific Council



Geoffrey Simon
Chair, Board of Directors

Dear Friends,

Philanthropic support for research is more important now than ever. Significant changes and uncertainty in government funding have made scientific research funded by Brain & Behavior Research Foundation (BBRF) grants absolutely crucial in supporting research leading to innovative new therapies that help people living with psychiatric illness.

The Brain & Behavior Research Foundation (BBRF) is the world's largest private funder of mental health research grants. In 2024 BBRF funded over \$11 million in research grants across a broad spectrum of brain illnesses. Since 1987 BBRF has awarded more than \$462 million in research grants to more than 5,600 scientists around the world who are working to find better treatments, cures, and methods of preventing mental illness.

Many important BBRF-funded research breakthroughs were published in major psychiatric and medical journals during 2024. This annual report highlights the *Leading Research Achievements by BBRF Grantees, Prizewinners & Scientific Council Members*. These important scientific advances and research discoveries underscore the vital role BBRF plays in helping people and families living with mental illness.

All BBRF grant recipients are chosen by our world-renowned Scientific Council which is comprised of 192 scientists who rigorously evaluate every grant application, identifying the most promising, innovative science, with the greatest potential for significant breakthroughs. This past year the Scientific Council evaluated more than 900 grant proposals and awarded 150 Young Investigator Grants, which fund two years of research for \$35,000 per year, and 10 Distinguished Investigator Grants, which fund one year of research for \$100,000 per year.

In July, BBRF hosted its annual *Scientific Council Dinner* and celebrated the exceptional life and accomplishments of the late Dr. Herbert Pardes, who led the BBRF Scientific Council from its inception nearly 40 years ago. BBRF also awarded the highly esteemed Klerman & Freedman Prizes at the event.

In October, at BBRF's *International Mental Health Research Symposium*, six award-winning scientists presented their outstanding research on schizophrenia, bipolar disorder, pediatric mood and anxiety disorders, and cognitive neuroscience. A presentation was also given by the winner of the Pardes Humanitarian Prize in Mental Health.

All presentations from the 2024 Symposium are available to watch online at: www.bbrfoundation.org/event/international-mental-healthresearch-symposium.

At the *Annual Awards Dinner* following the Symposium, we presented the BBRF Outstanding Achievement Prizes, as well as the Pardes Humanitarian Prize in Mental Health.

BBRF's periodical, ***Brain & Behavior Magazine***, highlights many of the latest mental health breakthroughs of our grant recipients. In order to provide the most timely mental health news, BBRF publishes a weekly email newsletter, "***eNews***," that is available free of charge to donors, the scientific community, and the public. It features research breakthroughs of BBRF grantees, award-winners, and Scientific Council members.

Meet the Scientist is our free monthly webinar series that offers viewers the latest findings on psychiatric illnesses from international experts in the field of brain and behavior research.

BBRF also produces the award-winning television series ***Healthy Minds***, which is broadcast on public television stations throughout the U.S. It is also available online at: pbs.org. The series provides vital information about psychiatric conditions and treatments, as well as cutting-edge research advancements. Season 9 is available to watch online at: <https://bbrfoundation.org/healthy-minds-tv> and Season 10 will be available on PBS this fall.

BBRF is very enthusiastic about three new initiatives to raise mental health awareness among news reporters and the public: The Carter Center's Mental Health Journalism Fellowship Program and Mental Health Parity Newsroom Collaborative, The Poynter Institute for Media Studies' Mental Health Reporting Project, and MindSite News.

We are inspired by the magnitude and impact of the discoveries being made by the thousands of scientists BBRF has been able to fund thanks to your generous ongoing support.


Our shared goal of a world free from debilitating mental illnesses relies first and foremost upon you, our donors—in partnership with the scientists selected by the BBRF Scientific Council. While steady advancements in brain research are being made, more still needs to be done. **As always, 100% of your contribution for research directly supports research, as our operating expenses are covered by separate foundation grants.**

With all the uncertainty now facing mental health research, your solid commitment to help BBRF guarantee funding for research grants that develop improved treatments, cures, and methods of prevention for people living with mental illness is more important now than ever before. Together, we will continue to fund innovative and impactful research that will lead to new mental health breakthroughs.

Sincerely,



Jeffrey Borenstein, M.D.
President & CEO



Judith M. Ford, Ph.D.
President, Scientific Council



Geoffrey Simon
Chair, Board of Directors

2024 **LEADING RESEARCH
ACHIEVEMENTS** BY
FOUNDATION GRANTEES,
PRIZE WINNERS,
& SCIENTIFIC COUNCIL
MEMBERS

Suicide Risk Fluctuates Across the Menstrual Cycle, Affecting Different Women Differently

Basic Research; Diagnostic Tools/Early Intervention: **Suicide Prevention**

Story Highlights:

A new study reveals how suicide risk fluctuates not only in correspondence with the menstrual cycle and shifting hormone levels, but also how symptoms fluctuate daily within individuals and how impacts vary from person to person. Increased depressive symptoms accounted for perimenstrual worsening of suicidal ideation and planning, suggesting a focus for future intervention efforts.

Journal:
American Journal of Psychiatry
January 1, 2024

Women and men are known to have different vulnerabilities to psychiatric and other illnesses. There are a variety of reasons, including biological differences between the sexes and a vast number of socio-demographic and cultural factors.

Thanks in significant part to research by BBRF Scientific Council member, three-time BBRF Distinguished Investigator and Selo Prize winner Myrna M. Weissman, Ph.D., it has been known for several decades that women have a much greater lifetime risk than men of developing depression—as much as a 70 percent greater risk.

One remarkable and related fact that is rarely discussed is that women are three times more likely than men to report suicidal ideation, suicidal planning, or a suicide attempt over the lifespan.

Both of these disparities in risk have some relation to cyclical ovarian hormone fluctuations; the details in each case have been the subject of intense research over many years. Recently, a team of investigators led by 2018 BBRF Young Investigator **Tory Anne Eisenlohr-Moul, Ph.D.**, of the University of Illinois Chicago, published findings of what may be the most detailed study to date seeking to understand how daily changes in a range of psychiatric symptoms influence acute changes in suicidal ideation and planning, and how

brain-based sensitivities to normal cycling hormones can shape these changes. Dr. Jaclyn Ross and Jordan Barone were co-first authors of the team's paper, which appeared in the *American Journal of Psychiatry*.

Given the greater female vulnerability to suicidal behavior, the team notes, "understanding suicide risk factors that are unique to females is critical to addressing the public health crisis" that suicide represents. There were nearly 50,000 deaths by suicide reported in the U.S. in the most recent year for which statistics are available.

A litany of psychiatric symptoms, noted at single time points, have been strongly correlated with suicide risk. These symptoms include depression, hopelessness, and anhedonia (the inability to experience pleasure), as well as the perception of being a burden to others, heightened sensitivity to rejection, agitation, anxiety, and anger. Although research identifying these correlates has begun to clarify who is most vulnerable to suicidal ideation and suicide attempts across the lifespan, "questions of when and how suicide risk increases remain largely unanswered," the team notes in its paper. A knowledge gap of particular importance concerns short-term risk factors that can help clinicians predict when their patients may transition from thinking about suicide to making an actual plan for suicide, the team stresses. This helped



Tory A. Eisenlohr-Moul, Ph.D.

University of Illinois, Chicago
2018 BBRF Young Investigator

to guide the design of their study.

Risk factors that vary over time, “beyond the usual suspects of psychopathology and sociodemographic variables,” were their focus, and specifically, the monthly menstrual cycle. “Accumulating evidence shows that ovarian hormone fluctuations modulate imminent suicide risk for many females, resulting in increased likelihood of suicide attempts and deaths during the premenstrual and menstrual weeks.” But studies to date have tended to involve small numbers of patients, have not distinguished chronic suicidal ideation from acute suicidal planning, and haven’t taken into account that people differ widely in their response to the monthly cycle. Patients with the cycle-linked mood disorder premenstrual dysphoric disorder (PMDD), who often report symptoms such as irritability and rage, have been found to have very high rates of suicidal behavior. According to another paper published by the team, about 72% of women with PMDD report suicidal thinking and about one-third report a history of suicide attempt.

The team recruited 119 psychiatric outpatients who experienced regular periods and reported past-month suicidal ideation. These participants provided a series of daily ratings of psychiatric symptoms across at least one menstrual cycle.

Nearly all of the psychiatric symptoms varied in correspondence with fluctuations (up or down) in daily suicidal ideation. A limited

set of symptoms—depression, hopelessness, rejection sensitivity, and the perception of being a burden—were found to specifically predict an individual’s increases in suicidal planning. Of note, individuals also differed from one another with respect to which psychiatric symptoms were the best predictors of daily suicide risk, indicating a need for personalized approaches in the future, the team said.

It was observed that many patients demonstrated worsening of psychiatric symptoms, suicidal ideation, and suicidal planning over the “perimenstrual” period, i.e., around the time leading up to and during menstruation. Depressive symptoms (depression, hopelessness, perception of being a burden, and anhedonia) “were the most robust statistical factors predicting perimenstrual exacerbation of suicidality,” the team reported.

“While most past suicide research has highlighted broad psychopathological and sociodemographic factors as predictors of suicide risk, our study reveals an acute perimenstrual risk period for suicidal ideation and planning,” the team wrote. This, they said, “presents an opportunity for biological and psychosocial intervention” among those particularly at risk. By measuring fluctuations in suicidality over time, the research may help caregivers formulate predictions about when specific individuals are most at risk.

“We urge researchers to model individual symptom trajectories,” the team wrote, to better identify subtypes of neurobehavioral hormone sensitivity. The study’s finding that depressive symptoms are robust predictors of perimenstrual worsening of suicidal ideation and planning suggests to the team that “intervention efforts may benefit from strategies that specifically target depressive symptoms as they fluctuate across the cycle, given their powerful role in the cycle-suicidality relationship.”

Preliminary Trial of Psychoactive Drug Ibogaine Yields ‘Initial Evidence’ for Powerful Therapeutic Potential

Next-Generation Therapies: PTSD, Depression, Anxiety

Story Highlights:

In a preliminary clinical test in military veterans, researchers obtained “initial evidence” suggesting the psychoactive compound ibogaine, when co-administered with magnesium, “could be a powerful therapeutic” to safely treat a variety of psychiatric symptoms, including PTSD, depression, anxiety, and suicidality, which can emerge following traumatic brain injury.

Journal:
Nature Medicine
January 5, 2024

In an exploratory and preliminary clinical test, a team of researchers at Stanford University has obtained “initial evidence” suggesting that a psychoactive compound called ibogaine, when co-administered with magnesium, “could be a powerful therapeutic” to safely treat a variety of psychiatric symptoms, including PTSD, major depression and anxiety, and suicidality, all of which may emerge following traumatic brain injury (TBI).

Ibogaine, derived from the root bark of a shrub, has been used for traditional religious and healing purposes in Africa for centuries. Sometimes called an atypical psychedelic, the Stanford researchers prefer to classify it as an “oneirogen,” based on a Greek word that describes its main psychotropic effect: therapeutic dosing leads to dreamlike states of consciousness that persist for several hours and sometimes even longer. Proponents of the compound say it facilitates self-reflection and self-evaluation. These are qualities that in recent years have been attributed to psychedelic compounds such as MDMA, psilocybin, and LSD. Like those agents, ibogaine since 1970 has been listed by the U.S. Drug Enforcement Administration as a Schedule I compound, with no officially recognized medical use and with a “high potential for misuse.”

Subsequent experience suggests that ibogaine is not addictive, although it does have powerful and potentially harmful effects on users. Until now little

academic research has been conducted into its possible therapeutic value. The paucity of research is directly due to its illegality in the U.S., although the drug can be used legally in Mexico and Canada.

Ibogaine is a drug of interest to some researchers for several reasons, the chief of which is that those who suffer from traumatic injuries to the brain are often not helped, or helped only partly, by existing FDA-approved therapies. TBI is considered the “signature injury of U.S. military veterans from recent military conflicts, most often caused by blast exposure,” note the authors of the paper reporting results of a small trial with ibogaine just published in the journal *Nature Medicine*. Lead author of the study was **Nolan R. Williams, M.D.**, of Stanford, winner of BBRF’s Colvin Prize in 2024 and its Klerman Prize in 2019, and a BBRF Young Investigator in 2018 and 2016. **Jennifer Keller, Ph.D.**, a 2009 BBRF Young Investigator, was among the co-authors.

First-line therapies for conditions often arising following TBI—cognitive rehabilitation, psychotherapy, and medications that target specific symptoms—tend to be less effective for veterans compared with other populations, the Stanford team says, with remission rates ranging from 20% to 40% following treatment. “Most concerning, veterans make up 20% of U.S. suicides,” they note, although they account for only 6% of the population.



Nolan R. Williams, M.D.

Stanford University
2024 BBRF Colvin Prize
2019 BBRF Klerman Prize
2018, 2016 BBRF Young Investigator

The Stanford researchers entered into a collaboration with a company called Ambio Life Sciences, which had received a grant from a nonprofit called Veterans Exploring Treatment Solutions (VETS), Inc. to test ibogaine in a group of 30 male volunteers who, independently of the university, had enrolled themselves in what is called an open-label trial to be conducted at a clinic in Tijuana, Mexico.

All of the participants were males who had served in U.S. special forces and had suffered mild to moderate traumatic brain injury which impaired their functioning.

Prior to treatment with ibogaine the 30 participants were found to have an average rating of 30 on a WHO disability scale, which translates into “mild to moderate” disability. “These men were incredibly intelligent, high-performing individuals who experienced life-altering functional disability from TBI during their time in combat,” Dr. Williams said. “They were all willing to try most anything that they thought might help them get their lives back.”

After being administered ibogaine along with concurrent injections of magnesium to reduce the potential impact on heart arrhythmia and other known potential cardiac side effects, “participants showed a remarkable reduction in symptoms” of disability, PTSD, depression and anxiety,” the team reported. The benefits were sustained at the 1-month follow-up. In fact, disability measures “continued to improve and psychiatric symptom remission and response rates remained high” after 1 month, the team noted. “Neuropsychological testing

revealed areas of improvement after treatment particularly in processing speed and executive function, without any detrimental changes observed. With regard to safety, no serious or unexpected adverse events occurred and management of adverse effects was uncomplicated.” Such adverse effects included nausea, headache, and anxiety. Motor effects were uncommon and resolved within 24 hours.

The disability score of a typical participant declined from 30 to 19.9 in the assessment immediately following treatment; this further plunged to 5.1 after one month (“no disability”). Mean percentage reduction in PTSD, depression and anxiety symptoms was 81%; 93% were “responders” and the remission rate was 83%. Suicidal ideation, present in 47% pre-treatment, fell to 0% just after treatment and 7% after one month. The tests of neurocognitive functioning included a finding that reaction time slowed significantly post-treatment, which may translate into a reduction in impulsivity among those in whom this was a problem. Impulsivity is associated with relapse after substance-use treatment and also with suicidality.

An important factor in considering the strong results is the potential impact of “complementary therapies” which all participants received as part of the trial in Tijuana. Each participant was paired with a licensed therapist experienced in coaching patients undergoing ibogaine treatment. Each was coached prior to the administration of the treatment, during the treatment while the dream-like effects of ibogaine were being experienced, and following

treatment—the next day, when coaches and patients discussed the processing of their emotions and how to interpret and “integrate” insights they may have gained from the treatment into their everyday lives.

Further study of the data from the brain scans made before and after the treatments will lead to additional papers by the team. Dr. Williams hopes that results of subsequent studies with more diverse patient populations including those with more severe TBI, will reveal “a host of different brain areas” that may be involved in any therapeutic impact of ibogaine—data that might “help us to treat other forms of PTSD, anxiety, and depression that aren’t necessarily linked to TBI.”

In Childhood Anxiety, CBT Helps By Normalizing Hyperactive Brain Circuits, Study Finds

Basic Research: [Anxiety](#)

Story Highlights:

A study of brain network changes in young people with anxiety disorders treated with CBT suggests how the therapy helps normalize some but not all circuit irregularities. The latter might be separately targeted to further reduce symptoms.

Journal:
American Journal of Psychiatry
January 24, 2024

A new study of brain network and circuit responses in young people with anxiety disorders who were treated with a course of cognitive behavioral therapy (CBT) suggests how the therapy helps to normalize some but not all irregularities that are likely involved in generating anxiety symptoms. This in turn suggests how CBT and possible adjuncts to it might be modified to improve outcomes.

CBT is a first-line treatment for pediatric anxiety disorders, which are highly prevalent and can be impairing if left untreated. The therapy usually involves graded exposures of the patient to stimuli that evoke fear. The premise behind the approach is extinction of fear through restructuring of cognitive responses to fear stimuli. The impact of such therapy, when effective, is an interruption of processes that lead the patient to avoidant behavior and thinking which makes it difficult to carry on normal activities, from schooling to play and socializing.

A research team led by Melissa A. Brotman, Ph.D., Chief of the Neuroscience and Novel Therapeutics Unit at the National Institute of Mental Health (NIMH), sought to discover treatment-related changes in regional activation patterns throughout the brain in young people with anxiety disorders after they were treated for 12 weeks with CBT plus an adjunctive treatment using computerized cognitive training.

First author of the paper reporting the team's results was **Simone P. Haller, D. Phil.**, a 2020 BBRF Young Investigator. Three other BBRF-affiliated researchers were members of the team, including **Ned H. Kalin, M.D.**, of the University of Wisconsin, a BBRF Scientific Council member and editor-in-chief of the *American Journal of Psychiatry*, in which the team's paper appeared.

As the team points out, neurobiological models posit that pathological anxiety "arises from dysregulated cognitive processes and defensive responses." Alterations in functional brain networks are presumed to account for this, including circuitry involved in attention, salience (determining the relative importance of stimuli coming in from the senses), and threat perception.

While CBT is well proven to be effective in many pediatric anxiety patients, it is by no means perfect. "Response rates are variable, leaving a large portion of treated youths with significant symptoms following treatment," the team notes. "The moderate success rate may be due, in part, to limited understanding of the mechanisms" in the brain that are therapeutically modified by CBT.

To address the paucity of research on CBT-related brain mechanisms in young people, the team studied responses in 69 young people, two-thirds female, diagnosed with primary anxiety disorders (generalized, social,



Simone P. Haller, D. Phil

National Institute of Mental Health
2020 BBRF Young Investigator

separation, phobia) who received CBT plus computer-guided cognitive therapy for 12 weeks. These children, who on average were about 12–13 years old and were unmedicated, received functional MRI (fMRI) brain scans prior to beginning treatment, and then again following the full course of treatment. The scans were made while the participants were asked to perform a simple task while emotionally neutral or angry faces were displayed on a computer screen. The results in these children were compared with scans made under the same conditions for a group of 62 demographically matched healthy children. Most of the participants in the anxiety group and many in the comparison group came from families with annual incomes of \$90,000 or more.

The team reported several major findings. Among these was that the unmedicated children with anxiety disorders who received CBT differed from healthy children at baseline, when the first fMRI scan was made. Prior to treatment, youths with anxiety disorders showed widespread hyperactivation of neural circuits, consistent with previous research. These treated children differed at baseline in reaction time to stimuli (slower) and in levels of activation (hyperactivated) brain-wide. Second, in children with anxiety, reaction time as well as hyperactivation specifically in the fronto-parietal region reverted to normal levels with CBT treatment. Third, a number of regions in the brain's cortex and in subcortical regions "remained hyperactive in patients after CBT treatment."

Subcortical regions include the brain's limbic circuitry which handles lower-order emotional processing of inputs from sensory systems and includes the amygdala.

Perhaps the most important aspect of the study was the finding that in young patients, some patterns of hyperactivation, including several frontal regions of the brain as well as the right amygdala, did not change with treatment. The team cannot be certain why this is the case, but theorized that while cognitive aspects of CBT "may first reduce subjective feelings of fear or anxiety, defensive systems may show more persistent dysfunction." They speculate that CBT may more effectively target cortical circuits, while subcortical (including limbic) dysfunction "may lag in responsivity and/or might require more direct interventions" to alter exaggerated defensive reactions.

The team suggested that longer-term follow-up of youths who complete CBT treatment "may reveal normalization of amygdala function," adding to the benefit the therapy may have on cortical circuitry. It is possible, they say, that youths who continue to demonstrate aberrant cortical and subcortical functioning may be especially prone to relapse as time passes. Overall, it makes sense, they suggest, to follow treated youths over time, and also to assess the effectiveness of complementary adjunctive treatments given alongside CBT, particularly those that have a direct impact on subcortical structures of the brain such as the amygdala.

The research team also included: **Rany Abend, Ph.D.**, 2019 BBRF Young Investigator; **Katharina Kircanski, Ph.D.**, 2013 BBRF Young Investigator.

How Immune Activation May Alter the Brain and Cause Depression-Related Behavior During Chronic Social Stress

Basic Research: **Depression**

Story Highlights:

A protein called MMP8, released during chronic social stress by circulating immune cells, can invade the brain and alter the shape of the space between neurons, research shows. This can adversely affect the nucleus accumbens and possibly other brain areas. In mouse experiments, such changes were causally linked with adverse changes in behavior such as social avoidance.

Journal:
Nature
February 7, 2024

Extensive research over several decades, some of it led by investigators supported by BBRF, has demonstrated that stress, including psychosocial stress (stress that arises from social interactions) is one of the most important risk factors for depression.

Great effort has therefore been devoted to research seeking to reveal precisely how stress perturbs the biology of the brain and other bodily systems to produce the diverse range of depression symptoms.

A new study appearing in the journal *Nature* reports on experiments that add an important new dimension to what is known about how, when someone is experiencing social stress, the functioning of the body's immune system may be involved in helping to cause depression or increase its risk.

The new study was led by 2020 BBRF Young Investigator **Flurin Cathomas, M.D.**, of the Icahn School of Medicine at Mount Sinai; the senior author of the team's paper was **Scott J. Russo, Ph.D.**, a member of BBRF's Scientific Council, a two-time BBRF Young Investigator grantee, and Director of the Brain-Body Research Center at Mount Sinai. Seven other BBRF grantees were involved in this study, including **Eric J. Nestler, M.D., Ph.D.**, a member of BBRF's Scientific Council, a three-time BBRF prize winner, and 1996 Distinguished Investigator.

As authors of the new study note, immune system interactions with the central nervous system (the CNS: the brain and spinal cord) and organs of the body are tightly regulated, biologically. Psychosocial stress can affect the two-way communications between these two elements—the CNS and the rest of the body. In people experiencing chronic stress, past research has shown that the innate immune system is activated, resulting in the mobilization of immune cells including white blood cells in peripheral organs and blood, as well as the production of tiny proteins called cytokines, which can trigger inflammation.

One intriguing discovery in psychiatry research has been that a subset of people with stress-related psychiatric disorders, including major depression, “display a state of chronic low-grade inflammation.” Two phenomena associated with such inflammation are an increase in the affected individual's pro-inflammatory cytokines in circulation throughout the body, as well as an increase in white blood cell numbers. In experiments in mice, it has been shown that stress also can induce changes to the thin but vital membrane separating the brain and the rest of the body, the blood-brain barrier (BBB), which normally plays a protective role, keeping toxins and microbes out of the brain. When modified by stress-induced inflammation, the BBB in mice allows the entry of circulating proteins into



Scott J. Russo, Ph.D.

Icahn School of Medicine at Mount Sinai
BBRF Scientific Council
2008, 2006 BBRF Young Investigator



Flurin Cathomas, M.D.

Mount Sinai / Psychiatric
University Hospital Zurich
2020 BBRF Young Investigator

the brain that normally can not pass through the barrier. One region in the brain affected by such invasion, in mice, is the nucleus accumbens (NAc), which is central in the processing of rewards and also in the response to aversive stimuli, and implicated in depression.

All of these processes are potentially involved in causing depression symptoms in people, although much remains to be learned about the mechanisms that enable these changes to occur. The new study by Drs. Cathomas, Russo and colleagues reveals new detail about mechanisms through which stress-induced immune changes can affect the function of the brain's neurons and ultimately, behavior.

In the presence of stress, immune factors at work in the body's periphery, such as a rise in the circulation of pro-inflammatory cytokines, likely have a direct impact on neurons—for example, by binding directly to receptors expressed in neurons. The new study demonstrates a distinct way in which stress promotes interactions of immune cells in the periphery with the brain—an indirect way that appears to result in adverse changes in social behavior.

The new research focuses on the role in this process of enzymes called MMPs (matrix metalloproteinases) and in particular MMP8. This enzyme, like others in the MMP family, has roles in shaping and regulating the space between neurons, called extracellular space (ECS), as well as the extracellular matrix (ECM), which is a dense web-

like material that individual neurons extend out into ECS.

Experiments by the team in mice and humans leads them to conclude that MMP8, which is released during chronic social stress by immune cells circulating in the body's periphery, can invade the brain perhaps due to damage to the BBB, and alter the shape of ECS and ECM in the brain's nucleus accumbens and possibly other brain areas. In mouse experiments, such changes were causally linked by the team with changes in behavior—changes analogous to those observed when a person experiences chronic social stress (social avoidance, for example).

In short, therefore, the new research provides evidence for a specific mechanism by which the peripheral immune system can affect, via alteration of the ECS, the functioning of neurons in the brain and alter behavior. One potential implication is that it may be possible to develop treatments that target not the brain directly (which is always difficult), but rather molecules such as MMP8 in the peripheral immune system—a totally novel approach to potentially treat psychiatric illnesses including depression.

The researchers note the need for further studies to “more specifically manipulate different components of the ECS in various brain regions,” to link them with specific changes in brain physiology and behavioral changes, and also to identify additional factors that might alter the ECS under conditions of chronic stress. A mouse

experiment in which MMP8 was depleted resulted in stressed mice that were not socially avoidant; this approach had no impact on non-social behaviors. “Further research is needed to untangle neuroimmune mechanisms of stress-induced vs. non-social behavior alterations,” they say. Still, the current results suggest MMP8 or ECS changes may serve as biomarkers for psychiatric illness as well as novel targets for future treatments.

The research team also included: **James W. Murrough, M.D.**, 2009 BBRF Young Investigator; **Eric M. Parise, Ph.D.**, 2021 Young Investigator; **Romain Durand-de Cuttoli, Ph.D.**, 2022 BBRF Young Investigator; **Lyonna F. Parise, Ph.D.**, 2022 BBRF Young Investigator; **Long Li, Ph.D.**, 2021 BBRF Young Investigator; **Kenny L. Chan, Ph.D.**, 2022 BBRF Young Investigator.

Food-Seeking Circuit in the Brain That Can Override Hunger or ‘Fullness’ Signals May Shed Light on Eating Disorders

Basic Research: [Eating Disorders](#)

Story Highlights:

Researchers discovered that a specific group of neurons in a region of the brainstem previously associated with fear, when activated, induces mice to forage and eat, even when they are not hungry—especially rewarding highly caloric foods. The research could provide important insights into eating disorders such as binge eating disorder and anorexia nervosa.

Journal:
Nature Communications
March 7, 2024

Research that was initially focused on fear, anxiety, and defensive behaviors has resulted in a series of unexpected discoveries that have shed new light on eating behaviors, and, possibly, on eating disorders involving both compulsive eating when already “full” as well as aversion to food even when hungry.

In a paper newly appearing in *Nature Communications*, a team led by 2014 BBRF Young Investigator **Avishek Adhikari, Ph.D.**, of UCLA, reports that it has identified a brain circuit in mice whose activation causes the animals to search for food even when they are not hungry. By manipulating the circuit, the researchers demonstrated they could increase or decrease food-seeking in mice, a discovery that might have translational potential in people with eating disorders since the circuit, or one very similar to it, likely also exists in the human brain.

The paper’s first author, who designed and performed many of the experiments just reported, was **Fernando M. C. V. Reis, Ph.D.**, also of UCLA. His 2018 BBRF Young Investigator award helped support research that was originally focused on fear memory. A second Young Investigator grant in 2022 funded work that enabled Dr. Reis and colleagues to pursue unexpected discoveries pertaining not just to fear and defensive behaviors but to the brain’s food-seeking circuitry as well.

The investigators were studying an area in the brain called the periaqueductal grey, or PAG. This region was known to have an important role in fear, but not in the pursuit of food. The team was initially investigating how cells in the PAG that release the neurotransmitter GABA (called VGAT-expressing neurons) affect fear. In the course of their experiments, the team was surprised to discover that these VGAT-expressing neurons can dramatically alter feeding—their activation led the animals to forage for food and to eat on a full stomach.

The PAG is located in the brainstem, notes Dr. Adhikari, “which is very old in evolutionary history, and because of that, it’s functionally similar between humans and mice.” While acknowledging the team’s findings were a surprise, he said it did “make sense that foraging is rooted in such an ancient part of the brain, since foraging is something all animals must do.”

Dr. Adhikari received his graduate and postdoctoral training in the labs of two past BBRF grantees, both of whom are members of BBRF’s Scientific Council: Joshua Gordon, M.D., Ph.D., who is director of the National Institute of Mental Health, and Karl Deisseroth, M.D., Ph.D., who in 2021 received the Lasker Basic Medical Research Award for his role in developing optogenetics technology.



Fernando M.C.V. Reis, Ph.D.

University of California, Los Angeles
BBRF Scientific Council
2022, 2018 BBRF Young Investigator



Avishek Adhikari, Ph.D.

University of California, Los Angeles
2014 BBRF Young Investigator

Dr. Adhikari’s studies initially focused on how fear and anxiety help animals assess risks and minimize exposure to threats. The PAG is particularly associated with the panic response, in rodents and people. “When we used optogenetics to selectively simulate only this specific group of VGAT-expressing GABA neurons in the PAG, we found it did not affect the animals’ fear responses; rather, it caused them to forage and eat,” he notes.

The team further observed that when these cells were stimulated, mice that were not hungry started to specifically crave fatty food—so much that they were willing to endure mild electrical shocks to their feet in order to obtain this food. (The harmless but unpleasant shocks are like those one gets when experiencing static electricity.) Stimulation of the cells was not, in other words, inducing feeding by creating hunger, which is an unpleasant feeling; rather, activation was associated with pleasure and reward.

Conversely, when the researchers experimentally suppressed the activity of the same cells in the PAG, mice that were very hungry ate significantly less. This shows, says Dr. Reis, that “this circuit can bypass normal hunger pressures regarding how, what, and when to eat.”

This suggests the potential relevance of the results to eating disorders in people. It is almost certain that humans also have VGAT cells in the PAG, as these neurons have been confirmed in a wide range of animals, including rodents, cats, and monkeys.

If additional research confirms that humans also have VGAT-expressing cells in the PAG, researchers can then try to determine if overactivity in the circuit is correlated with the feeling of reward and with craving high-calorie food even when an individual is not hungry. It is also conceivable that if underactive, the same circuit might also help explain reduced pleasure associated with eating, perhaps leading in some people to the avoidance of food. Compulsive eating when not hungry is a behavior seen in binge eating disorder. Avoiding nutrition even when deprived of calories is seen in anorexia nervosa.

In the near-term, there is much more basic research to do. In their paper, the team suggests the need to investigate, for instance, how connections between the VGAT-expressing cells in the PAG and cells in a brain area called the zona incerta may regulate important aspects of the motivation to forage and eat. Circuits controlling appetite and eating behaviors, they say, can perhaps “be viewed as a broad complex loop network” whose distinct functional and computational components “require further characterization.”

The research team included **Jonathan C. Kao, Ph.D.**, 2020 BBRF Young Investigator; **Alcino J. Silva, Ph.D.**, a 1999 BBRF Independent Investigator.

A Stem Cell-Based Therapeutic ‘Rescue Strategy’ is Developed for Timothy Syndrome, an Autism Spectrum Disorder

Next-Generation Therapies: **Autism Spectrum Disorders**

Story Highlights:

A BBRF grantee has published results of experiments demonstrating a potential therapeutic “rescue strategy” using stem cell technology for a devastating neurodevelopmental disorder called Timothy Syndrome (TS), one of the autism spectrum disorders. By modifying messenger RNA activity for a gene involved in disease pathology, they prevented the emergence of disease pathology in human neurons implanted in living mice.

Journal:
Nature
April 24, 2024

A team of researchers led by two-time BBRF grantee **Sergiu Pasca, M.D.**, of Stanford University, has published results of experiments demonstrating a potential “rescue strategy” using stem cell-based models for a devastating neurodevelopmental disorder called Timothy Syndrome (TS).

TS is widely considered to be among the autism spectrum disorders, with patients often having severely impaired communication and socialization skills, as well as delayed development of speech and language. TS also can have other serious impacts on health including epilepsy and a cardiac disorder called long QT syndrome that affects heart rhythm. The newly reported experiments, while specifically targeting pathology in severe TS, could have future applications in other illness involving the brain including schizophrenia, bipolar disorder, and intellectual disability.

The new research that Dr. Pasca and colleagues report in a cover story in the journal *Nature* has its origins over 15 years ago in the Pasca lab. Dr. Pasca received his first grant from BBRF in 2012 (Young Investigator) and in 2017 he received a BBRF Independent Investigator grant. He is among the pioneering researchers who have harnessed stem-cell technology to grow human brain cells in the laboratory. His lab developed guided neural “organoids” from stem cells and has pioneered the first “assembloids” that model circuit formation in three

dimensions in the lab setting. In a more recent innovation, they have transplanted organoids into living animal brains, where they make connections and take part in functional circuits. This has made possible unprecedented experiments to reveal pathologies in human brain illnesses, particularly those like schizophrenia and autism which in some forms likely have origins in the first months of life, during development of the fetal brain and other organ systems. The lab’s technologies, deployed in living rodents, are especially valued because we cannot access the human fetus experimentally to observe emerging pathology. The same approach has also provided a unique test-bed for assessing new therapeutics, as the newly reported research demonstrates.

The organoids used by Dr. Pasca and others are based on cells harmlessly sampled from patients; skin cells, for example, can be reprogrammed in the lab to redevelop as cells of the brain, heart, or any organ. Importantly, every reprogrammed cell bears the genome of the patient-donor. If the donor has genetic mutations linked with an illness like Timothy Syndrome, then a novel kind of experiment becomes possible. One can watch these cells from their earliest days as they develop and begin to manifest pathologies caused (at least in part) by their illness-related variant genes.

As reported last year in BBRF’s magazine *Brain & Behavior*, Dr. Pasca’s



Sergiu P. Pasca, M.D.

Stanford University
2017 BBRF Independent Investigator
2012 BBRF Young Investigator

team engrafted cortical organoids derived from cells donated by patients with a severe kind of Timothy Syndrome called type 1 (TS1). These organoids developed in the lab, and after transplantation into a living rodent, integrated with the host brain in ways that clearly revealed pathologies consistent with the illness. This provided key insights that led to the dramatic experiments just reported.

It began to be clear even from earlier experiments in test tubes performed more than a decade ago by Dr. Pasca that neurons grown from cells donated by TS patients displayed certain characteristic pathologies. For example, these cells had problems regulating the flow of calcium into and out of neurons, a flaw that is associated with abnormally high levels of neural excitation. There were also pathologies affecting the way neurons migrate in the brain.

These defects are caused by a mutation in a gene called *CACNA1C*, known to be mutated in TS (and several other psychiatric illnesses) and, much more specifically, the way in which the *CACNA1C* gene is processed in cells to ultimately give rise to *CACNA1C* proteins.

Every gene in our bodies, when activated, generates a “message” in the form of RNA (“messenger RNA”) that tells a cell to manufacture a specific protein. Under normal conditions, the *CACNA1C* gene produces several variants, or “alternate” messenger RNAs (mRNAs). These alternate messages are the result of a process called “alternate mRNA splicing” that occurs just before the message is sent to protein production factories in cells called

ribosomes. These messages contain instructions for making the *CACNA1C* protein. The variant of *CACNA1C* carrying the TS mutation is present early in the developing brain and patient-derived neurons seem to make even more of it than those from healthy controls.

As development progresses, the *CACNA1C* RNA “message” normally transitions to a slightly different, more mature form. Dr Pasca reasoned that interfering with RNA splicing to yield the more mature non-mutated form might prevent defects associated with Timothy Syndrome type 1.

To achieve this, his lab developed a therapeutic strategy that has been used successfully to treat several other serious illnesses including spinal muscular atrophy and Duchenne muscular dystrophy. Both also have pathologies rooted in splicing variations in RNA messages. As was done in those illnesses, the researchers created chemically modified pieces of RNA called antisense oligonucleotides (ASOs). The ASOs act like missiles within cells, homing in precisely on specific spots in pre-spliced RNA messages of a gene, causing the splicing of the message to be slightly modified. This modification can do a variety of things depending on the ASO’s design. In the case of Dr. Pasca’s team, the ASO was designed to interfere with the splicing of *CACNA1C* favoring the variation not carrying the TS1 mutation.

In rats that had received cortical organoid transplants grown from the cells of TS patients, the team injected the tiny ASO molecules into the fluid that bathes the spinal cord and brain.

These did indeed alter the splicing of RNA messages in the human cells growing inside the rodent brains, resulting in “robust” reversal, or “rescue” of pathologies in the neurons caused by the mutation—those involving calcium flow as well as migration.

The proof-of-concept experiment was successful, but much more work needs to follow before ASOs can be considered for treating people with Timothy Syndrome. It is not yet clear what impact, if any, the therapeutic strategy will have on cardiac symptoms in TS; tests with cardiac organoids grown from patients’ cells are a near-term priority. It is not clear what impact the treatments will have on pathology that happens to predate the treatment. Also, long-term tests must be performed in experimental animals to evaluate toxicities potentially related to the treatment, as well as to determine if the design of the ASOs can be optimized to generate better therapeutic results.

Yet the strategy is an important and promising one, the team believes, and illustrates how this platform involving stem cells and organoids could be used to study other neuropsychiatric diseases and to evaluate the therapeutic efficiency and safety of ASOs and other approaches including small molecule candidate drugs. The approach will be particularly relevant, the team says, when animal models are not available or do not fully recapitulate human pathophysiology for a given illness.

New First-in-Class Schizophrenia Medicine Reduced Positive and Negative Symptoms in Decisive Phase 3 Trials

Next-Generation Therapies: **Schizophrenia**

Story Highlights:

KarXT, a new medicine for treating schizophrenia—one that appears to help reduce both positive and negative symptoms of the illness—has passed a first hurdle in phase 3 clinical testing. If ultimately approved, it would be the first antipsychotic treatment that does not target the D2 dopamine receptor.

Journal:
JAMA Psychiatry,
May 1, 2024

The Lancet,
January 13, 2024

*KarXT, marketed under the trade name Cobenfy, was approved by the FDA in September, 2024.

A new medicine for treating schizophrenia—one that appears to help reduce both positive and negative symptoms of the illness—has passed a first hurdle in phase 3 clinical testing. Phase 3 is often pivotal in deciding whether a medicine is effective and safe enough to obtain FDA approval.*

The medicine, xanomeline-trospium, is called KarXT by Karuna Therapeutics, the company that is developing it and which paid for the initial phase 3 trial. The drug has a novel mechanism of action that distinguishes it from all previously approved antipsychotic medicines.

In December 2023, the pharmaceutical giant Bristol-Myers Squibb Co. entered into a deal valued at over \$14 billion to purchase Boston-based Karuna. The announcement came just weeks after positive results of the first of two positive KarXT phase 3 trials were published in the journal *Lancet*. Senior author of the paper reporting the results was **Steven M. Paul, M.D.**, a BBRF Scientific Council emeritus member who is currently Chief Scientific Officer and President of R&D at Karuna. One of the paper's co-authors was 2007 BBRF Young Investigator **Christoph U. Correll, M.D.** of Northwell/Zucker Hillside Hospital.

252 patients with acute psychosis requiring hospitalization were enrolled in the randomized, double-blinded, placebo-controlled trial. Half received KarXT for 5 weeks and half received

placebo. KarXT was observed to significantly reduce both “positive” and “negative” symptoms of schizophrenia compared with placebo. In addition to reductions in both kinds of symptoms, patients receiving the new medicine in most cases were able to tolerate it well, reporting only moderate side effects. Larger and longer phase 3 clinical trials are now underway.

KarXT is the culmination of research begun decades ago to find a new way of treating symptoms of schizophrenia. Since the first antipsychotic medicine approved in the 1950s, every antipsychotic approved to date targets a cellular receptor for the neurotransmitter dopamine called the D2 receptor. Some “atypical” or second-generation antipsychotic medicines, including clozapine, also have important therapeutic effects related to their impact on receptors for serotonin. Both first- and second-generation antipsychotics are often very effective in reducing delusions and hallucinations that are the chief positive symptoms of the illness. But they have essentially no impact on negative symptoms such as blunted affect, anhedonia, lack of motivation and asociality, and no appreciable impact on cognitive symptoms.

The idea that led to KarXT began with the aim of developing a drug with a novel mechanism of action—one that would not block D2 dopamine receptors but rather would stimulate cellular receptors called the M1 and



Steven M. Paul, M.D.
(Lancet and JAMA Psychiatry papers)
 BBRF Scientific Council Emeritus



Carol A. Tamminga, M.D.
(JAMA Psychiatry paper)
 BBRF Scientific Council
 2011 BBRF Lieber Prize;
 2010, 1998 BBRF Distinguished Investigator

M4 muscarinic receptors. These receptors are part of the cholinergic (acetylcholine) neurotransmitter system. The theory was that agents targeting the muscarinic acetylcholine receptors might indirectly impact the balance in the brain between the dopamine and acetylcholine systems, including in the brain's striatum, which in turn might help therapeutically address pathology that gives rise to psychosis.

For many years, preliminary tests of medicines targeting the muscarinic M1 and M4 receptors suggested that they had excellent potential for reducing schizophrenia's positive, psychosis-related symptoms. The problem has always been side effects: the early candidate drugs had significant side effects in the body's gastrointestinal system, including nausea and vomiting. To potentially overcome this obstacle, developers of KarXT have tested the idea of combining a compound (xanomeline) that stimulates the M1 and M4 muscarinic receptors in the brain with a compound (trospium chloride) that blocks the M1 and M4 receptors in bodily tissue outside the brain, including the gastrointestinal tract. In phase 1 and 2 trials, KarXT appeared to demonstrate antipsychotic efficacy while reducing the frequency and severity of gastrointestinal side effects.

The 252 individuals recruited for the phase 3 trial just reported were drawn from 22 inpatient sites in the U.S.; all had experienced a recent worsening of psychosis warranting hospital admission. The average participant was about 46 years old; about three-fourths were Black. On a scale of

symptom severity (called PANSS, the Positive and Negative Symptom Scale), the average participant scored close to 100 (the scale ranges from 30 to 210). Participants went through a "wash-out" period from prior antipsychotic medications that lasted in most cases for one week. Then, participants were randomly assigned to receive KarXT or placebo twice a day for 5 weeks. Those receiving KarXT were started on a dose of 50mg of xanomeline and 20mg of trospium twice daily for 2 days, then 100mg and 20mg of the two drugs, respectively, from days 3-7. Beginning on the 8th day, dosing was flexible, and increased to 125mg/30mg twice daily if tolerated by the patient, otherwise the dose was reduced to the 100mg/20mg level. Nearly all participants were able to tolerate the maximum dose after day 8 for the duration of the trial.

After 5 weeks, those in the KarXT group had significant reductions in both positive and negative schizophrenia symptoms, as measured by the PANSS assessment tool. From an average total symptom score of about 98, the typical participant had a 21-point reduction after 5 weeks on KarXT, compared with an 11.6-point reduction in the placebo group. On separate "subscales" measuring positive or negative symptoms, KarXT was also superior to placebo. KarXT-treated patients had a reduction of nearly 7 points compared with about 4 points in the placebo group. Negative symptoms declined 3.4 points in the KarXT group vs. 1.6 points in the placebo group. In the KarXT group, 55% had an overall symptom reduction of 30% or greater, compared with 28% in the placebo group.

Side effects were present, as they are with virtually all medications, but were considered comparatively mild to moderate by the researchers. Noting KarXT's apparent ability to significantly reduce both positive and negative schizophrenia symptoms as well as the reports on side effects, the researchers concluded that KarXT "has the potential to be the first of a new class of effective and well-tolerated antipsychotic medicines."

The team looked forward to results from additional clinical trials now in progress. Among other things, these may help assess whether the observed decline in negative symptoms in the KarXT patients was a direct result of the medicine's mechanism of action or might be related in part to its ability to reduce positive symptoms. Also, trials in progress will explore over the longer-term the drug's impact as adjunctive treatment on patients with ongoing positive symptoms due to only a partial response to currently available antipsychotics.

Study of One Psychedelic Drug Suggests How It Might be Modified to Eliminate Psychedelic Effects While Retaining Therapeutic Ones

Basic Research; Next-Generation Therapies: **PTSD, Anxiety, Depression**

Story Highlights:

A detailed study of how the psychedelic drug 5-MeO-DMT interacts with receptors for the neurotransmitter serotonin has suggested that a modified version of the drug that targets the serotonin 1A receptor may not generate psychedelic effects while preserving some of the potential therapeutic effects attributed in various studies to psychedelics in depression, PTSD, and other illnesses.

Journal:
Nature
May 8, 2024

Among those studying psychedelic drugs to treat psychiatric illnesses, there is new research exploring the possibility that structurally modified versions of these agents may reduce or eliminate their powerful mind-altering psychedelic effects while preserving some or all of their potential therapeutic effects.

Reporting in the journal *Nature*, a team co-led by Daniel Wacker, Ph.D., of the Icahn School of Medicine at Mount Sinai, and Dalibor Sames, Ph.D., of Columbia University, used a powerful kind of microscopy called cryogenic electron microscopy (cryo-EM) in concert with medicinal chemistry and experiments in living mice to study with great precision at the level of molecules and individual atoms how various psychedelics and approved drugs interact with two kinds of cellular receptors for serotonin.

Lyonna F. Parise, Ph.D., a 2022 BBRF Young Investigator, and **Scott J. Russo, Ph.D.**, a member of BBRF's Scientific Council and a 2008 and 2006 BBRF Young Investigator, were members of the research team.

Serotonin is a neurotransmitter that is ubiquitous in the brain. It engages with individual cells at a variety of receptors, some located on the surface of cells, others within them. The “family” of serotonin-specific receptors includes types 1A and 2A, which were the focus of the new study. The serotonin 2A receptor is an important receptor

for excitatory neurons in the brain, and also happens to be the primary target for several psychedelic drugs, including LSD and psilocybin (the active ingredient in “magic mushrooms”). Those drugs are called “agonists” of the 2A serotonin receptor—they bind to it and activate intracellular signaling.

It is widely believed that LSD, psilocybin, and other psychedelics called tryptamine hallucinogens exert both their hallucinogenic and therapeutic effects when they bind at the serotonin 2A receptor. But those and some other psychedelic compounds also engage with a variety of other receptors, including the serotonin 1A receptor. One such psychedelic is 5-MeO-DMT (sometimes called “five methoxy,” “bufo,” or “toad venom”), a toxin found in the glands of a toad found along the Colorado River. It's very similar to the powerful psychedelic DMT (the active ingredient in ayahuasca), and like it and others, is being considered for possible use in certain psychiatric conditions. A small study conducted recently in Mexico with U.S. Special Forces Veterans tested 5-MeO-DMT in concert with the psychedelic ibogaine for relief of acute PTSD and depression. Both are Schedule I substances banned for human use in the U.S.

As noted by the researchers, the type 1A serotonin receptor is a validated target of several FDA-approved drugs, including anti-anxiety and anti-depressant agents (buspirone



Lyonna F. Parise, Ph.D.

Icahn School of Medicine at Mount Sinai
2022 BBRF Young Investigator

and vilazodone). Yet, they say, “little is known about how psychedelics engage it, and which of their effects are mediated by this receptor.” Hence, their study, which sought to perform a detailed structural and functional exploration of the mechanisms through which several “classical” tryptamine psychedelics as well as 5-MeO-DMT and several prescription drugs bind to and activate the 1A serotonin receptor at the molecular and atomic levels.

In a mouse model of depression, they also tested a compound different but structurally analogous to 5-MeO-DMT that selectively targets the 1A serotonin receptor. One of the implicit questions they sought to shed light on was whether a drug targeting the 1A receptor alone, i.e., that did not engage the 2A receptor, might still generate psychedelic effects, and whether it would still generate therapeutic effects (lowering anxiety and depression) ascribed to some psychedelics that bind primarily at the 2A receptor.

Because the serotonin 2A receptor “is responsible for the visual and other sensory disturbances elicited by classical psychedelics, it is typically assumed that these receptors also mediate therapeutic effects.”

But, says the team, “there is currently no clinical evidence to support this hypothesis,” while evidence generated in animal studies “is mixed.”

The team tested the 5-MeO-DMT analogue compound in mice subjected to a kind of chronic stress called “social defeat,” which leads the animals to

avoid social interaction and to cease caring about seeking treats (analogous to anhedonia in people). The compound, which other experiments showed was a highly selective agonist of the serotonin type 1A receptor, “rescued” these deficits, the team reported, a finding with “potential implications for the therapeutic effects” of 5-MeO- class compounds in treating human psychiatric illnesses perhaps including depression, anxiety, and PTSD.

Other parts of the study generated data supporting the idea that both the 1A and 2A serotonin receptors are involved in stress-coping mechanisms on both a psychological and cellular level; the role of the 1A receptor in stress resilience; and the previously reported antidepressant effect of drugs that specifically target the 1A receptor in animals.

There was also preliminary evidence that the 5-MeO-DMT-analogue targeting the 1A receptor that was tested in mice “lacked the preclinical indications of classical psychedelic effects [the “head-twitch response” is one such sign in rodents], which suggests that some of these compounds may not be hallucinogenic while retaining therapeutic effects.”

The team described how the configuration of tiny three-dimensional spaces in receptors called subpockets—highly specific to type 1A vs. 2A serotonin receptors—“determine both the potency and efficacy” of tryptamine hallucinogens at both receptors. This, they said, “provides a structure-

guided framework that enables the development” of tryptamine psychedelic analogues “with finely tuned pharmacological activities and varying degrees of selectivity” for 1A and 2A serotonin receptor binding. Synthesizing and testing such compounds will be the subject of future studies.

Importantly, the team also suggested that FDA-approved medicines buspirone, vilazodone, and the antipsychotic aripiprazole, all of which target the type 1A receptor, engage with it differently than 5-MeO-DMT, generating signaling that is distinct from that produced when the psychedelic docks at the receptor to generate signaling outputs. These differences, as well as engagement of other receptor targets, probably accounts for the different effects of these medicines compared with the 5-MeO-DMT analogue tested in the socially defeated mice, the researchers said.

This research was co-led by Daniel Wacker, Ph.D., of the Icahn School of Medicine at Mount Sinai, and Dalibor Sames, Ph.D., of Columbia University.

Experiments Point to Possible Next-Gen Drug Therapies for Bipolar Disorder, Including for Lithium Non-Responders

Basic Research; Next-Generation Therapies: **Bipolar Disorder**

Story Highlights:

Researchers used stem cell-based technology to discover two ways to reduce hyperactivity in neurons, a characteristic problem in bipolar disorder (BD). The research suggests activation of Akt, a signaling pathway, and AMPK, a protein complex, could be targets for next-gen therapeutics for BD.

Journal:
The Lancet
June 1, 2024

Long-term use of mood-stabilizing drugs has long been a cornerstone of clinical treatment for bipolar disorder (BD). Lithium, which has been in use longer than any other, can be highly effective. In particular it can prevent or reduce the intensity of episodes of mania. Symptoms of mania include hyperactivity, euphoria or highly elevated mood, rushed speech, poor judgment, reduced need for sleep, aggression, and anger.

But lithium doesn't help every patient; in fact, only about 1 patient in 3 responds to it. Among those who do, an important added benefit is that suicide and overall mortality rates are significantly reduced. But toxicity has been associated with lithium administration over the long-term, and its use has been replaced in some patients with drugs not originally approved to treat bipolar disorder, including anticonvulsants such as valproate and lamotrigine.

Given lithium's well-documented ability to be of great benefit to a sizeable subset of BD patients, researchers have taken great pains to discover why it works for them: how the drug affects the central nervous system, at the level of cells, networks, and circuits. The answer has remained elusive, but new research co-led by BBRF grantees and published in the journal *Lancet* not only sheds light on the drug's mechanism of action, but also points to novel therapeutic approaches for patients, including those who do not respond to lithium.

2022 BBRF Young Investigator **Anouar Khayachi, Ph.D.**, of McGill University, Canada, is first author of the new paper, and part of a Canadian team that includes co-leaders **Guy A. Rouleau, M.D., Ph.D.**, a 2010 BBRF Distinguished Investigator, Austen J. Milnerwood, Ph.D., and **Martin Alda, M.D., FRCPC**, 2020 BBRF Colvin Prize winner and a 2003 and 1999 BBRF Independent Investigator.

Among the many insights about lithium's mechanism of action is a recent finding by members of the Canadian team that in neurons of the mouse cerebral cortex, long-term exposure to lithium decreased the flow of sodium ions, reduced firing rates, and lowered the range of calcium ion levels. Ions are atoms that carry an electric charge; their flow into and out of neurons is one of the ways in which the activation of brain cells is regulated.

In the current research, the team used a stem cell-based technology called iPSC (induced pluripotent stem cell). Cells—in this case, blood cells—are harmlessly sampled from individuals both with the illness under study as well as healthy controls. In the lab, these cells are grown in culture and brought back to a stem cell-like state, then re-programmed to re-develop as neurons. The team grew cultures of this kind from 5 BD patients who were responsive to lithium, 4 who were not responders, and 5 age and sex-matched healthy controls (all participants in the study were male).



Anouar Khayachi, Ph.D.

McGill University
2022 BBRF Young Investigator

The point of such research is to discover processes in cells from patients that differ from those in cells from controls. In this case, the BD patient-derived neurons enabled further comparison—between cells derived from patients who were lithium responders and those who weren't.

One important observation made in prior work by the team as well as other researchers was replicated in this work: all of the patient-derived neurons, regardless of the donors' lithium response status, displayed hyperexcitability. When these cells were treated with lithium over 7 days, the hyperactivity was reversed in cells derived from lithium responders, but, as expected, it was not reversed in cells from lithium non-responders.

The next step was to conduct many different kinds of tests on these three sets of neurons grown in culture dishes. Many things were revealed. First: In cells grown from lithium responders—in which hyperactivity was reversed with lithium treatment—the team noted changes in the ability of positively charged sodium ions to flow into and out of the cells, relative to cells grown from lithium non-responders.

Additional experiments that included analyses of protein activity and gene expression revealed that the potentially therapeutic effect of lithium on neurons derived from lithium responders was associated with a specific intracellular signaling pathway, called the Akt signaling pathway. Neurons (and other cells) regulate their survival and growth, in part, via this important pathway.

Additional experiments demonstrated that a compound that activates the Akt pathway mimicked the effect that lithium has on neurons—it reverses their hyperexcitability—but only in neurons grown from patients who responded to lithium, not in those from non-responders. Among the implications of this discovery is that it may make sense to develop and test Akt pathway activators to treat mania in bipolar patients. If the activity of such an agent was as therapeutically beneficial as that of lithium, and the agent was found to be less toxic or have fewer long-term side effects, it might be considered as a replacement for lithium.

Another key finding from the team's experiments also has therapeutic implications. In all BD patient-derived neurons grown in culture—neurons from both lithium responders and non-responders—activation of a protein complex called AMPK (AMP-activated protein kinase) reduced heightened neural network activity that seems to be characteristic in BD. AMPK is an energy sensor inside of cells, a major cellular regulator of lipid and glucose metabolism. Targeting AMPK in neurons might be a strategy to address neuropathology in lithium non-responders and responders alike.

One approved AMPK activator, metformin, is taken by millions of people. People with BD have a 2-fold increased risk of type II diabetes, and insulin resistance is present, the team notes, in about 50% of patients, "which might correlate with disease severity/progression." There has been some suggestion that lithium exerts

therapeutic effects in BD via its impact on insulin signaling. Akt and AMPK are both also involved in insulin signaling and the development of insulin resistance. One study has found that metformin improved clinical outcomes in BD patients, not only lowering insulin resistance but improving mood symptoms as well. This preliminary finding "and the results of our work here support use of AMPK activation for BD," the team said, although, of course, this will remain a hypothesis until considerable additional research is performed.

The team noted the main limitation of their study. Studying cells grown in culture in the lab, even those derived from BD patients, are by definition only suggestive, as they were conducted outside the context of the full human (or any animal) system. Reversal of hyperactivation in neurons derived from patients needs to be tested in living organisms—but at this point, no animal model is available to test it.

Nevertheless, the reported experiments suggest specific alternative strategies for treating BD, and provide "a framework for a personalized drug screening platform to accelerate development of alternative therapeutic strategies for BD," the team wrote. Personalized medicine for BD, if realized, could potentially address the frequent lag between diagnosis and therapy selection, as well as significantly reduce the risk of suicide, they said.

Team Develops an Innovative, Implantable Ultrasound Device to Stimulate Neurons in Deep-Brain Regions

New Technologies: **Deep-Brain Stimulation**

Story Highlights:

Researchers developed and tested a tiny, implantable neurostimulation device that uses ultrasound to modify the activity of neurons deep in the brain. The neural stimulator, called ImPULS, could become “a potent neuromodulatory tool” for therapeutic applications ranging from major depression to Alzheimer’s.

Journal:
Nature Communications
June 4, 2024

A research team led by 2018 BBRF Young Investigator **Canan Dağdeviren, Ph.D.**, of the Massachusetts Institute of Technology, reports in *Nature Communications* that it has designed, developed, and successfully tested a tiny, implantable neurostimulation device that uses ultrasound to modify the activity of neurons deep in the brain.

Although still very much an experimental device, their neural stimulator, called ImPULS, in the team’s view has promise to become “a potent neuromodulatory tool” for therapeutic applications in people in illnesses ranging from major depression to Alzheimer’s. It may also prove useful in basic research on the brain.

ImPULS stands for “implantable piezoelectric ultrasound stimulator.” Ultrasound consists of sound waves that vibrate at greater than 20,000 cycles per second (20 kHz), a frequency that is very close to the upper limit of human detection. Many animals can hear in ultrasound wavelengths—from dogs and cats at the lower end to dolphins at the higher end. Ultrasonic waves with much higher frequencies are used for a wide range of medical applications, perhaps the most familiar being the visualization of the human fetus during pregnancy.

ImPULS is not the first device that uses ultrasound to stimulate the brain and alter the activity of neurons. Ultrasound has also been used, so

far on a limited basis, to stimulate the brain non-invasively. In transcranial-focused ultrasound (tFUS) treatments in depression, Alzheimer’s and epilepsy, low-intensity ultrasonic waves are transmitted through the skull. Unlike the most common form of non-invasive neurostimulation, transcranial magnetic stimulation (TMS), which uses magnetism rather than sound waves to alter neuronal activity, tFUS has the advantage of being able to reach much deeper into the brain. It is thought ultrasound exerts its effects by affecting the tiny pores called ion channels that regulate the electrical activity of neurons. tFUS beams can be precisely focused (on the scale of millimeters), and penetrate several centimeters into regions far “beneath” the brain’s cortex, which lies immediately below the skull. Structures in the deeper subcortical regions include those such as the hippocampus and amygdala that play a central role in mood, memory, and learning.

Yet, as the MIT-led research team notes, “ultrasound, when transmitted from outside the human skull, faces significant scattering and reflection.” This can cause the stimulation of brain areas beyond the therapeutic target(s), and in some cases can potentially cause damage to the brain. These unintended “off-target” impacts are among the chief motivations for the MIT team’s work. Dr. Dagdeviren’s 2018 Young Investigator grant supported her work on developing a



Canan Dagdeviren, Ph.D.

Massachusetts Institute of Technology
2018 BBRF Young Investigator

new, implantable interface that could precisely target areas of the brain known to be involved in Parkinson's disease. The current project is related to that effort, in that it also seeks to develop and test a device that can be surgically implanted in the brain to deliver ultrasound with a specificity and precision that exceeds what is possible in tFUS and other non-invasive ultrasound applications.

Implantable technology to deliver neurostimulation is also not a new idea. Helen S. Mayberg, M.D., a BBRF Scientific Council member, prizewinner, and 3-time grantee, pioneered DBS, or deep-brain stimulation, in the 1990s, to treat refractory depression. DBS involves the surgical implantation of electrodes and a device to supply power for stimulatory pulses. These have had dramatic and enduring results in a limited number of patients. Optogenetics, a technology pioneered by BBRF Scientific Council member and grantee Karl Deisseroth, M.D., Ph.D., uses beams of colored laser light delivered through very thin probes implanted in the brain to alter the activity of specific neurons, but has not been applied in humans in part due to its reliance on genetic manipulation of nerve cells, which is not yet feasible in people.

"A miniaturized, non-genetic platform for localized stimulation is therefore needed to fill the gap for next-generation neural interfaces to reach high standards of safety and longevity," the MIT team says. Some early attempts at making ultrasound devices that fit this description have been proposed, but they may not be

suitable for implantation deep in the brain "due to their rigid form factors, material composition, or high power requirements," the researchers say.

ImPULS, the implantable piezoelectric ultrasound device they developed, is innovative in several respects. It has no active electrochemical elements. It is highly miniaturized, engineered at the micron-scale (1000 microns = 1 millimeter), is biocompatible, and uses very little power. Piezoelectricity is the electric charge that accumulates in certain solid materials, such as crystals, certain ceramics, and biological matter, in response to applied mechanical stress. To deliver the ultrasound, ImPULS uses a piezoelectric ceramic material micromachined to be only 30 microns thick, with an active element 100 microns in diameter. It is designed to be implanted in deep-brain regions, where its emission of ultrasound energy alters the behavior of adjacent neurons. In tests, the device resisted significant electrical and mechanical degradation over a period of days and did not raise the temperature of brain tissue during ultrasound generation beyond safe levels.

For the initial tests described in their paper, the ImPULS device was connected to an external printed circuit board via a special cable. The extremely thin probe whose implanted 100 micron-wide tip delivers the ultrasound energy was used in the laboratory to excite neurons in a preserved slice of mouse hippocampal tissue. Then, implanted deep in the brain of an anesthetized mouse, ImPULS was used in the living setting to prompt neurons to express a

specific gene called c-Fos. Perhaps most intriguing, ImPULS was used in living mice to stimulate neurons that release dopamine in a part of the brain called the substantia nigra pars compacta. Careful application of ultrasound enabled the team to modulate dopamine release over a specific period of time. In Parkinson's disease, large numbers of dopamine neurons in this region at the back of the brain die or cease to function.

The team says the fabrication process enables them to scale ImPULS devices to target larger areas of the brain, if wanted. In future studies, they seek to gain finer control of neural stimulation and evaluate potentially distinct effects such as excitation vs. inhibition in a variety of cell types, neural circuits and brain regions. The team also hopes to produce versions of the device that can deliver ultrasound carrying greater energy. They will also study the durability of the device, hoping to demonstrate that it can survive a month-long implantation. Still other research will try to adapt the technology for specific basic research projects seeking to better understand brain function.

"We believe this implanted ultrasound stimulation device can be developed into a versatile tool for both basic systems neuroscience research and potential therapeutic applications," the researchers said.

The research team included **Steve Ramirez, Ph.D.**, 2016 BBRF Young Investigator.

Network Connectivity Patterns in High-Risk Pre-Adolescents Correctly Predicted Depression Symptom Onset 2 Years Later

Diagnostic Tools/Early Intervention: **Depression**

Story Highlights:

Imaging scans from over 1,700 of the 11,000+ children enrolled in an ongoing study of brain development through adolescence revealed connectivity patterns, in the scans of healthy 9- and 10-year olds with parental history of depression, that predicted the onset of depression symptoms only 2 years later.

Journal:
Developmental Cognitive Neuroscience
June 4, 2024

Researchers have used functional brain imaging data to discover biomarkers that have the potential to predict early-onset depression in pre-adolescent youths with a family history of depression.

Dylan G. Gee, Ph.D., a 2015 BBRF Young Investigator at Yale University, led a team that made use of data collected by an important NIMH-funded study called the Adolescent Brain Cognitive Development (ABCD) Study. Between 2016 and 2018, a diverse cohort of 11,878 young people from around the nation were recruited for ABCD, which was set up to track their developing brains from pre-adolescence through the end of adolescence. The brain is extremely plastic during these years, in which both neurobiological and social changes are associated with increased vulnerability to developing psychiatric problems.

Taylor J. Keding, Ph.D., a 2023 BBRF Young Investigator, and **Jutta Joermann, Ph.D.**, a 2006 BBRF Young Investigator, were members of the research team in the new study. Bailey Holt-Gosselin was first author of the team's paper appearing in the journal *Developmental Cognitive Neuroscience*.

Dr. Gee and colleagues used a subset of the vast—and still growing—multi-dimensional ABCD database that included 559 children who had no psychiatric symptoms or history at the time of their enrollment, but did have

at least one parent with a history of major depressive disorder. Resting-state functional brain imaging scans of these children, enrolled at ages 9 to 10, were compared with scans made of 1,203 children enrolled at the same age who had no psychiatric history and no parental history of depression. The children in the first group were considered, for purposes of the study, at high familial risk for depression, while those in the second group were considered at low familial risk.

Youths who have a parent with depression have a 3- to 5-fold increased risk for developing depression themselves, the research team noted. This, along with the increased vulnerability experienced by all young people for development of psychopathology, “highlights the pressing need to identify predictive neural markers for development of depression prior to the onset of adolescence, especially among children already at high familial risk,” the team said.

Evidence from past studies suggests that familial depression risk manifests itself via atypical development of neural circuits implicated in reward and emotion processing, even in children with no history of depression symptoms in pre-adolescence. But the evidence for children is relatively sparse and it is not clear how atypical circuitry emerges over time or where precisely in key brain regions it appears.



Dylan G. Gee, Ph.D.

Yale University
2015 BBRF Young Investigator

Past studies based on resting-state functional brain scans of high familial risk youths prior to the beginning of adolescence have often lacked comparison data from children with low familial risk. Also, the age range of participants in prior studies has been comparatively large, e.g., ages 8–14 or 8–17 years. Dr. Gee and colleagues made certain to limit the age range in their study to 9–10, with the aim of searching for biomarkers that predicted onset of depression symptoms just 2 years later, at ages 11–12. This near-term outcome data was already in the ABCD database.

“Pre-adolescence is a particularly useful window to identify pre-existing neural vulnerability markers,” the team said. Vulnerability markers that may be present prior to the emergence of depression “are valuable because this knowledge can lead to early identification of vulnerable youth,” who, if treated promptly, stand to have better outcomes.

Each of the 1,762 youths whose data was examined in the study, like all children enrolled in the ABCD study, completed four 5-minute resting-state fMRI scans when they entered the study. Resting-state fMRI measures connectivity in brain circuits while an individual is not focused on a particular mental task. Dr. Gee and colleagues used a variety of methods to spot functional connectivity patterns involving areas involved in processing reward and emotions: the amygdala, putamen, nucleus accumbens, and caudate regions of the brain.

They were able to identify a number of potentially important patterns in the scans. Specific functional connectivity patterns between the amygdala and striatal regions and visual and sensory-sensorimotor networks were found to be predictive of depression 2 years later.

These patterns—again, seen in scans of preadolescents without a diagnosis of a psychiatric disorder at ages 9 and 10—appeared to the team to be potential biomarkers for depression onset by ages 11–12, particularly for youth with a family history of depression.

“The majority of depression-predictive functional connectivity patterns involved regions within visual and sensory/sensorimotor networks which typically mature earlier in development,” the researchers pointed out. “Association networks are still undergoing significant development within the age range of our sample. By contrast, sensorimotor networks may have reached greater relative maturity by this age, and therefore may be more likely to differentially shape future [depression] symptom development as a function of familial risk status.” It is possible, they speculated, that as neurodevelopment progresses within association networks, these networks “may begin to be more predictive of future symptoms at older ages (e.g., ages 14–18).”

For this reason, the team suggests future studies with the ABCD data investigate later-developing functional connectivity patterns and their

possible relation to development of depression symptoms at older ages. They said that being able to predict symptoms at later time points following the pre-adolescent scan (5 or 6 years after) is an important goal for future research, as is consideration of how environmental factors such as early-life adversity affect risk profiles for the emergence of depression.

In identifying vulnerability factors that can be discerned in children before adolescence begins, the current study is a step toward early treatment and perhaps one day prevention of depressive disorders in vulnerable youth.

Researchers Develop ‘Mood Instability’ Measures to Re-Think How Best to Care for Bipolar Disorder Patients

Diagnostic Tools/Early Intervention; Next-Generation Therapies: **Bipolar Disorder**

Story Highlights:

New evidence calls into question the assumption in clinical medicine that periods between low and high mood in bipolar disorder are ones of “normal” mood. The finding of considerable “mood instability” between episodes of depression and mania/hypomania could lead to future efforts to treat such mood fluctuations to improve quality of life for patients.

Journal:
Nature Mental Health
August 8, 2024

Research led by 2022 BBRF Young Investigator **Sarah H. Sperry, Ph.D.**, of the University of Michigan, has led to her team’s development of an innovative method for assessing the course of bipolar disorder (BD) in those who have been diagnosed.

The new method, which focuses on assessing mood instability in individual patients—frequently and over an extended period—could result, if it were widely adopted, in what Dr. Sperry and colleagues call “a paradigm shift in monitoring outcomes” in BD.

Accurate diagnosis of bipolar disorder is often delayed, Dr. Sperry and colleagues note in their new paper appearing in *Nature Mental Health*, “and even when diagnosed properly, efficient treatment options remain stagnant.” It is standard practice, they explain, to think of BD as a “relapsing disorder,” in which distinct episodes of depression, mania, or hypomania alternate with periods of normal mood. The deep lows of depressive episodes stand in contrast to the extreme highs of mania in Bipolar I or the somewhat lesser highs of hypomania in Bipolar II.

“Relapsing” is an important term and point of reference for the research by Dr. Sperry and colleagues. As BD is usually thought of, in between depressive episodes on the one hand, and episodes of either mania or hypomania on the other hand, there are periods of “remission,” which are conceived as those periods

of time when “euthymic” or normal mood prevails—neither qualifying as depressed nor manic/hypomanic. These periods can be of widely varying duration, long or short, depending on the patient.

But, say Dr. Sperry and colleagues, including senior author on the new paper, **Melvin G. McInnis, M.D., FRCPsych** (a 1999 BBRF Independent Investigator and 1992 Young Investigator), the picture is changing because, in recent years, more and more attention has been devoted to studying people with BD over time—what are called longitudinal studies—and assessing them repeatedly over short time periods. There are now wearable digital technologies that enable monitoring of certain behavioral patterns minute by minute and hour by hour. Assessments in the new study did not employ such technologies, but rather depended on patients’ self-assessments every 2 months.

In the study that gave rise to their new “paradigm” for assessing BD, Dr. Sperry and colleagues used data from 603 people collected over 10 years or longer for each individual. These people had been enrolled in the Prechter Longitudinal Study of Bipolar Disorder (PLS-BD), and included 385 people diagnosed with BD, 71 with other or nonaffective diagnoses, and 147 with no history of psychiatric diagnosis and none among first-degree relatives. The participants were



Sarah H. Sperry, Ph.D.

University of Michigan
2022 BBRF Young Investigator

typically in their 30s at study entry and White; about 60% were female.

What made this study distinctive was the repeated monitoring of participants, every 2 months, over 10 or more years. The so-called PROMS (patient-reported outcome measures) included assessment questionnaires for depression, mania/hypomania, anxiety, and overall mental and physical functioning.

The scores generated by all of these questionnaires were used to calculate the variation in each measure for each participant, combining results over rolling 1-year periods, as the study progressed. Advanced statistical calculations enabled the team to establish three broad “thresholds” for assessing the degree of variations in symptoms—labeled “mood (in) stability”—over the entire cohort. Low, moderate, and high instability were identified.

The purpose in designing the study in this way was to test the team’s hypothesis about a new way of assessing what each patient with BD experiences over the course of time. Are “remissions” between “episodes” the best way to characterize what happens to most people with BD?

This question has great bearing on what kind of care patients receive. Current gold-standard clinical care of BD aims to reduce symptoms or achieve remission in both depressive and manic/hypomanic episodes, as well as to prevent such episodes from occurring where possible. Dr. Sperry has devoted her young career to investigating whether some or

even many BD patients experience important mood shifts—significant “mood instability”—even in those periods usually thought of as “between” episodes. Evidence of such instability would call into question the standard assumption in clinical medicine that the “in-between” periods are ones of essentially “normal” mood, what psychiatrists call euthymia. If there is considerable mood instability “in between” episodes of diagnosable depression and mania/hypomania, how might that affect the care BD patients receive and their outcomes?

With the hypothesis that “alternative ways to measure change in BD [status] based on mood instability are needed,” the team did arrive at what they consider a “clinically meaningful instability score that is simple to calculate and easy to interpret.” They were also able to identify low, moderate, and high instability thresholds, based on individual scores, and used these classifiers to try to predict how individual patients fared both mentally and physically over time.

First, compared with participants in the study who had psychiatric issues other than BD as well as healthy controls, those participants with a BD diagnosis consistently had higher 1-year rolling “mood instability” scores. The effects were largest with respect to symptoms of depression and mania/hypomania, and smaller but still significant for anxiety. Those with BD, compared with those with other psychiatric issues, had larger instability variations in their scores within the 1-year time horizons, indicating to the team that this specifically reflects the trajectory of BD.

Regarding the power of the scores to predict: those participants with higher rolling 1-year instability scores in the measure of depression symptoms tended, if they were in the moderate- and high-threshold subgroups, to have worse mental and physical health functioning. Other questionnaire-based assessors of variations in individual mood status over rolling one-year periods were useful, in various ways, for predicting other outcomes for BD patients as the months and years of the study passed.

Broadly speaking, the team said, their results “provide guidelines for practical clinical monitoring in the daily patient-care setting, and offer an innovative strategy for outcomes assessments.”

The team said it might then be possible for research to tackle the question of how to reduce mood instability—fluctuations over comparatively short periods of time within each patient—as a way of improving their outcomes, which include not only mental and physical functioning, but also feelings of well-being, cognition, interpersonal relationships, and occupational outcomes.

Evidence Grows of the Effectiveness of Rapid-Acting Brain Stimulation to Treat Bipolar Depression

Next-Generation Therapies: **Bipolar Disorder**

Story Highlights:

New research is providing additional evidence of the effectiveness and safety of SAINT, a rapid-acting non-invasive brain stimulation therapy, to treat people suffering from bipolar depression.

Journals:

Williams et al:
Journal of Affective Disorders, Brain Stimulation,
August 16, 2024
March 4, 2024

Sheline et al:
JAMA Psychiatry,
July 10, 2024

Published research is providing additional evidence of the effectiveness and safety of rapid-acting non-invasive brain stimulation therapy to treat people suffering from bipolar depression.

Bipolar disorder (BD) involves fluctuations in mood and energy that can result in severe cognitive and functional impairment. High-energy moods (mania or less intense hypomania) can be treated with lithium or anticonvulsants. Depressive moods are treated with a variety of medications. Although patterns can vary greatly from patient to patient, on average, bipolar disorder patients are in the “depressive phase” of the illness between 70% to 80% of the time, and a significant number do not respond satisfactorily or cannot tolerate drug therapies which include mood stabilizers, antidepressants, and antipsychotic medicines. There is also the issue of testing potential drug therapies one by one to see by trial and error which (if any) are effective. Each trial takes weeks and costs the patient more time.

The emerging evidence regarding use of rapid-acting non-invasive brain stimulation to treat bipolar depression is of particular importance given the greatly elevated risk of suicide among adults with BD (estimated at 10%–15% or higher). The new evidence is about a protocol called SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), pioneered

by BBRF grantee and prize winner **Nolan R. Williams, M.D.**, of Stanford University.

As Dr. Williams and colleagues reported beginning in 2018, SAINT, non-invasively delivering 90,000 magnetic pulses to modify cortical activity over the course of only 5 days, has had remarkable efficacy in small initial trials, enabling a majority of patients with severe, refractory depression to achieve remission in just days. SAINT was approved for commercialization by the FDA for use in depression early in 2024.

SAINT uses an accelerated form of iTBS (aiTBS: accelerated intermittent theta-burst stimulation), which delivers five times as many magnetic pulses to patients than conventional TMS (transcranial magnetic stimulation) in a course of therapy. TMS, pioneered by BBRF Scientific Council member and past grantee Mark S. George, M.D. and others and approved by the FDA in 2009, is usually given five times a week in 38-minute sessions over 6 weeks. In SAINT, over a 5-day course, ten stimulation sessions are given each day separated by about an hour.

SAINT is individually targeted. A resting-state functional MRI scan of the patient’s brain made prior to treatment provides an optimized location at which to focus the stimulation. Dr. Williams and colleagues aim the pulses at a spot on the scalp above the left dorsolateral prefrontal cortex (DLPFC)



Nolan R. Williams, M.D.

Stanford University
2024 BBRF Colvin Prize
2019 BBRF Klerman Prize
2018, 2016 BBRF Young Investigator



Yvette I. Sheline, M.D.

University of Pennsylvania
BBRF Scientific Council
2005, 2002 BBRF Independent Investigator
1998 BBRF Young Investigator

that, when stimulated, generates a specific neural response in a brain area much farther below the scalp called the subgenual anterior cingulate cortex (sgACC). Precise targeting, Dr. Williams and colleagues believe, can enhance the therapeutic impact in patients receiving SAINT.

The approach has been highly effective in treating patients with unipolar depression (i.e., patients with a major depression diagnosis, as opposed to BD, which also involves episodes of mania/hypomania).

In July, BBRF Scientific Council member and three-time grantee **Yvette I. Sheline, M.D.**, and colleagues at the University of Pennsylvania, reported on a randomized, blinded aiTBS clinical trial involving 24 patients currently experiencing a depressive bipolar episode that had not responded to prior treatment attempts. That trial generated “a large antidepressant effect” in patients who received the therapy, whose depression scores “were significantly lower” after 5 days of treatment. Five of 12 patients receiving the active treatment had achieved a remission at that point. That trial utilized an identical aiTBS stimulation approach to SAINT and a similar resting-state fMRI targeting approach.

Now, in the *Journal of Affective Disorders*, Dr. Williams and colleagues at Stanford and Johns Hopkins Universities have reported similarly impressive results with SAINT in treatment-resistant bipolar depression. SAINT was not paired in this “open-label” trial with an alternate or placebo treatment; all 10 patients knew the treatment they were receiving. Each patient

was carefully monitored for possible “emergent” mania symptoms, which in past conventional rTMS trials had been observed in rare cases.

All of the patients were able to receive all of the planned treatment sessions over the 5 days of the trial. There were no serious adverse side effects including an absence of emergent mania symptoms, and no negative impact on cognition. Importantly, SAINT appeared to work just as powerfully as it had in the past for unipolar depression patients.

The participants, who were rated with moderate to severe bipolar depression that had resisted treatment in the current episode, had an average reduction of about 17 points on a depression scale called MADRS. (The typical participant had entered the trial with a score of about 30.) Immediately following the end of the 5-day course of treatment, half the participants had experienced a response (defined as a reduction in depression symptoms of 50% or more); 40% qualified for remission (in essence, the absence of depression symptoms). The remission rate grew to 60% one month following the completion of treatments.

All of the participants in the SAINT trial were diagnosed with bipolar I depression—they had been diagnosed on the basis of experiences of depression and full mania. Several months earlier, another small open-label SAINT study conducted by Dr. Williams and Stanford and Johns Hopkins colleagues included 2 patients with bipolar I (depression and mania) as well as 5 patients diagnosed with bipolar II (depression and

hypomania—a less intense form of mania). As reported in the journal *Brain Stimulation*, this study also generated impressive results: large decreases in depression scores, remissions in some patients, and an absence of severe side effects, including an absence of emergent hypo/mania.

Having now shown powerful preliminary results (in terms of safety, tolerability, feasibility, and efficacy) with individuals with moderate and severe bipolar depression—patients with both bipolar I and bipolar II diagnoses—Dr. Williams and colleagues in both recent publications say the time is right for much larger, double-blind, placebo-controlled trials for SAINT in bipolar depression, with larger and more diverse patient samples needed to confirm both efficacy and safety.

While there are “a few first-line treatment options for bipolar depression,” they noted in one of their recent papers, “none are rapid-acting.” SAINT, if one day approved for depression in BD, would address both “the time constraints posed by 6-week conventional rTMS course and the need for fast-acting treatments for acute suicidality in high-risk populations,” they noted.

The Sheline team included **Nicholas L. Balderston, Ph.D.**, 2021 BBRF Klerman Prize, 2021 and 2018 BBRF Young Investigator; and **Robin Cash, Ph.D.**, 2020 BBRF Young Investigator. Among co-authors of one the Williams papers was **Peter Zandi, Ph.D., MPH, MHS**, a 2004 BBRF Young Investigator.

A Possible Biomarker for Cocaine Misuse and a Novel Treatment for Cocaine Addiction Based on Compound in Rosemary

Diagnostic Tools/Early Intervention; Next-Generation Therapies: **Addiction**

Story Highlights:

Researchers found that activity of certain neurons in the brain's globus pallidus can predict behavioral responses to cocaine in mice. This potential biomarker also suggests a possible basis for novel treatment of cocaine and other substance abuse: administration of carnosic acid obtained from rosemary extract.

Journal:
Neuron
August 16, 2024

Researchers led by 2017 BBRF Young Investigator **Kevin T. Beier, Ph.D.**, have discovered a way to predict individual behavioral responses to cocaine in mice never exposed to the drug, and have also found that carnosic acid, which is found in extract from the herb rosemary, can reduce volitional cocaine use in mice by reducing activity in a key brain circuit that controls cocaine-induced behavioral changes.

Dr. Beier, of the University of California, Irvine, is among researchers who in recent years have studied the system that regulates release of the neurotransmitter dopamine from a region called the ventral tegmental area (VTA). Dopamine release from cells in this area has been implicated in all phases of substance misuse (not only cocaine), from the initial rewarding effect to withdrawal and ultimately to compulsive drug-seeking.

But as Dr. Beier and colleagues note in their new paper, appearing in the journal *Neuron*, "it is precisely because the dopamine system is central to so many functions that it has proved to be a poor target to combat substance abuse." Given dopamine's ubiquity in the brain, rather than try to regulate the dopamine system as a whole as a way of modifying drug addiction, researchers including Dr. Beier and colleagues have turned to the idea of modulating signaling in particular dopamine subcircuits.

In prior research, Dr. Beier's team demonstrated the role of a key subcircuit centered on dopamine-releasing cells in the VTA that contributed to some of the later stages of substance misuse including withdrawal and reinstatement of use after forced cessation. In the team's new experiments just reported, they sought to map circuits that control the earliest stages of substance use disorder (SUD)—those that mediate drug reward as well as the urge to take the drug.

While most SUD research has focused on several brain regions involved in reward and aversion processing including the VTA, nucleus accumbens, and medial prefrontal cortex, Dr. Beier's team has focused on a less-explored region called the globus pallidus externus (GPe), which appears to play an important role in mediating behavioral changes that occur following use of an addictive drug like cocaine.

The question in the new study was which areas of the brain controlled individual differences in behavioral response to cocaine. While cocaine is an addictive drug, not everyone who uses cocaine develops an SUD; Dr. Beier's team was interested in whether individual differences in behavioral responses to cocaine could be predicted prior to repeated use of cocaine. Through a series of experiments in living mice, the team was able, first, to implicate the GPe



Kevin T. Beier, Ph.D.

University of California Irvine School of Medicine
2017 BBRF Young Investigator

“as the central mediator” in cocaine reward as well as in sensitization to the drug (responding more strongly to each subsequent drug exposure). Beyond this, they were able to show that by dampening the activity of parvalbumin (PV)-containing cells in the GPe, they could reduce volitional cocaine intake in mice. This likely occurred through modulating activity in a subset of dopamine cells in the VTA that critically regulate cocaine reward. PV is a protein whose presence is used to distinguish a particular subset of neurons in the brain.

Importantly, the researchers identified a specific mechanism that appeared to be essential in getting this response: they “dampened” GPe cell activity by activating proteins called KCNQ3 and KCNQ5. These are proteins that help regulate the flow of charged molecules (ions) of potassium into and out of nerve cells. The flow of ions like potassium is one of the essential ways that nerve cells regulate their activity—whether and how often they fire.

Interestingly, the experiments demonstrated that in cocaine-naïve mice, levels of firing activity of PV-containing GPe cells correlated directly with how rewarding a mouse found a subsequent cocaine dose to be. Cocaine-naïve animals with high levels of activity in such cells were more susceptible to long-lasting behavioral effects of cocaine than those with low levels of activity.

This result provided a rationale to test whether artificially lowering the activity level in PV-containing GPe cells would lower the behavioral response to

cocaine, including the desire of animals to self-administer it when offered. This proved to be the case. The effect was the same in mice of both sexes and was thought by the team to occur via the blocking or lowering of reward from taking the drug.

There were two important takeaways. One is that measuring the baseline activity of PV-containing cells in the GPe is a potential biomarker for cocaine sensitivity—perhaps in people, as in mice. This is important, says Dr. Beier, because “only a subset of people is vulnerable to developing substance-use disorder, but we cannot yet identify who they are. If globus pallidus cell activity can effectively predict behavioral responses to cocaine, it could serve as a biomarker for the most vulnerable, which could be an important method for reducing dependence and ultimately, substance misuse.”

The second major takeaway was that the method used to lower the activity of PV-containing GPe cells—administration of carnosic acid obtained from rosemary extract—is a potential novel treatment for cocaine-use disorder and perhaps for other substance use disorders. As Dr. Beier notes, “there are no effective therapeutics for dependence on psychostimulants like cocaine. Our study deepens our understanding of basic brain mechanisms that increase vulnerability and provides a foundation for development of new interventions.”

The team noted: “Carnosic acid has [previously] been reported to exhibit wide-ranging health benefits,

demonstrating anti-inflammatory, antiviral, anti-obesity, anti-carcinogenic, and anti-depressive properties, and generally shows promise as a neuroprotective agent, including against Alzheimer’s and Parkinson disease. However, to our knowledge, this is the first report of its potential as an anti-addictive agent. As such, we should note that much remains unknown about carnosic acid’s effects on the brain, both acutely and long term.”

Translation of results in rodents to humans is a major undertaking. The next steps in the research include thoroughly assessing any negative side effects of carnosic acid, and determining optimal dosages and timing of treatments. This would precede any tests of efficacy in people. The team is also interested in testing carnosic acid’s effectiveness in reducing the desire for other drugs.

The research team included **Jason Aoto, Ph.D.**, 2016 BBRF Young Investigator.

tDCS Non-Invasive Brain Stimulation Fares Well in Trials for PTSD and Major Depression

Next-Generation Therapies: PTSD, Depression

Story Highlights:

Results of two recently published clinical trials co-led by BBRF grantees demonstrate the versatility and potential effectiveness of transcranial direct current stimulation (tDCS), low-power form of non-invasive brain stimulation, in reducing symptoms of PTSD and major depressive disorder.

Journals:

Fu et al:
Nature Medicine,
October 21, 2024

van 't Wout-Frank et al:
JAMA Psychiatry,
March 6, 2024

Results of two recently published clinical trials demonstrate the versatility and potential effectiveness of transcranial direct current stimulation (tDCS) in reducing symptoms of psychiatric illness, specifically, in PTSD and major depressive disorder. BBRF grantees co-led both trials, which were entirely independent of one another.

tDCS is a form of non-invasive brain stimulation. It is less powerful than the most widely used form of non-invasive stimulation, TMS (transcranial magnetic stimulation) and rapid-acting variants such as SAINT (Stanford Accelerated Intelligent Neuromodulatory Therapy).

tDCS applies a weak direct current (0.5 to 2 milliamperes) to the scalp via two electrodes, typically held in place by rubber headbands or embedded in a cap worn by the patient. The direct current of tDCS is thought to alter the excitability of brain cells beneath the scalp, but does not directly trigger nerve cell firing or inhibition as in TMS. Unlike some forms of iTBS such as the SAINT protocol, tDCS is not rapid-acting.

In *JAMA Psychiatry*, a team co-led by **Noah S. Philip, M.D.**, a 2024 BBRF Distinguished Investigator, and **Mascha van 't Wout-Frank, Ph.D.**, a 2010 BBRF Young Investigator, both of Brown University, reported encouraging results of a double-blinded, randomized, placebo-controlled trial using tDCS to treat U.S. military veterans with warzone-related PTSD.

At the VA Providence (RI) Healthcare

System, 54 veterans who had chronic PTSD and warzone-related exposure were recruited for the trial.

These individuals were randomized into two groups: 26 received active tDCS which was delivered during six 25-minute sessions of virtual reality-based exposure therapy sessions given over a period of 2 to 3 weeks. tDCS was delivered at 2 milliamperes via a rubber band over the forehead, with the anode targeting the brain's ventromedial prefrontal cortex (vmPFC). Twenty-eight participants received a placebo ("sham") version of tDCS that was designed to be indistinguishable from active tDCS; no electricity was delivered to the scalp. All 54 participants received the active/sham tDCS while they were receiving a form of virtual reality (VR) exposure that was designed to be immersive yet not based specifically on each participant's traumatic experience(s); rather it was designed to incorporate "broadly shared traumatic experiences."

Active tDCS simultaneously delivered with VR exposure, relative to the "sham" version, did yield "significantly meaningful" reductions in PTSD symptoms, measured by a standard, self-report scale—improvements that were observed to increase over time. Those in the active tDCS group experienced enhanced psychophysiological habituation to VR warzone cues, which the team suggested may indicate that the combined treatment facilitated learning and memory, and helped patients both



Mascha van 't Wout-Frank, Ph.D.

Brown University
2010 BBRF Young Investigator



Cynthia H. Y. Fu, M.D., Ph.D.

King's College London, UK
2006, 2002 BBRF Young Investigator

anticipate their fears and learn how to extinguish them. PTSD symptoms continued to improve over time in the active tDCS treatment group over the month following the end of treatments. The results at 3 months were harder to interpret due to dropouts from the participant group, lowering the statistical power of the numbers. Nonetheless, the active tDCS treatment also showed significant and meaningful improved social and occupational functioning at 3 months. Adverse effects were mild and typical for tDCS—most often, tingling or itching and skin redness under the electrodes.

Given that both parts of the active treatment (tDCS during VR) are inexpensive and “accessible,” the team said that if the current results are replicated in much larger groups, this brief tDCS-augmented VR intervention might be widely applied, including perhaps in home-based use.

The second recently reported tDCS trial explored home-based tDCS in the treatment of people diagnosed with major depressive disorder. In a fully remote, phase 2, randomized, placebo-based study, researchers tested a 10-week home-based course of tDCS. Leaders of the study included **Cynthia H. Y. Fu, M.D., Ph.D.**, a 2006 and 2002 BBRF Young Investigator; **Allan H. Young, M.D., Ph.D.**, a 2000 BBRF Independent Investigator; and **Jair Soares, M.D., Ph.D.**, a 2002 BBRF Independent Investigator and 1999 and 1997 Young Investigator.

The team reported results of their trial in *Nature Medicine*. They recruited 174 participants, average age in the

late 30s, and equally divided them into two groups. One received 5 self-administered active tDCS treatments per week for 3 weeks, then 3 sessions weekly for 7 weeks. The other group received a sham version of the same treatments. Then, in a second 10-week period, all participants received active tDCS. Each tDCS session lasted 30 minutes. The anode of the device was placed over the location on the scalp corresponding with the brain's left dorsolateral prefrontal cortex (DLPFC); the cathode was placed over right DLPFC. tDCS was delivered at 2 milliamperes, the same strength as in the PTSD trial.

tDCS is amenable to self-administered home use, the team said, since it has proven both portable and safe in many past tests.

The participants in the trial were at least moderately depressed—their average score on a standard scale called HDRS was 19 (below 16 is considered “mild” and above 24 “severe”). About one-third were not receiving current treatment; two-thirds were taking antidepressant medication and about 15% were in psychotherapy.

The group receiving the active tDCS treatment experienced “a significant improvement” in depression symptoms as measured by the HDRS score; the average decrease in score was 9.4 points and the score after 10 weeks was 9.5, on average. Those receiving placebo also improved: an average decrease of about 7 points and a score after week 10 of about 11.6. But the response rate to the active treatment was also significantly greater: nearly

60% for those receiving tDCS compared with about 38% for the placebo group. 45% in the active group had a remission after 10 weeks, compared with about 22% in the placebo group.

The significantly better results in those receiving active tDCS was also reflected in other depression rating scores as well as in a score based on patient self-reports. Meaningful efficacy was seen in both first-episode depressed participants as well as those with chronic and treatment-resistant major depression.

The second 10 weeks of the trial, in which all participants received active treatment, helped to keep as many participants as possible in the trial until the conclusion. While there were no serious adverse effects of active tDCS, active stimulation was associated with higher rates of skin redness, irritation and dry skin compared with sham stimulation.

In the view of the researchers, the 10-week course of tDCS as tested against placebo in this trial is evidence supporting its consideration as a first-line treatment in the future, although under the assumption that any home-based treatments will include ongoing safety monitoring by consulting medical personnel.

A Strategy to Sharply Blunt Addictive Reward From Opioids While Retaining Their Pain-Relieving Properties

Basic Research; Next-Generation Therapies: **Addiction**

Story Highlights:

Researchers administered the drug JZL184 in mice to raise levels of 2-AG, a naturally occurring neuromodulator in the endocannabinoid system. This greatly reduced reward from opioids but had no impact on opioids' pain-relieving properties, suggesting a possible adjunctive therapy to reduce opioid addiction in pain patients.

Journal:
Science Advances
November 29, 2024

Since the 1990s, deaths due to opioid overdoses have become a leading cause of death for Americans under age 50. While a portion of these deaths are due to recreational use of opioids, many others can be traced to people who became dependent after being prescribed FDA-approved opioid-based drugs, typically for the relief of acute or chronic pain.

Now, a team including BBRF Scientific Council member and three-time BBRF grantee **Francis S. Lee, M.D., Ph.D.**, of Weill Cornell Medicine, and collaborators Anjali Rajadhyaksha, Ph.D., and Arlene Martinez-Rivera, Ph.D., now at Temple University, report finding a way to significantly blunt the rewarding properties of opioids while preserving their analgesic (i.e., pain-relieving) properties. The new research appears in the journal *Science Advances* and could indicate a potentially new therapeutic strategy for opioid-related pain treatments. Four other BBRF grantees were members of the team.

The widespread prevalence of opioid use disorder and the high mortality associated with opioid misuse in connection with medical treatment for pain "has highlighted the urgent need to develop non-opioid analgesic alternatives," write Dr. Lee and colleagues. But "an additional strategy," they note, "is to develop adjunctive treatments that can specifically attenuate the rewarding but not the analgesic properties of opioids."

The team tested its approach in mice undergoing various behavioral tasks tied to opioid rewards. The team's approach was to pharmacologically enhance the brain's endocannabinoid system. This system, which is naturally occurring, helps regulate a wide range of functions in the body ranging from cognition to appetite, mood, memory, and pain, among others. Two endocannabinoid compounds, neuromodulators usually referred to by their chemical abbreviations 2-AG and AEA, interact with cannabinoid receptors called CB1 in cells throughout the body. These receptors are widespread in the central nervous system and play key roles in regulating the release of neurotransmitters such as dopamine.

One key place in the brain where 2-AG and AEA interact with CB1 receptors is in the circuit linking the ventral tegmental area (VTA) and the nucleus accumbens (NAc), which are central to the brain's reward system. This circuit is at the core of the opioid reward response. When a person (or mouse) ingests an opioid, dopamine levels in the NAc increase markedly, an action that has been directly linked with the feeling of reward that occurs after taking the drug.

Much research has been devoted to understanding how the endocannabinoid system works, and how it is perturbed by chronic or acute drug use. Cannabis from plants targets the CB1 receptor. Abuse of



Francis S. Lee, M.D., Ph.D.

Weill Cornell Medicine
BBRF Scientific Council
2010 BBRF Independent Investigator
2005, 2002 BBRF Young Investigator

cannabis is thought to dysregulate the body's endocannabinoid system, with various potential impacts including dependency.

Studies of the interplay between the endocannabinoid system and opioid reward has mainly focused on two enzymes (called catabolic enzymes) that tightly regulate the level of the two endocannabinoid molecules, 2-AG and AEA. One of these enzymes, called MAGL, breaks down 2-AG. Another, called FAAH, breaks down AEA. Previous research has indicated that inhibiting these two enzymes has distinct and sometimes opposing effects on opioid reward, highlighting the complexity of these systems.

Drs. Martinez-Rivera, Rajadhyaksha, and Lee set out to systematically study and clarify the specific impact of raising 2-AG and AEA levels in the brain upon the rewarding effect of opioid intake. Using a MAGL inhibitor called JZL184, the team conducted experiments throughout the mouse system as well as in a specific brain region. They found that raising levels of 2-AG greatly reduced opioid reward in various opioid reward tests, including in mice trained to self-administer oxycodone intravenously. Interestingly, using a different compound to raise levels of the other endocannabinoid, AEA, had no effect on morphine reward.

Further experiments focused on the circuitry known to be involved in reward. When the researchers blocked MAGL in the mouse brain's VTA, they found that the rewarding effects of morphine were reduced. They also observed that a decrease in reward

was linked to lower activity of the NAc and lower levels of dopamine.

In short, the experiments demonstrated that 2-AG selectively dampens the rewarding effects of opioids—by disrupting signaling between the VTA and NAc. Equally important, while JZL184 substantially reduced opioid reward, two separate tests demonstrated that it had no effect on the analgesic properties of the opioids tested.

For this reason, the team concluded that their findings “provide a compelling rationale for developing a new class of adjunctive endocannabinoid-based treatments that could dissociate the rewarding and analgesic properties of opioids.” In other words, they say, it may be possible to develop a drug similar to JZL184 that can be taken alongside an opioid to treat chronic or acute pain while greatly reducing (or even eliminating) the risk of addiction.

Developing a drug treatment that alleviates pain without the addictive side effects of opioids could be a major step toward addressing one key component of the opioid crisis, the team said. “By targeting the brain's reward system without affecting pain relief, we may be able to create a treatment that provides the benefits of opioids while avoiding their addictive potential—an exciting step forward,” said Dr. Rajadhyaksha.

The research team included **Conor Liston, M.D., Ph.D.**, 2013 BBRF Young Investigator; **Virginia M. Pickel, Ph.D.**, 2001 BBRF Distinguished Investigator; **Lisa A. Briand, Ph.D.**, 2015 BBRF Young Investigator; and **Kristen Pleil, Ph.D.**, 2017 BBRF Young Investigator.

Our Scientific Council

- 192 Scientific Council Members
- 46 Chairs of Psychiatry & Neuroscience Departments
- 45 Members of the National Academy of Medicine
- 13 National Institutes of Health Chiefs & Directors
- 7 Members of the National Academy of Sciences
- 3 Recipients of the National Medal of Science
- 1 Nobel Prize Winner

PRESIDENT

Judith M. Ford, Ph.D.

VICE PRESIDENT

John H. Krystal, M.D.

Ted Abel, Ph.D.

Anissa Abi-Dargham, M.D.

Nii A. Addy, Ph.D.

Susanne E. Ahmari, M.D., Ph.D.

Olusola Ajilore, M.D., Ph.D.

Schahram Akbarian, M.D., Ph.D.

Susan G. Amara, Ph.D.

Stewart A. Anderson, M.D.

Nancy C. Andreasen, M.D., Ph.D.

Carmen Andreescu, M.D.

Victoria Arango, Ph.D.

Amy F.T. Arnsten, Ph.D.

Gary S. Aston-Jones, Ph.D.

Randy P. Auerbach, Ph.D.

Tracy L. Bale, Ph.D.

Debra A. Bangasser, Ph.D.

Tallie Z. Baram, M.D., Ph.D.

Deanna M. Barch, Ph.D.

Samuel H. Barondes, M.D.

Carrie E. Bearden, Ph.D.

Francine M. Benes, M.D., Ph.D.

Karen F. Berman, M.D.

Wade H. Berrettini, M.D., Ph.D.

Randy D. Blakely, Ph.D.

Julie A. Blendy, Ph.D.

Pierre Blier, M.D., Ph.D.

Hilary P. Blumberg, M.D.

Vadim Bolshakov, Ph.D.

Kathleen T. Brady, M.D., Ph.D.

Kristen J. Brennand, Ph.D.

Robert W. Buchanan, M.D.

William E. Bunney, Jr., M.D.

Joseph D. Buxbaum, Ph.D.

Tyrone D. Cannon, Ph.D.

William Carlezon, Ph.D.

Cameron S. Carter, M.D.

Edwin H. Cook, Jr., M.D.

Richard Coppola, D.Sc.

Christopher W. Cowan, Ph.D.

Ronald L. Cowan, M.D., Ph.D.

Jacqueline N. Crawley, Ph.D.

Kathryn R. Cullen, M.D.

Z. Jeff Daskalakis, M.D., Ph.D.

Karl Deisseroth, M.D., Ph.D.

J. Raymond DePaulo, Jr., M.D.

Robert Desimone, Ph.D.

Ariel Y. Deutch, Ph.D.

Ralph DiLeone, Ph.D.

Lisa Beth Dixon, M.D., M.P.H.

Wayne C. Drevets, M.D.

Kafui Dzirasa, M.D., Ph.D.

André Fenton, Ph.D.

Robert L. Findling, M.D., MBA

Cecilia Flores, Ph.D.

Stan B. Floresco, Ph.D.

Erika Forbes, Ph.D.

Alan Frazer, Ph.D.

Robert Freedman, M.D.

Aurelio Galli, Ph.D.

Mark S. George, M.D.

Elliot S. Gershon, M.D.

Mark A. Geyer, Ph.D.

Jay N. Giedd, M.D.

Jay A. Gingrich, M.D., Ph.D.

James M. Gold, Ph.D.

David Goldman, M.D.

Andrea Beth Goldschmidt, Ph.D.

Rita Z. Goldstein, Ph.D.

Joshua A. Gordon, M.D., Ph.D.

Elizabeth Gould, Ph.D.

Anthony A. Grace, Ph.D.

Dorothy E. Grice, M.D.

Raquel E. Gur, M.D., Ph.D.

Suzanne N. Haber, Ph.D.

Philip D. Harvey, Ph.D.

Stephan Heckers, M.D.

René Hen, Ph.D.

Takao K. Hensch, Ph.D.

Elliot Hong, M.D.

Laura Marianne Huckins, Ph.D.

Yasmin L. Hurd, Ph.D.

Robert B. Innis, M.D., Ph.D.

Alicia Izquierdo, Ph.D.

Jonathan A. Javitch, M.D., Ph.D.

Daniel C. Javitt, M.D., Ph.D.

Dilip V. Jeste, M.D.

Shafali Spurling Jeste, M.D.

René S. Kahn, M.D., Ph.D.

Ned H. Kalin, M.D.

Peter W. Kalivas, Ph.D.

Eric R. Kandel, M.D.

Thomas L. Kash, Ph.D.

Ege T. Kavalali, Ph.D.

Richard S.E. Keefe, Ph.D.

Christoph Kellendonk, Ph.D.

Martin B. Keller, M.D.

John R. Kelsoe, M.D.

Kenneth S. Kendler, M.D.

James L. Kennedy, M.D.

Robert M. Kessler, M.D.

Mazen Kheirbek, Ph.D.

Mary-Claire King, Ph.D.

Arnold Kriegstein, M.D., Ph.D.

Cecile D. Ladouceur, Ph.D.

Amanda J. Law, Ph.D.

James F. Leckman, M.D., Ph.D.

Ellen Lee, M.D.

Francis S. Lee, M.D., Ph.D.

Robert H. Lenox, M.D.

David A. Lewis, M.D.

Jeffrey A. Lieberman, M.D.

Gregory A. Light, Ph.D.

Kelvin O. Lim, M.D.

Sarah Hollingsworth Lisanby, M.D.

Daniel Lodge, Ph.D.

Joan L. Luby, M.D.

Irwin Lucki, Ph.D.

Beatriz Luna, Ph.D.

Gary Lynch, Ph.D.

Robert C. Malenka, M.D., Ph.D.

Anil K. Malhotra, M.D.

J. John Mann, M.D.

John S. March, M.D., M.P.H.

Stephen Maren, Ph.D.

Keri Martinowich, Ph.D.

Daniel H. Mathalon, Ph.D., M.D.

Helen S. Mayberg, M.D.

Carla A. Mazefsky, Ph.D.

Colleen A. McClung, Ph.D.

Ronald McKay, Ph.D.

James H. Meador-Woodruff, M.D.

Herbert Y. Meltzer, M.D.

Kathleen R. Merikangas, Ph.D.

Guo-Li Ming, M.D., Ph.D.

Karoly Mirnics, M.D., Ph.D.

Bitá Moghaddam, Ph.D.

Lisa M. Monteggia, Ph.D.

David A. Morilak, Ph.D.

Charles B. Nemeroff, M.D., Ph.D.

Eric J. Nestler, M.D., Ph.D.

Thomas Neylan, Ph.D.

Andrew A. Nierenberg, M.D.

Patricio O'Donnell, M.D., Ph.D.

Dost Ongur, M.D., Ph.D.

Maria A. Oquendo, M.D., Ph.D.

Martin P. Paulus, M.D.

Godfrey D. Pearlson, M.D., Ph.D.

Peter Penzes, Ph.D.

Mary L. Phillips, M.D., M.D. (CANTAB)

Marina R. Picciotto, Ph.D.

Daniel S. Pine, M.D.

Robert M. Post, M.D.

James B. Potash, M.D., M.P.H.

Susan Powell, Ph.D.

Pasko Rakic, M.D., Ph.D.

Perry F. Renshaw, M.D., Ph.D., M.B.A.

Kerry J. Ressler, M.D., Ph.D.

Victoria B. Risbrough, Ph.D.

Carolyn Rodriguez, M.D., Ph.D.

Bryan L. Roth, M.D., Ph.D.

Laura M. Rowland, Ph.D.

Scott J. Russo, Ph.D.

Gerard Sanacora, M.D., Ph.D.

Akira Sawa, M.D., Ph.D.

Alan F. Schatzberg, M.D.

Nina R. Schooler, Ph.D.

Robert Schwarcz, Ph.D.

Yvette I. Sheline, M.D.

David A. Silbersweig, M.D.

Vikaas S. Sohal, M.D., Ph.D.

Matthew W. State, M.D., Ph.D.

Murray B. Stein, M.D., M.P.H.,
F.R.C.F.C.

Joanna C. Steinglass, M.D.

Stephen M. Strakowski, M.D.

Carol A. Tamminga, M.D.

Laurence H. Tecott, M.D., Ph.D.

Flora M. Vaccarino, M.D., Ph.D.

Rita J. Valentino, Ph.D.

Jeremy M. Veenstra-VanderWeele, M.D.

Susan M. Voglmaier, M.D., Ph.D.

Aristotle N. Voineskos, M.D., Ph.D.

Nora D. Volkow, M.D.

Karen Dineen Wagner, M.D., Ph.D.

Daniel R. Weinberger, M.D.

Myrna M. Weissman, Ph.D.

Rachel Yehuda, Ph.D.,

Jared W. Young, Ph.D.

L. Trevor Young, M.D., Ph.D.,
F.R.C.P.C., F.C.A.H.S.

Carlos A. Zarate, Jr., M.D.

Jon-Kar Zubieta, M.D., Ph.D.

2024 New BBRF Scientific Council Members

The high quality of the research we fund is made possible by the BBRF Scientific Council.

This group of 192 prominent mental health researchers reviews each grant application and selects the most promising ideas with the greatest potential to lead to breakthroughs.

The Scientific Council guides the Foundation to fund creative and impactful basic, translational, and clinical research relevant to the whole spectrum of mental health.

We welcome our newest members.



Cecilia Flores, Ph.D.
McGill University



Erika Forbes, Ph.D.
University of Pittsburgh
2014 Independent Investigator Grantee
2006 Young Investigator Grantee



Mazen Kheirbek, Ph.D.
University of California San Francisco
2010 Young Investigator Grantee



Ellen Lee, M.D.
University California San Diego
2020 Klerman Prize for Exceptional Clinical Research
2017 Young Investigator Grantee



Daniel Lodge, Ph.D.
University of Texas Health Science Center at San Antonio
2009, 2006 Young Investigator Grantee



Tom Neylan, Ph.D.
University of California San Francisco
1994 Young Investigator Grantee



Rachel Yehuda, Ph.D.
Icahn School of Medicine at Mount Sinai
2016 Distinguished Investigator Grantee

“Each year, we grow the Council by adding a few new members who are committed to our mission, and importantly, who are expert in the new ‘next generation’ technologies being proposed and who are actively investigating the neurobiology of serious mental illness.”

— Dr. Judith Ford, President of the BBRF Scientific Council

BBRF 2024 GRANTEES

BBRF Grants Drive Scientific Breakthroughs Leading Toward Improved Treatments, Cures, and Methods of Prevention

BY THE NUMBERS SINCE 1987

As of February 2025

AWARDED TO SCIENTISTS



\$462+ MILLION

GRANTS

6,707



GRANTEES

5,605



UNIVERSITIES & MEDICAL CENTERS

605



COUNTRIES, INCLUDING THE U.S.

41

Research Categories



Basic Research

To understand what happens in the brain to cause mental illness



Diagnostic Tools/Early Intervention

To recognize early signs of mental illness and treat as early as possible



New Technologies

To advance or create new ways of studying and understanding the brain



Next-Generation Therapies

To reduce symptoms of mental illness and ultimately cure and prevent brain and behavior disorders

The path to being awarded a BBRF Grant starts with an application. Grant applicants describe why they think their project could help lead to new insights and advances in the field of mental illness. Applicants represent the best and the brightest talent from world-class institutions. BBRF's Scientific Council, led by Dr. Judith Ford, volunteers their time to review and evaluate applications. BBRF Grants support a broad range of the best ideas in brain research. Funding is focused on four priority areas to better understand and treat mental illness, aiming toward prevention and cures:

BBRF 2024 Distinguished Investigator (DI) Grants



The BBRF **Distinguished Investigator Grants** provide support for 10 experienced investigators conducting neurobiological and behavioral research. These grants are funded by the generous support of the WoodNext Foundation, a component fund administered by Greater Houston Community Foundation.

Recipients of the \$100,000, one-year grants are awarded to established scientists who are pursuing particularly innovative research projects which may provide new approaches to understanding or treating psychiatric illness. These grants are among the most competitive in mental health research and demonstrate the power of investigator-initiated research to bring out new and creative ideas.

The 2024 DI's are exploring new frontiers in understanding a wide range of neuropsychiatric disorders, including autism, anxiety, bipolar disorder, schizophrenia and the potential connection between mental illness and cannabis use.



"It is wonderful to see the relaunching of this very important component of BBRF's research portfolio. The DI award program serves a unique niche by supporting established investigators to explore high-risk but also high-yield ideas. We are delighted with the slate of DI award winners this year. The new awards were selected from a large group of highly competitive applications and will support exciting and innovative lines of research consistent with BBRF's mission to better understand and ultimately treat severe mental illness."

Eric J. Nestler, M.D., Ph.D.

Chair of the BBRF Distinguished Investigator Grant Committee

2024 BBRF Distinguished Investigator Grants by Illness

One of these grantees is listed under multiple categories as their grant project is relevant to more than one illness.

ADDICTION / SUBSTANCE USE DISORDERS

Karin Johanna Hendrika Verweij, Ph.D.

 *Basic Research*

ANXIETY DISORDERS

Elizabeth A. Phelps, Ph.D.

 *Next-Generation Therapies*

Carmen Sandi, Ph.D.

 *Next-Generation Therapies*

AUTISM SPECTRUM DISORDERS

Laura Lee Colgin, Ph.D.

 *Basic Research*

BIOLOGY OF THE BRAIN

This project focuses on how the brain works

ADAPTIVE DECISION MAKING

Kate M. Wassum, Ph.D.

 *Basic Research*

BIPOLAR DISORDER

Mary L. Phillips, M.D., M.D. (Cantab)

 *Basic Research*

DEPRESSION

Noah Stephen Philip, M.D.

 *Next-Generation Therapies*

Carmen Sandi, Ph.D.

 *Next-Generation Therapies*

PTSD

Sanjay J. Mathew, M.D.

 *Basic Research*

SCHIZOPHRENIA

Dorit Ben-Shachar, Ph.D., DSc,

 *Basic Research*

 *Next-Generation Therapies*

Peter Penzes, Ph.D.

 *Diagnostic Tools/Early Intervention*

“WoodNext is very proud to support innovative research via the Brain & Behavior Research Foundation Distinguished Investigator Grants with a total commitment of \$5 million across five years. We recognize that scientific research is the key to discovering new pathways to understanding and treating psychiatric illnesses. The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness. We applaud these scientists for their extraordinary dedication, innovation, and leadership.”

Nancy Chan, Executive Director of the WoodNext Foundation

BBRF Young Investigator Grants in 2024



BBRF **Young Investigator Grants** give early-career scientists the initial funding they need to begin to test their ideas and solidify their academic research careers. YI Grants provide scientists with \$35,000/year for two years totaling \$70,000. This seed money enables them to generate the preliminary data, or “proof of concept” that they need to compete for larger grants from traditional funding sources like the National Institutes of Health.

Co-Chairs of the Young Investigator Grant Selection Committee



Judith M. Ford, Ph.D.
Professor, Department of Psychiatry
University of California,
San Francisco
President, BBRF Scientific Council
2003 BBRF Independent Investigator



Suzanne N. Haber, Ph.D.
Professor, Department of Pharmacology and Physiology
University of Rochester School of Medicine and Dentistry
BBRF Scientific Council Member
2011 BBRF Distinguished Investigator

“The Young Investigator Grants are the crowning jewel of BBRF. They provide crucial funding for our rising stars in clinical and basic science who are at the frontier of understanding, probing and developing new therapies for mental illness. The awards allow these investigators to explore innovative approaches and generate preliminary data for larger grants from other sources, including the National Institutes of Health (NIH). Moreover, these competitive and prestigious BBRF grants are highly regarded by granting agencies. Years later, grantees regularly express their gratitude for having received Young Investigator awards, citing how influential these grants were in their career development.”

— Dr. Suzanne Haber

2024 BBRF Young Investigator Grants by Illness

Some grantees are listed under multiple categories as their grant projects are relevant to more than one illness.

ADDICTION / SUBSTANCE USE DISORDERS

Laika Aguinaldo, Ph.D.

Diagnostic Tools/Early Intervention

Miguel Barretto-García, Ph.D.

Basic Research

Erin Campbell, Ph.D.

Next-Generation Therapies

Basic Research

Yifeng Cheng, Ph.D.

Basic Research

Kauê Costa, Ph.D.

Basic Research

Priscila Dib Goncalves, Ph.D.

Basic Research

Yang Li, Ph.D.

Basic Research

Carolina Luft, Ph.D.

Basic Research

Diagnostic Tools/Early Intervention

Peter Manza, Ph.D.

Next-Generation Therapies

Freddyson Martinez-Rivera, Ph.D.

Basic Research

Next-Generation Therapies

Suzanne Nolan, Ph.D.

Basic Research

Brenden Tervo-Clemmens, Ph.D.

Basic Research

Yvan Vachez, Ph.D.

Basic Research

Terril Verplaetse, Ph.D.

Basic Research

Heather Webber, Ph.D.

Next-Generation Therapies

Natalie Zlebnik, Ph.D.

Basic Research

ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

Ryan Doan, Ph.D.

Basic Research

Cassandra Eng, Ph.D.

Next-Generation Therapies

Zhongzheng Fu, Ph.D.

Basic Research

Masashi Hasegawa, Ph.D.

Basic Research

Jaekyoon Kim, Ph.D.

Basic Research

Hannah Lapp, Ph.D.

Basic Research

Martin Munz, Ph.D.

Basic Research

New Technologies

Heather Snell, Ph.D.

Basic Research

New Technologies

ANXIETY DISORDERS

Elisa Baek, Ph.D.

Basic Research

Liam Barry-Carroll, Ph.D.

Basic Research

Johnathan Borland, Ph.D.

Basic Research

Daniela Calvigioni, Ph.D.

Basic Research

Simon Chang, Ph.D.

Basic Research

Kevin Clancy, Ph.D.

New Technologies

Next-Generation Therapies

Austin Coley, Ph.D.

Basic Research

Jacob Crouse, Ph.D.

Diagnostic Tools/Early Intervention

Basic Research

Camila de Avila Dal'Bo, Ph.D.

Basic Research

Alessandro De Nadai, Ph.D.

Basic Research

Mario Fernandez, Ph.D.

Basic Research

Zachary Harvanek, M.D., Ph.D.

Basic Research

Maryam Hasantash, Ph.D.

 *Basic Research*

Ann Iturra Mena, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Charline Kambrun, Ph.D.

 *Basic Research*

Arielle Keller, Ph.D.

 *Diagnostic Tools/Early Intervention*

Esther Klingler, Ph.D.

 *Basic Research*

Laura Luyten, Ph.D.

 *Basic Research*

Kahlilia Morris-Blanco, Ph.D.

 *Basic Research*

Laura Quinones Camacho, Ph.D.

 *Basic Research*

Divyangana Rakesh, Ph.D.

 *Basic Research*

Natale Sciolino, Ph.D.

 *Basic Research*

Ourania Semelidou, Ph.D.

 *Basic Research*

Joseph Stujenske, M.D., Ph.D.

 *Basic Research*

 *Next-Generation Therapies*

Jiandong Sun, Ph.D.

 *Basic Research*

Hwei Ee Tan, Ph.D.

 *Basic Research*

Najah Walton, Ph.D.

 *Basic Research*

Lauren White, Ph.D.

 *Diagnostic Tools/Early Intervention*

Ye Wu, Ph.D.

 *Basic Research*

Mingmin Zhang, Ph.D.

 *Basic Research*

Qiancheng Zhao, Ph.D.

 *Basic Research*

Yangzhi Zhu, Ph.D.

 *Diagnostic Tools/Early Intervention*

 *New Technologies*

AUTISM SPECTRUM DISORDER (ASD)

Gabriela Bodea, Ph.D.

 *Basic Research*

Caitlin Clements, Ph.D.

 *Diagnostic Tools/Early Intervention*

Marta Cosin-Tomas, Ph.D.

 *Basic Research*

Veronika Dudarev, Ph.D.

 *Basic Research*

Julien Ferent, Ph.D.

 *Basic Research*

Yi Gu, Ph.D.

 *Basic Research*

Charline Kambrun, Ph.D.

 *Basic Research*

Jaekyoon Kim, Ph.D.

 *Basic Research*

Hannah Lapp, Ph.D.

 *Basic Research*

Hsiang-Yuan Lin, M.D.

 *Basic Research*

 *Next-Generation Therapies*

Martin Munz, Ph.D.

 *Basic Research*

 *New Technologies*

Lingdi Nie, Ph.D.

 *Basic Research*

Heather Snell, Ph.D.

 *Basic Research*

Ye Wu, Ph.D.

 *Basic Research*

Xiyu Zhu, Ph.D.

 *Basic Research*

BIOLOGY OF THE BRAIN

These projects focus on how the brain works

ILLNESS-LINKED COPY NUMBER VARIATIONS

Paola Giusti-Rodriguez, Ph.D.

 *Basic Research*

GLIA IN NEURAL DEVELOPMENT

Husniye Kantarci, Ph.D.

 *Basic Research*

NEURAL BASIS OF SELF-MONITORING

Tadeusz Kononowicz, Ph.D.

 *Basic Research*

INDIVIDUAL VARIATION IN BRAIN DEVELOPMENT

Julia Moser, Ph.D.

 *Basic Research*

ACCELERATED BIOLOGICAL AGING

Julian Mutz, Ph.D.

 *Basic Research*

ESTROGEN RECEPTORS IN BRAIN DEVELOPMENT

Nevena Radonjic, M.D., Ph.D.

 *Basic Research*

CEREBELLAR ALTERATIONS DURING ADOLESCENCE

Adrienne Romer, Ph.D.

 *Basic Research*

LATROPHILINS AND SYNAPSE FORMATION

Hamidreza Shaye, Ph.D.

 *Basic Research*

MICROGLIA IN CIRCUIT DEVELOPMENT

Valerie Tornini, Ph.D.

 *Basic Research*



OPIOID RECEPTORS AND VALENCE PROCESSING

Hector Yarur, Ph.D.

Basic Research

BIPOLAR DISORDER

JinYoung Choi, Ph.D.

Next-Generation Therapies

Basic Research

Adam Fijtman, M.D., Ph.D.

Next-Generation Therapies

Masashi Hasegawa, Ph.D.

Basic Research

Maria Koromina, Ph.D.

Basic Research

Leila Nabulsi, Ph.D.

Basic Research

Beier Yao, Ph.D.

Basic Research

BORDERLINE PERSONALITY DISORDER

Miguel Barretto-García, Ph.D.

Basic Research

Andreea Diaconescu, Ph.D.

Basic Research

Masashi Hasegawa, Ph.D.

Basic Research

Natassia Robinson, Ph.D.

Diagnostic Tools/Early Intervention

CHILDHOOD & ADOLESCENCE

Laika Aguinaldo, Ph.D.

Diagnostic Tools/Early Intervention

Liam Barry-Carroll, Ph.D.

Basic Research

Caitlin Clements, Ph.D.

Diagnostic Tools/Early Intervention

Jacob Crouse, Ph.D.

Diagnostic Tools/Early Intervention

Basic Research

Christina Cruz, M.D.

Diagnostic Tools/Early Intervention

Alessandro De Nadai, Ph.D.

Basic Research

Elvisha Dhamala, Ph.D.

Diagnostic Tools/Early Intervention

Priscila Dib Goncalves, Ph.D.

Basic Research

Cassandra Eng, Ph.D.

Next-Generation Therapies

Ann Iturra Mena, Ph.D.

Basic Research

Diagnostic Tools/Early Intervention

Liat Itzhaky, Ph.D.

Diagnostic Tools/Early Intervention

Kiera James, Ph.D.

Diagnostic Tools/Early Intervention

Arielle Keller, Ph.D.

Diagnostic Tools/Early Intervention

Esther Klingler, Ph.D.

Basic Research

Hannah Lapp, Ph.D.

 *Basic Research*

Carolina Luft, Ph.D.

 *Basic Research*

Julia Moser, Ph.D.

 *Basic Research*

Laura Quinones Camacho, Ph.D.

 *Basic Research*

Divyangana Rakesh, Ph.D.

 *Basic Research*

Natassia Robinson, Ph.D.

 *Diagnostic Tools/Early Intervention*

Adrienne Romer, Ph.D.

 *Basic Research*

Brenden Tervo-Clemmens, Ph.D.

 *Basic Research*

Michelle Thai, Ph.D.

 *Basic Research*

Halide Turkozer, M.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Terril Verplaetse, Ph.D.

 *Basic Research*

Lauren White, Ph.D.

 *Diagnostic Tools/Early Intervention*

Jiahe Zhang, Ph.D.

 *Next-Generation Therapies*

DEPRESSION

Amanda Arulpragasam, Ph.D.

 *Next-Generation Therapies*

Vanessa Babineau, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Miguel Barretto-García, Ph.D.

 *Basic Research*

Mandakh Bekhbat, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Mirjam Bloemendaal, Ph.D.

 *Basic Research*

Johnathan Borland, Ph.D.

 *Basic Research*

Alexei Bygrave, Ph.D.

 *Basic Research*

Simon Chang, Ph.D.

 *Basic Research*

Roselyne Chauvin, Ph.D.

 *Basic Research*

Austin Coley, Ph.D.

 *Basic Research*

Katharine Dunlop, Ph.D.

 *Diagnostic Tools/Early Intervention*

Franco Giarrocco, Ph.D.

 *Basic Research*

Zachary Harvanek, M.D., Ph.D.

 *Basic Research*

Maryam Hasantash, Ph.D.

 *Basic Research*

Zoe Hawks, Ph.D.

 *Diagnostic Tools/Early Intervention*

Sarah Herzog, Ph.D.

 *Basic Research*

Orna Issler, Ph.D.

 *Basic Research*

Liat Itzhaky, Ph.D.

 *Diagnostic Tools/Early Intervention*

Arielle Keller, Ph.D.

 *Diagnostic Tools/Early Intervention*

Bora Kim, M.D.

 *Next-Generation Therapies*

Esther Klingler, Ph.D.

 *Basic Research*

Sangjun Lee, Ph.D.

 *Next-Generation Therapies*

Hsiang-Yuan Lin, M.D.

 *Basic Research*

 *Next-Generation Therapies*

Clara McCarthy, Ph.D.

 *Basic Research*

 *Next-Generation Therapies*

Kahlilia Morris-Blanco, Ph.D.

 *Basic Research*

Suzanne Nolan, Ph.D.

 *Basic Research*

Marco Pagliusi Jr, Ph.D.

 *Basic Research*

Mohammed Mostafizur Rahman, Ph.D.

 *Basic Research*

Divyangana Rakesh, Ph.D.

 *Basic Research*

Soroosh Sanatkhani, Ph.D.

 *Next-Generation Therapies*

Karel Scheepstra, M.D., Ph.D.

 *Basic Research*

 *Next-Generation Therapies*

 *New Technologies*

Tien Hong Stanley Seah, Ph.D.

 *Basic Research*

Urszula Skupio, Ph.D.

 *Basic Research*

Rachel June Smith, Ph.D.

 *Next-Generation Therapies*

 *Basic Research*

Benjamin Spurny-Dworak, Ph.D.

 *Basic Research*

 *New Technologies*

Brian Sweis, M.D., Ph.D.

 *Basic Research*

Hwei Ee Tan, Ph.D.

 *Basic Research*

Michelle Thai, Ph.D.

 *Basic Research*

Nicholas Trapp, M.D.

 *Diagnostic Tools/Early Intervention*

Najah Walton, Ph.D.

 *Basic Research*

Bo Wang, Ph.D.

 *Diagnostic Tools/Early Intervention*

Junsung Woo, Ph.D.

 *Basic Research*

Ye Wu, Ph.D.

 *Basic Research*

Jiahe Zhang, Ph.D.

 *Next-Generation Therapies*

Tingxin Zhang, Ph.D.

 *Basic Research*

Qiancheng Zhao, Ph.D.

 *Basic Research*

Yangzhi Zhu, Ph.D.

 *Diagnostic Tools/Early Intervention*

 *New Technologies*

EATING DISORDERS

Miguel Barretto-García, Ph.D.

 *Basic Research*

Maxime Chevee, Ph.D.

 *Basic Research*

Alexandre Fiset, Ph.D.

 *Basic Research*

Masashi Hasegawa, Ph.D.

 *Basic Research*

Hector Yarur, Ph.D.

 *Basic Research*

OBSESSIVE-COMPULSIVE DISORDER (OCD)

Zhongzheng Fu, Ph.D.

 *Basic Research*

Franco Giarrocco, Ph.D.

 *Basic Research*

Ann Iturra Mena, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Jaekyoon Kim, Ph.D.

 *Basic Research*

Liming Qiu, M.D.

 *Basic Research*

 *Next-Generation Therapies*

OTHER DISORDERS

ALZHEIMER'S

Camila de Avila Dal'Bo, Ph.D.

 *Basic Research*

EPILEPSY

Lingdi Nie, Ph.D.

 *Basic Research*

EPILEPSY

Rachel June Smith, Ph.D.

 *Next-Generation Therapies*

 *Basic Research*

PARKINSON'S DISEASE

Nikolai Gil Reyes, M.D.

 *Basic Research*

STROKE

Kahlilia Morris-Blanco, Ph.D.

 *Basic Research*

TRAUMATIC BRAIN INJURY

Dongtak Lee, Ph.D.

 *Next-Generation Therapies*

 *New Technologies*

POST-TRAUMATIC STRESS DISORDER (PTSD)

Vanessa Babineau, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Liam Barry-Carroll, Ph.D.

 *Basic Research*

Johnathan Borland, Ph.D.

 *Basic Research*

Fenglin Cao, Ph.D.

 *Basic Research*

Kevin Clancy, Ph.D.

 *New Technologies*

 *Next-Generation Therapies*

Xin Deng, Ph.D.

 *Basic Research*

Mario Fernandez, Ph.D.

 *Basic Research*

Thomas Hainmueller, M.D., Ph.D.

 *Basic Research*

 *Next-Generation Therapies*

Zachary Harvanek, M.D., Ph.D.

 *Basic Research*

Maryam Hasantash, Ph.D.

 *Basic Research*

Ann Iturra Mena, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Munir Kutlu, Ph.D.

 *Basic Research*

Joseph Stujenske, M.D., Ph.D.

 *Basic Research*

 *Next-Generation Therapies*

Najah Walton, Ph.D.

 *Basic Research*

Lauren White, Ph.D.

 *Diagnostic Tools/Early Intervention*

PRENATAL BRAIN DEVELOPMENT

Vanessa Babineau, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Marta Cosin-Tomas, Ph.D.

 *Basic Research*

Julien Ferent, Ph.D.

 *Basic Research*

Husniye Kantarci, Ph.D.

 *Basic Research*

Martin Munz, Ph.D.

 *Basic Research*

 *New Technologies*

Nevena Radonjic, M.D., Ph.D.

 *Basic Research*

Ai Tian, Ph.D.

 *Basic Research*

Valerie Tornini, Ph.D.

Basic Research

Yingying Zhang, Ph.D.

Basic Research

PSYCHOSIS

Jacob Crouse, Ph.D.

Diagnostic Tools/Early Intervention

Basic Research

Elvisha Dhamala, Ph.D.

Diagnostic Tools/Early Intervention

Tom Franken, M.D., Ph.D.

Basic Research

Leanna Hernandez, Ph.D.

Basic Research

Diagnostic Tools/Early Intervention

Katie Lavigne, Ph.D.

Basic Research

Emmanuel Mwesiga, M.D., Ph.D.

Basic Research

Danielle Pratt, Ph.D.

Basic Research

Nikolai Gil Reyes, M.D.

Basic Research

Rik Schalbroeck, Ph.D.

Basic Research

Diagnostic Tools/Early Intervention

Satoshi Terada, Ph.D.

Basic Research

New Technologies

Ralitsa Todorova, Ph.D.

Basic Research

Halide Turkozer, M.D.

Basic Research

Diagnostic Tools/Early Intervention

Veith Weilhhammer, M.D., Ph.D.

Basic Research

Nicholas Wright, Ph.D.

Basic Research

Beier Yao, Ph.D.

Basic Research

SCHIZOPHRENIA

Samantha Abram, Ph.D.

Next-Generation Therapies

Gabriela Bodea, Ph.D.

Basic Research

Marta Cosin-Tomas, Ph.D.

Basic Research

Henry Cowan, Ph.D.

Basic Research

Diagnostic Tools/Early Intervention

Jacob Crouse, Ph.D.

Diagnostic Tools/Early Intervention

Basic Research

Elvisha Dhamala, Ph.D.

Diagnostic Tools/Early Intervention

Michael-John Dolan, Ph.D.

Basic Research

Iris Donga Vilares, Ph.D.

Basic Research

Diagnostic Tools/Early Intervention

Julien Ferent, Ph.D.

Basic Research



Tom Franken, M.D., Ph.D.

 *Basic Research*

Zhongzheng Fu, Ph.D.

 *Basic Research*

Yi Gu, Ph.D.

 *Basic Research*

Leanna Hernandez, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Kevin Kelley, M.D., Ph.D.

 *Basic Research*

Jaekyoon Kim, Ph.D.

 *Basic Research*

Hannah Lapp, Ph.D.

 *Basic Research*

Katie Lavigne, Ph.D.

 *Basic Research*

Martin Munz, Ph.D.

 *Basic Research*

 *New Technologies*

Emmanuel Mwesiga, M.D., Ph.D.

 *Basic Research*

Lingdi Nie, Ph.D.

 *Basic Research*

Suzanne Nolan, Ph.D.

 *Basic Research*

Christopher Parkhurst, M.D., Ph.D.

 *Basic Research*

Danielle Pratt, Ph.D.

 *Basic Research*

Nikolai Gil Reyes, M.D.

 *Basic Research*

Rik Schalbroeck, Ph.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Rajyashree Sen, Ph.D.

 *Basic Research*

Satoshi Terada, Ph.D.

 *Basic Research*

 *New Technologies*

Ai Tian, Ph.D.

 *Basic Research*

Ralitsa Todorova, Ph.D.

 *Basic Research*

Halide Turkozer, M.D.

 *Basic Research*

 *Diagnostic Tools/Early Intervention*

Alban Voppel, Ph.D.

 *Basic Research*

Ryan Walsh, Ph.D.

 *Basic Research*

Veith Weilnhammer, M.D., Ph.D.

 *Basic Research*

Frederike Winkel, Ph.D.

 *Basic Research*

Nicholas Wright, Ph.D.

 *Basic Research*

Yingying Zhang, Ph.D.

 *Basic Research*

Xiaoqing Zhou, Ph.D.

 *Basic Research*

Xiyu Zhu, Ph.D.

 *Basic Research*

SUICIDE PREVENTION

Laika Aguinaldo, Ph.D.

 *Diagnostic Tools/Early Intervention*

Brian Albanese, Ph.D.

 *Diagnostic Tools/Early Intervention*

Hongsheng Gui, Ph.D.

 *Diagnostic Tools/Early Intervention*

Sarah Herzog, Ph.D.

 *Basic Research*

Liat Itzhaky, Ph.D.

 *Diagnostic Tools/Early Intervention*

Kiera James, Ph.D.

 *Diagnostic Tools/Early Intervention*

Bora Kim, M.D.

 *Next-Generation Therapies*

Junsung Woo, Ph.D.

 *Basic Research*

2024 Young Investigators: Institutional Affiliations at the Time of the Grant

(in alphabetical order)

Amsterdam University Medical Centers,
The Netherlands (2)

Arizona State University

Barcelona Institute for Global Health, Spain

Baylor College of Medicine

Brown University/Ocean State Research Institute, Inc.

Collège de France, France

Columbia University (8)

Dell Medical School, University of Texas at Austin (3)

Emory University

Feinstein Institute for Medical Research/Northwell
Health

Harvard University

Harvard University/Boston Children's Hospital (2)

Harvard University/Brigham and
Women's Hospital, Inc.

Harvard University/Massachusetts General
Hospital (4)

Harvard University/McLean Hospital (3)

Henry Ford Health System

Icahn School of Medicine at Mount Sinai (2)

INSERM, France (3)

Johann Wolfgang Goethe University, Germany

Johns Hopkins University

Karolinska Institute, Sweden (2)

King's College London, UK

King's College London/ Institute of Psychiatry, UK

Krembil Research Institute/University Health
Network, Canada

Leuven University, Belgium

Makerere University, Uganda

McGill University, Canada (2)

McLean Hospital (4)

Medical University of Vienna, Austria

Memorial Sloan-Kettering Cancer Center

Michigan State University

Nanyang Technological University, Singapore

National Institute of Mental Health (NIMH/NIH) (3)

National Institute of Neurological Disorders and
Stroke (NINDS/NIH)

National Institute on Alcohol Abuse & Alcoholism
(NIAAA/NIH)

NeuroCenter Magendie U1215 (INSERM), France

New York University (2)

Northeastern University

Northwestern University

Paris-Saclay University, France

Pontifical Catholic University of Rio Grande do Sul,
Brazil

Research Foundation for Mental Hygiene, Inc./
Nathan Kline Institute (2)

Research Foundation for the State University of
New York, Upstate Medical University

Rowan University

Rutgers University

Stanford University (4)
Terasaki Institute for Biomedical Innovation
Texas A&M University
Trinity College, Dublin, Ireland
Tufts University (2)
Unity Health Toronto, Canada
Université du Québec à Trois-Rivières Canada,
University of Alabama at Birmingham (2)
University of Alberta, Canada
University of Bordeaux, France
University of British Columbia, Canada
University of Calgary/The Hospital for Sick Children,
Canada,
University of California, Berkeley
University of California, Los Angeles (6)
University of California, Riverside
University of California, San Diego
University of California, San Francisco/ Gladstone
Institutes
University of California, San Francisco/San
Francisco VA Medical Center
University of Connecticut
University of Florida (2)
University of Iowa (2)
University of London/Maudsley Hospital/
King's College London, UK
University of Minnesota (5)
University of Newcastle, Australia
University of North Carolina at Chapel Hill (2)
University of Notre Dame
University of Pennsylvania (3)
University of Pennsylvania/
Children's Hospital of Philadelphia
University of Pittsburgh (3)
University of Queensland, Australia
University of Regensburg, Germany
University of São Paulo, Brazil,
University of Southern California (2)
University of Sydney, Australia
University of Texas Health Science Center at
Houston
University of Texas Southwestern Medical Center
at Dallas (2)
University of Toronto/Centre for Addiction and
Mental Health, Canada (2)
University of Toronto/University Health Network,
Canada,
University of Washington
Vanderbilt University (3)
VIB-KU Leuven Center for Brain & Disease
Research, Belgium
Virginia Polytechnic Institute and State University
Washington University, St. Louis
Washington University School of Medicine (2)
Weill Cornell Medical College
Western Washington University
Yale University (2)
Yale University/Yale University School of
Medicine (2)

2024 BBRF EVENTS

“The Quest for Healthy Minds” January 11, 2024



Dr. Judy Genshaft, President Emerita of the University of South Florida and BBRF Board Secretary, hosted an event at the Judy Genshaft Honors College, where attendees learned about BBRF’s unique model for advancing the frontiers of brain science.

The BBRF video, also entitled “The Quest for Healthy Minds,” highlights how BBRF’s support for brain research is paving the way to new treatments and methods of prevention.



Dr. Judy Genshaft,
BBRF Board Secretary



Geoffrey Simon,
BBRF Chairman of the Board

The video features four groundbreaking scientists—now world leaders in mental health research—who were supported by BBRF early in their careers, when they were struggling for funding.

Watch it here:

<https://www.youtube.com/watch?v=qh0QWi2zTBs>

Scientific Council Dinner Honoring Herbert Pardes, M.D.



The 2024 BBRF Scientific Council Dinner celebrated and honored the extraordinary life of Herbert Pardes, M.D., a dynamic leader in psychiatry and mental health, and Founder and President of the BBRF Scientific Council.

Dr. Pardes was a champion of mental health research. He believed it was vital to encourage and support talented scientists in their work to expand the frontiers of neuropsychiatric research, which he fervently believed was our best hope for ending the immense suffering caused by mental illness.

Dr. Pardes' legacy in the field of psychiatry is unparalleled. He played leadership roles in psychiatric care, neuroscience research, medical education, and health care policy. BBRF remains dedicated to building upon Dr. Pardes' extraordinary legacy of expanding the frontiers of psychiatric research, with the same passion and commitment he lovingly shared with us for 37 years.

The evening also celebrated the BBRF Klerman & Freedman Prizes and honored five young researchers for their significant findings related to suicide prevention, PTSD, substance-use disorders, autism, brain biology, and therapeutic drug development. These Prizes recognize exceptional clinical and basic research conducted by BBRF Young Investigator Grantees.

Their important work is furthering the quest to identify the biological roots of mental illness to enable the development of new diagnostic tools, more effective and targeted treatments, and to pave the way toward prevention. The prizewinners are selected by special committees of the Foundation's Scientific Council.



**ANNUAL KLERMAN PRIZE
FOR EXCEPTIONAL CLINICAL
RESEARCH**

Juliet Beni Edgcomb, M.D., Ph.D.
University of California, Los Angeles

HONORABLE MENTION

Elizabeth V. Goldfarb, Ph.D.
Yale University

**ANNUAL FREEDMAN PRIZE
FOR EXCEPTIONAL BASIC
RESEARCH**

Christina K. Kim, Ph.D.
University of California, Davis

HONORABLE MENTIONS

Erin Gibson, Ph.D.
Stanford University

Hugo A. Tejada, Ph.D.
National Institute of Mental Health

Top Photo: Geoffrey Simon, Dr. Elizabeth Goldfarb, Dr. Christina Kim, Dr. Erin Gibson, Dr. Juliet Beni Edgcomb, and Dr. Jeffrey Borenstein.

Bottom Photo: Geoffrey Simon, Chairman of the BBRF Board, Dr. Judith Ford, President of the BBRF Scientific Council, and Dr. Jeffery Borenstein, BBRF President & CEO.



**STRIVING TOWARD
CURES THROUGH
RESEARCH**

Scientist Spotlight with: **Christina K. Kim, Ph.D.**

2024 BBRF Freedman Prize for Exceptional Basic Research

2021 BBRF Young Investigator Grant

Dr. Kim seeks to develop new methodologies for recording and perturbing neuronal activity in animal models, specifically in brain regions implicated in neuropsychiatric diseases. Specifically, her lab engineers technologies to identify molecular biomarkers in neurons modulated by novel therapeutic drugs for treating depression and anxiety. She aims to determine which specific neurons and molecules can be targeted to improve disease symptoms. The hope is that an understanding of the targeted cellular mechanisms of therapeutic drugs in the brain can serve as the basis for designing modifications to these agents to increase their specificity and reduce their undesired side effects.

WHAT IS THE CURRENT STATE OF YOUR BBRF-FUNDED RESEARCH?

This first half of our BBRF-funded Research is described in a completed manuscript currently under revision at a journal. The second half has been presented in its entirety at Society for Neuroscience, and is currently being prepared for submission as a manuscript.

WHAT DID YOUR BBRF GRANT MEAN TO YOU?

The BBRF Young Investigator Grant gave me the freedom to try a risky but fruitful new project, which is now the foundational basis of many other ongoing projects in my lab. Without this support, it would have been challenging for us to launch this exciting research direction in our lab.

“I am so grateful to be receiving the Freedman Prize from BBRF. It is a wonderful recognition that comes right at the beginning of my career. This award empowers me to continue pursuing challenging and risky problems in neuropsychiatric disease research.”

WHAT HAS BBRF SUPPORT MEANT TO YOUR CAREER?

BBRF support has sparked my career as a technology developer studying neuropsychiatric disorders. This early support guided my independent lab's current research program and vision..

HOW DO YOUR INTERACTIONS WITH PEOPLE LIVING WITH MENTAL ILLNESS AFFECT YOUR RESEARCH AND VICE-VERSA?

People living with mental illness can teach us so much about these disorders, and what aspects of these illnesses are the most challenging to cope with. Their resilience is the inspiration for why we as researchers continue to seek answers in the lab. Through interactions with people living with mental illnesses, I'm able to share knowledge and hope with those who need it. These interactions also motivate me to think deeply about the purpose and motivation of our lab's research.

IN THE BEST POSSIBLE SCENARIO, HOW WOULD YOUR WORK IMPACT THE PEOPLE LIVING WITH MENTAL ILLNESS AND THEIR FAMILIES?

In the best possible scenario, we hope that our research reveals an understanding of how certain treatments work to combat symptoms of mental illness in patients. By understanding the targeted cellular mechanisms of these drugs in the brain, we can then begin to design modifications to them to increase their specificity and reduce their undesired side effects. The ultimate hope is to improve the day-to-day lives of patients and their families.

Scientist Spotlight with: **Juliet Beni Edgcomb, M.D., Ph.D.**

2024 BBRF Klerman Prize for Exceptional Clinical Research

2020 BBRF Young Investigator Grant

Dr. Edgcomb seeks to develop a set of rules for clearly identifying children and adolescents with suicide-related symptoms from within noisy and complex electronic health record (EHR) data. This would be a significant step forward in suicide prevention. She has worked with an EHR “training set” that includes data from 400 children and adolescents, to identify those presenting to healthcare providers with suicidal thoughts and behaviors. The aim is to identify the predictive variables best defining each pertinent phenotype and to produce a predicted probability of each suicide-related phenotype for each child.

“This is an extraordinary honor that deeply humbles and inspires me. It is a recognition not just of individual efforts, but of collaborative spirit and dedication that drive the field of psychiatric research. This accolade is a powerful reminder of our shared purpose and energizes my commitment.”

WHAT IS THE CURRENT STATE OF YOUR BBRF-FUNDED RESEARCH?

The project developed methods to detect suicide and self-harm from electronic health records of 600 children receiving emergency care. Results demonstrated a gap in detection with commonly used strategies and the potential of new computational methods to enhance detection. We since expanded this project to develop and validate methods to detect suicide-related visits among 3400 children. Preliminary findings from this larger study reveal disparities in detection by age, sex, and race/ethnicity with existing strategies, and the potential for medical record phenotyping to attenuate disparities in detection of populations at-risk and in need.

WHAT DID YOUR BBRF GRANT MEAN TO YOU?

Receiving a BBRF Young Investigator Grant was not only a tremendous honor but also has been vital catalyst for my research. This grant represents both recognition and support from the scientific community for my work in exploring innovative approaches to understanding mental health. I am deeply grateful for this opportunity to make a difference in the lives of those affected by mental illness.

HOW DO YOUR INTERACTIONS WITH PEOPLE LIVING WITH MENTAL ILLNESS AFFECT YOUR RESEARCH AND VICE-VERSA?

Every encounter offers me a deeper understanding of the unique struggles and strengths of young people facing mental health challenges. These conversations not only deepen my empathy but also continuously refine my approach to treatment and prevention. On a personal level, as a parent, these interactions remind me of the resilience of the human spirit and the impact of empathy. They reinforce my commitment to destigmatizing mental health issues and advocating for better mental health resources. .

WHAT HAS BBRF SUPPORT MEANT TO YOUR CAREER?

My project was honored with the Steven, Sally, and Isabella Grimes Investigator Award through the BBRF Young Investigator Grant. This dedication by a specific family instilled purpose in my work, and connected discovery and hope. While BBRF support tangibly made possible my research, it also reinforced a conviction that this work can transform care for children and save lives.

IN THE BEST POSSIBLE SCENARIO, HOW WOULD YOUR WORK IMPACT THE PEOPLE LIVING WITH MENTAL ILLNESS AND THEIR FAMILIES?

Labor-intensive manual chart reviews, diagnostic codes, and literal term searches remain the predominant mode of detecting suicidal behavior among children, limiting sample size to detect variation in care and access to life-saving suicide prevention interventions. By advancing strategies to efficiently detect need at scale, my goal is to reduce the time between research innovation and clinical practice.



**STRIVING TOWARD
CURES THROUGH
RESEARCH**

2024 INTERNATIONAL MENTAL HEALTH RESEARCH SYMPOSIUM

BBRF held its annual International Mental Health Symposium at the Kaufman Music Center in New York City, which was simultaneously live-streamed. Six 2024 BBRF Outstanding Achievement Prizewinners gave presentations on topics that included identifying risk factors for psychosis prior to the first appearance of symptoms; a cognitive neuroscience approach to understanding circuits and symptoms in psychosis; exploration of mechanisms in breakthrough rapid-acting therapies for mood disorders; and the investigation of differences in early social development in relation to their clinical and translational implications.

The symposium also featured a presentation from Franca Ma-ih Sulem Yong, the winner of the 2024 Pardes Humanitarian Prize in Mental Health.

This year's program was reflective of the greatly accelerating pace of discovery in mental health research as well as the expanded range of studies the Brain & Behavior Research Foundation has grown to support.

An overview of the entire Symposium was provided by Dr. Carol Tamminga, a BBRF Scientific Council member who served as the Symposium moderator.

The entire symposium is available to watch on the BBRF YouTube channel:

<https://bbrfoundation.org/blog/2024-international-mental-health-research-symposium-presentations>



Standing L to R: Dr. Carol Tamminga, Dr. Jeffrey Borenstein, Franca Ma-ih Sulem Yong, Dr. Cameron Carter, Dr. Deanna Barch, Dr. Nicole Karcher, Dr. Christopher McDougle, Dr. Nolan Williams, and Geoffrey Simon. Photos by Chad David Kraus.

Presentations

Identifying Risk For Developing Psychosis So We Can Promote Prevention

Deanna M. Barch, Ph.D.

Washington University in St. Louis

BBRF LIEBER PRIZEWINNER FOR OUTSTANDING ACHIEVEMENT IN SCHIZOPHRENIA RESEARCH

Identifying Risk Factors For Early Psychosis Spectrum Symptoms

Nicole Karcher, Ph.D.

Washington University in St. Louis

BBRF MALTZ PRIZEWINNER FOR INNOVATIVE AND PROMISING SCHIZOPHRENIA RESEARCH

Breakthrough Rapid-Acting Therapeutics: Exploring Efficacy and Mechanisms in Treatment-Resistant Mood Disorders

Nolan R. Williams, M.D.

Stanford University

BBRF COLVIN PRIZEWINNER FOR OUTSTANDING ACHIEVEMENT IN MOOD DISORDERS RESEARCH

New Horizons for Child Psychiatry From Research on Individual Differences in Early Social Development

John N. Constantino, M.D.

*Pediatric Institute, Children's Healthcare of Atlanta
Emory University*

BBRF RUANE PRIZEWINNER FOR OUTSTANDING ACHIEVEMENT IN CHILD & ADOLESCENT PSYCHIATRIC RESEARCH

The Psychopharmacology of Childhood-Onset Neuropsychiatric Disorders Across the Lifespan

Christopher J. McDougle, M.D.

Massachusetts General Hospital / Harvard Medical School

BBRF RUANE PRIZEWINNER FOR OUTSTANDING ACHIEVEMENT IN CHILD & ADOLESCENT PSYCHIATRIC RESEARCH

A Cognitive Neuroscience Approach to Understanding Circuits and Symptoms in Psychosis

Cameron S. Carter, M.D.

University of California, Irvine

BBRF GOLDMAN-RAKIC PRIZEWINNER FOR OUTSTANDING ACHIEVEMENT IN COGNITIVE NEUROSCIENCE RESEARCH

Navigating My ADHD Through Self Art Therapy

Franca Ma-ih Sulem Yong

Founder, Afrogiveness Movement

PRIZEWINNER, BBRF PARDES HUMANITARIAN PRIZE IN MENTAL HEALTH

We would also like to thank our 2024 Sponsors

BRONZE



BENEFACTOR

Miriam E. Katowitz

VIP





The Pardes Humanitarian Prize in Mental Health

The 2024 Pardes Humanitarian Prize in Mental Health was awarded on October 25th and honored **Franca Ma-ih Sulem Yong** for serving as an extraordinary advocate for tolerance, forgiveness, mental health, and human fraternity. She is a champion of mental health rights and a leading force for healing in Africa.



Dr. Jeffrey Borenstein and Franca Ma-ih Sulem Yong

The 2024 Honorary Pardes Humanitarian Prize in Mental Health was awarded to the **Graham Boeckh Foundation** for serving as a catalyst for transformational changes that significantly improve the lives of people living with, or at risk of, mental illness.

Bestowed annually since 2014, the Pardes Prize is named in honor of Dr. Herbert Pardes, the first recipient of the award. The Prize recognizes a person(s) or organization whose humanitarian work is transformative and of great magnitude, changing lives and bringing the joy of living to those facing challenges to mental health. It was established to honor those who comprehensively care, teach, investigate, work, and passionately advocate for improving the mental health of society and

have had a powerful impact on reducing the pain inflicted by psychiatric illness.

The recipient of the Pardes Humanitarian Prize in Mental Health is chosen by a distinguished international Selection Committee from nominations solicited worldwide. The Prize focuses public attention on the burden of mental illness on individuals and on society, and the urgent need to expand and enhance mental health services in the United States and globally.



(L–R): Tony Boeckh, Raymonde Boeckh, Dr. Jeffrey Borenstein, and Ian Boeckh

PREVIOUS PRIZE WINNERS

2023

SPECIAL OLYMPICS INTERNATIONAL

Honorary Tribute:

Henry Jarecki, M.D.

2022

Altha J. Stewart, M.D.,
Robert van Voren, FRCPsych (HON)

Honorary Tribute:

Clubhouse International, Sean Mayberry

2021

Kay Redfield Jamison, Ph.D., Elyn R. Saks,
J.D., Ph.D., & Charlene Sunkel

Honorary Tribute: John M. Davis, M.D.,

Michael R. Phillips, M.D., MPH, &

Norman Sartorius, M.D., Ph.D., FRCPsych

2020

Myrna M. Weissman, Ph.D.
& Sir Michael Rutter, FRS

Honorary Tribute: E. Fuller Torrey, M.D.

2019

William T. Carpenter, Jr., M.D.

Honorary Tribute: Cynthia Germanotta & Born This Way Foundation

2018

Judge Steven Leifman

Honorary Tribute: Suzanne and Bob Wright

2017

Doctors Without Borders/
Médecins Sans Frontières

Honorary Tribute: Constance E. Lieber

2016

Vikram Patel, Ph.D., F.Med.Sci. &
Charles F. Reynolds, III, M.D.

Honorary Tribute:

Senator Edward M. Kennedy

2015

Beatrix (Betty) A. Hamburg, M.D.
and David A. Hamburg, M.D.

Honorary Tribute: Rosalynn Carter

2014

Herbert Pardes, M.D.

INTERNATIONAL AWARDS DINNER

OCTOBER 25, 2024

The BBRF International Awards Dinner honored the winners of the Pardes Humanitarian Prize in Mental Health as well as the five Outstanding Achievement Prizewinners who are advancing the science that is changing what it means to live with a mental illness. Winners are selected by special committees of the BBRF Scientific Council.

LIEBER PRIZE

Outstanding Achievement in Schizophrenia Research



Deanna M. Barch, Ph.D.

Washington University, St. Louis

BBRF Scientific Council Member
2013 BBRF Distinguished Investigator
2006 BBRF Independent Investigator
2000, 1995 BBRF Young Investigator

RUANE PRIZE

Outstanding Achievement in Child & Adolescent Psychiatric Research



John N. Constantino, M.D.

*Pediatric Institute, Children's
Healthcare of Atlanta
Emory University*

MALTZ PRIZE

Innovative & Promising Schizophrenia Research



Nicole Karcher, Ph.D.

Washington University, St. Louis



Christopher J. McDougle, M.D.

*Massachusetts General Hospital /
Harvard Medical School*

1997 BBRF Independent Investigator
1994, 1990 BBRF Young Investigator

COLVIN PRIZE

Outstanding Achievement in Mood Disorders Research



Nolan R. Williams, M.D.

Stanford University

2019 BBRF Klerman Prize for
Exceptional Clinical Research
2018, 2016 BBRF Young Investigator

GOLDMAN-RAKIC PRIZE

Outstanding Achievement in Cognitive Neuroscience



Cameron S. Carter, M.D.

University of California, Irvine

BBRF Scientific Council Member
2007 BBRF Distinguished Investigator
2001 BBRF Klerman Prize for
Exceptional Clinical Research
1997, 1994 BBRF Young Investigator

Healthy Minds



The Emmy nominated television series, **Healthy Minds with Dr. Jeffrey Borenstein**, produced by BBRF, aims to remove the stigma of mental illness and demonstrate that with help, there is hope. The series features inspiring personal stories from people who have experienced mental health issues, as well as the latest information from experts on new approaches to the diagnosis, treatment, and prevention of mental illness.

Previous seasons can be found online at: www.bbrfoundation.org/healthyminds-tv

Season 10 will be available to watch in the Fall at: <https://www.pbs.org/show/healthy-minds-with-dr-jeffrey-borenstein/>

SEASON 9 EPISODES:

Episode 1 — Metabolic Psychiatry

A ketogenic diet focused on increased protein and decreased carbohydrates has shown positive results for patients with bipolar disorder, epilepsy, and schizophrenia. *Guests: Jan Ellison Baszucki, mother of bipolar patient, now funding research as President, Baszucki Group; Judith M. Ford, Ph.D., Professor of Psychiatry, University of California, San Francisco.*

Episode 2 — Update on COVID and Mental Health

A follow up to the 2022 season of “Healthy Minds” explores some potential long-term effects of COVID including depression, anxiety, psychosis, and brain fog, as well as treatments for these conditions. *Guest: Maura Boldrini, M.D., Associate Professor of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and Director, Quantitative Brain Biology Institute (Brain QUANT).*

Episode 3 — Helping People Who Are Homeless, Part 1

A model program in Boston offers a holistic approach to clinical care for the homeless built around a street team bringing mental health resources directly to those most in need, including case workers, psychiatrists, and a recovery coach who has experienced being homeless. *Guest: Katherine Koh, M.D., Assistant Professor of Psychiatry, Harvard Medical School and Street Psychiatrist, Boston Health Care for the Homeless Program.*

Episode 4 — Helping People Who Are Homeless, Part 2

Research to improve clinical care and positive outcomes for the homeless population includes understanding risk factors for homelessness, including the need for mental health support during transitions out of the military, jail, and foster care. *Guest: Katherine Koh, M.D., Assistant Professor of Psychiatry, Harvard Medical School and Street Psychiatrist, Boston Health Care for the Homeless Program.*

Episode 5 — Post-Traumatic Stress in Children and Adolescents

Topics covered: PTSD looks different in children and adolescents than in adults; What factors contribute to trauma’s long-term effects?; unique treatments for youth including eye movement desensitization and reprocessing (EMDR); the need for suicide prevention awareness after trauma in young people’s lives. *Guest: Ryan Herringa, M.D., Ph.D., University of Wisconsin Health Professor in Children and Adolescent Psychiatry, University of Wisconsin School of Medicine and Public Health.*

Episode 6 — Prenatal Choline and Brain Health

The nutrient choline has been shown to support fetal brain development, and supplements taken during pregnancy may lead to improved concentration and attention spans in childhood as well as a decreased risk of schizophrenia for these children later in life.

Guest: Robert Freedman, M.D., Department of Psychiatry, University of Colorado School of Medicine.

Episode 7 — Diagnosis and Treatment for Subtypes of Depression

New research using brain scans and biological markers has revealed areas of connectivity in the brain that can make diagnosis and treatment of the various types of depression more efficient and effective and identify the fundamental mechanisms that make moods change. *Guest: Conor Liston, M.D., Ph.D., Professor of Neuroscience and Psychiatry, Weill Cornell Medicine.*

Episode 8 — Treatment of Early Psychosis

Coordinated care including early intervention, education, a team of medical experts, and a strong support system of family as well as peers with shared experience can increase positive outcomes for young people after a first psychotic episode. The leader of the “On Track New York” program, a doctor and sibling of an early onset patient herself, explores the advances in understanding and treating adolescents and young adults experiencing hallucinations and other symptoms. *Guest: Lisa Dixon, M.D., Professor of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons.*

Episode 9 — Mental Health, Obesity and Diabetes

Research that looks at mental health holistically has revealed that half of all patients with depression or bipolar disorder patients are diabetic or pre-diabetic, leading to a new perspective on symptoms and treatment regarding insulin and brain function. *Guest: Roger McIntyre, M.D., FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto, Canada*

Episode 10 — ADHD: What You Need to Know

Demystifying the symptoms of Attention-Deficit Hyperactivity Disorder and understanding the variety of ways ADHD presents in young people including differences in which aspect of the disorder is manifested, and best advice for caregivers to help young people lead successful lives after diagnosis. *Guest: Stephen P. Hinshaw, Ph.D., Distinguished Professor of Psychology, University of California, Berkeley, and Professor of Psychiatry and Behavioral Sciences, University of California, San Francisco.*

Episode 11 — Education and Opportunities for People with Neurodiversity

A model academic program in Florida addresses the needs of neurodiverse students, founded by parents looking for resources. LiFT (Learning Independence for Tomorrow) Academy serves kindergarten through 12th grade, and LiFT University Transition Program is a four-year post-secondary transition program for students who have completed high school for continued academics, career readiness, and life skill training. *Guest: Keli Mondello, co-founder and Chairman of the Board, Learning Institute for Tomorrow (LiFT).*

Episode 12 — Anxiety in Youth

Diagnosing and treating anxiety in childhood and adolescence can decrease the risk of developing depression and other mental disorders later in life. Advice for parents to recognize the differences between normal worries and anxiety, and the impact of outside factors including bullying and social media. *Guest: Daniel Pine, M.D., National Institutes of Health Distinguished Investigator.*



Meet the Scientist Webinar Series

Dr. Jeffrey Borenstein hosts the free monthly “Meet the Scientist” webinar series where leading brain and behavior researchers discuss their current work on the latest in new technologies, early intervention strategies, and next-generation therapies for mental illness. Each hour-long webinar includes time for researchers to answer questions posed by the audience participants. This popular series offers the public access to some of the world’s top scientists who discuss their cutting-edge research.

All webinars are available for viewing on the BBRF website.

The following Webinars were offered in 2024:



PTSD: The Brain Basis of Susceptibility

Tuesday, January 9, 2024

Nathaniel G. Harnett, Ph.D.

*McLean Hospital
Harvard Medical School*



Motivational Modulation of Cognitive Control in ADHD

Tuesday, July 9, 2024

Kimberly S. Chiew, Ph.D.

University of Denver



Developing Biological Markers to Improve Clinical Care in Autism

Tuesday, February 13, 2024

James McPartland, Ph.D.

Yale School of Medicine



Timing is Everything: Repeated Neurocognitive Assessments Can Help Us Understand Symptom Patterns in Bulimia Nervosa

Tuesday, August 13, 2024

Laura A. Berner, Ph.D.

Icahn School of Medicine at Mount Sinai



Detection of Suicide-related Emergencies Among Children Using Real-world Clinical Data

Tuesday, March 12, 2024

Juliet B. Edgcomb, M.D., Ph.D.

University of California, Los Angeles



New Diagnostic Tools to Predict Symptom Improvements in Personality Disorders

Tuesday, September 10, 2024

Jenna M. Traynor, Ph.D.

Harvard Medical School



Enhancing Positive Emotions to Prevent Depression in Youth

Tuesday, April 9, 2024

Autumn Kujawa, Ph.D.

Vanderbilt University



Toward Brain-Based Prediction of Recovery: How Neuroimaging Can Help Combat the Substance-Use Epidemic

Tuesday, October 8, 2024

Sarah W. Yip, Ph.D., MSc

Yale School of Medicine



Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder

Tuesday, May 14, 2024

Allison C. Waters, Ph.D.

Icahn School of Medicine at Mount Sinai



Intergenerational Effects of Adversity on Mind-Body Health: Pathways Through the Gut-Brain Axis

Tuesday, November 12, 2024

Bridget Laura Callaghan, Ph.D.

University of California, Los Angeles



Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path to More Personalized Treatments

Tuesday, June 11, 2024

Katherine E. Burdick, Ph.D.

*Brigham and Women's Hospital
Harvard Medical School*



Investigating the Genetic and Biological Mechanisms That Predispose to Early-Onset Psychotic Illnesses

Tuesday, December 10, 2024

Catherine Astrid Brownstein, Ph.D., M.P.H.

Harvard Medical School, Boston Children's Hospital

BBRF EDUCATIONAL WEBINAR

ADHD: What You Need to Know – A Q&A with Dr. Stephen Hinshaw



This special webinar was broadcast via Zoom on December 4, 2024.

Teachers, school counselors and other educational professionals are on the front line in helping students with mental health challenges and can be among the first to notice when a child is struggling. In their pivotal relationships with students and families, these professionals are often in a position to match resources with needs. By expanding their knowledge of mental health issues experienced by young people, school faculty and staff may be better able to intervene earlier and make referrals for evaluation and assistance which can positively impact student well-being, performance and family life.

This conversation provided educators with a deeper understanding of Attention-Deficit Hyperactivity Disorder and the variety of ways ADHD presents in young people. BBRF President & CEO, Dr. Jeffrey Borenstein and Dr. Stephen Hinshaw discussed the different ways the disorder manifests, differences in presentation between boys and girls, and provided advice for caregivers and educators as to how to help young people lead successful lives after diagnosis.



This webinar is available on the BBRF website:

<https://bbrfoundation.org/event/adhd-what-you-need-know-qa-dr-stephen-hinshaw>

THANK YOU TO OUR DONORS

Your support this year enabled us to fund over \$11 million to scientists looking for better treatments, cures, and methods of prevention for mental illness.

Since 1987, in partnership with you, our donors, BBRF has awarded more than \$462 million to fund more than 6,700 grants to more than 5,600 leading scientists around the world.

With your help BBRF has been able to foster new research pathways that have led to transformative breakthroughs. We deeply appreciate your support and commitment to advance psychiatric research.

Dr. Herbert Pardes Tribute Fund

In Tribute and Memory of Herbert Pardes, M.D. and his continued legacy, importance, and leadership of the BBRF Scientific Council.



Herbert Pardes, M.D., President of the BBRF Scientific Council from its inception in 1987, passed away on April 30, 2024, at the age of 89. In 1987, Dr. Pardes was among the small group of patient advocates, physicians, and researchers who founded the National Alliance for Research on Schizophrenia and Depression (NARSAD), renamed the Brain & Behavior Research Foundation (BBRF) in 2011.

Today BBRF's Scientific Council is comprised of 192 members that include leaders in neurobiology, neuroscience, clinical care, psychology, and psychiatry. These esteemed individuals have recommended more than 6,700 grants for funding and are highly regarded in their respective fields. They have a profound understanding of psychiatric research funding, a deep knowledge of how the scientific community operates and are the bedrock of the organization.

In honor of Dr. Pardes' remarkable legacy and his unparalleled contributions to the field, a fundraising campaign for the Scientific Council was launched with the goal of supporting BBRF's mission and continuing the important work that Dr. Pardes dedicated his life to.

Dr. William Byerley (Scientific Council Member Emeritus) generously matched donations up to \$125,000 from the Scientific Council members.

Below is a listing of BBRF Scientific Council Members who raised \$195,360:

Ted Abel, Ph.D.
Deanna M. Barch, Ph.D.
Peter F. Buckley, M.D.
William F. Byerley, M.D.
Cameron S. Carter, M.D., M.S.
Jacqueline N. Crawley, Ph.D.
Lisa Beth Dixon, M.D., M.P.H.
Drs. Judith M. Ford and
Daniel Mathalon
Dr. and Mrs. Alan Frazer
Dr. and Mrs. Robert R. Freedman
Anthony A. Grace, Ph.D.
Dr. Suzanne N. Haber and
Mr. William L. Thomson
Jonathan A. Javitch, M.D., Ph.D.
Dilip V. Jeste, M.D.
Drs. John H. Krystal and
Bonnie Becker
Dr. and Mrs. George Lantos
Drs. James F. Leckman and
Hannah H. Leckman
Ellen E. Lee, M.D.
Dr. and Mrs. Robert H. Lenox
Helen S. Mayberg, M.D.
Dr. and Mrs. Herbert Y. Meltzer
David A. Morilak, Ph.D.
Dr. and Mrs. Eric J. Nestler
Thomas C. Neylan, M.D.
Patricio O'Donnell, M.D., Ph.D.
Dr. Daniel S. Pine and Ms. Judith Brazen
Dr. and Mrs. Robert M. Post
Gerard A. Sanacora, M.D., Ph.D.
Joanna E. Steinglass, M.D.
Jeremy M. Veenstra-VanderWeele, M.D.,
Ph.D.
Drs. Myrna M. Weissman and
James C. Frauenthal



In 2019, the **Moritz Hilder Innovative Brain Research Fund** was established by the Trustee of the Jane Hilder Harris Trust with an endowment gift of \$3.5 million. It was created to preserve and honor the memory of Moritz Hilder, the father of the late Jane Hilder Harris.

This generous endowment will be held in perpetuity to advance medical research with the objective of gaining a basic understanding of post-traumatic stress disorder (PTSD) and its prevention, treatment and cure. Primary emphasis will be given to research involving innovative concepts where, although there may be a high risk of failure, the rewards of success would be substantial, and to researchers who typically would not be in a position to secure funding from more traditional funding sources.

The Moritz Hilder Innovative Brain Research Fund is held in a professionally managed, separate endowment fund. On an annual basis, 5% of the endowment fund will be expended to support PTSD research. A special committee of the BBRF Scientific Council selects which BBRF Grants will be funded by this Endowment. In 2024, the Endowment provided \$199,852 for the funding of six PTSD research projects.

We are deeply honored to have received this generous and impactful gift.

BENEFITS OF BECOMING A RESEARCH PARTNER

“Marla and I donate to BBRF in support of science and the hope of finding better treatments for mental illness. Better treatments came too late for my brother who lost his battle with schizophrenia, and too late for my father who suffered from depression. But we believe that with ongoing research, it will not be too late for millions of other people. We know this because we have seen the scientific breakthroughs and results that have come from funding scientists. Marla and I are dedicated to helping people who live with mental illness and doing what we can to be a part of the solution by our continued giving to BBRF.”

—Ken Harrison,
BBRF Board Member



Many BBRF donors have a very personal interest in brain and behavior research. They know from often difficult, first-hand experience the devastation mental illness can bring upon family and friends, and they know that research will ultimately bring about better understanding and treatments.

Our **Research Partners Program** offers donors the opportunity to personally select and support scientists based on various criteria, including, but not limited to, illness specialty area or specific institutions, or a combination of these. Researchers are selected by the donor (our Research Partner) after members of our all-volunteer Scientific Council have conducted an independent peer review of the submitted applications and have made their recommendations for grant awards.

The **Research Partners Program** enables donors to choose among the best and brightest scientists and the most promising, cutting-edge proposals in mental illness research.

The results from these studies often provide the pilot data needed to apply for much larger federally funded grants (from the National Institute of Mental Health and the N.I.H., for example).

To date the BBRF **Research Partners Program** has funded more than 1,500 research grants.

To learn more about the Research Partners Program, please contact us at **646-681-4889** or **researchpartner@bbrfoundation.org**.

Visit us at bbrfoundation.org/researchpartners.

Research Partners Program

LYNN & JOEL ALTSCHUL

Jon Altschul Investigators

Young Investigator

Anouar Khayachi, Ph.D.

McGill University

Young Investigator

Heidi Catherine Meyer, Ph.D.

Boston University

ANONYMOUS

Young Investigator

Andrea Boscutti, M.D.

University of Texas Health - Houston

ANONYMOUS

Young Investigator

Lindsay D. Oliver, Ph.D.

*Centre for Addiction & Mental Health
University of Toronto*

ARAMONT CHARITABLE FOUNDATION

Aramont Charitable Foundation
Investigators

Young Investigator

Andrew M. Wikenheiser, Ph.D.

University of California, Los Angeles

Young Investigator

Xingjian Zhang, Ph.D.

University of California, Los Angeles

SIDNEY R. BAER, JR. FOUNDATION

Sidney R. Baer, Jr. Foundation
Investigator

Young Investigator

David Benrimoh, M.D.

Douglas Mental Health University Institute

BARRETTA FAMILY FOUNDATION

Gina & Russell Barretta Investigator

Young Investigator

Neal D. Amin, M.D., Ph.D.

Stanford University

BARBARA & MICHAEL BASS

Barbara and Michael Bass Investigator

Young Investigator

Guusje Collin, M.D., Ph.D.

Radboud University

JAN & BARRY BRANDT

Brandt Family Investigator

Young Investigator

Tyler Prestwood, M.D., Ph.D.

Stanford University

THE CASE FAMILY

James John Karatheodoris Memorial
Investigator

Young Investigator

Christopher N. Parkhurst, M.D., Ph.D.

Weill Cornell Medical College

FREDERICK & ALICE COLES AND THOMAS & NANCY COLES

Frederick & Alice Coles and Thomas
& Nancy Coles Investigators

Young Investigator

Henry R. Cowan, Ph.D.

Michigan State University

Young Investigator

Sarah H. Sperry, Ph.D.

University of Michigan

Young Investigator

Joongkyu Park, Ph.D.

Wayne State University

ANONYMOUS

Dana W. Investigator

Young Investigator

Toby Pillinger, Ph.D.

*Institute of Psychiatry/King's College
London*

BOB & RITA ELMEN FAMILY FOUNDATION

Bob & Rita Elmen Family Foundation
Investigator

Young Investigator

Ana P. Silva, Ph.D.

University of Saskatchewan

FAMILIES FOR BORDERLINE PERSONALITY DISORDER RESEARCH

Families For Borderline Personality
Disorder Research Investigators

Young Investigator

Lois W. Choi-Kain, M.D.

McLean Hospital - Harvard University

Young Investigator

Sarah Kathryn Fineberg, M.D., Ph.D.

Yale University

Young Investigator

Fabian Streit, Ph.D.

*Central Institute of Mental Health,
Mannheim - University of Heidelberg*

Young Investigator

Jenna M. Traynor, Ph.D.

McLean Hospital - Harvard University

ANONYMOUS

Nathan And Phyllis Goodman
Investigator

Young Investigator

Nicole M. Benson, M.D.

McLean Hospital - Harvard University

JUDY GENSHAFT & STEVEN GREENBAUM

Genshaft & Greenbaum Investigators

Young Investigator

Laura A. Berner, Ph.D.

Icahn School of Medicine at Mount Sinai

Young Investigator

Tina Chou, Ph.D.

*Massachusetts General Hospital -
Harvard University*

Young Investigator

Fernando Midea Cuccovia V. Reis, Ph.D.

University of California, Los Angeles

Young Investigator

Stefanie R. Russman Block, Ph.D.

University of Michigan

Young Investigator

Akina Umemoto, Ph.D.

Montclair State University

Research Partners Program

GRACE JONES RICHARDSON FAMILY FOUNDATION

GJR Foundation Investigators

Young Investigator
Dong Liu, Ph.D.
Columbia University

Young Investigator
Kevin J. Clancy, Ph.D.
McLean Hospital - Harvard University

JOHN KENNEDY HARRISON II

John Kennedy Harrison Investigator

Young Investigator
Rasmus Herlo, Ph.D.
Columbia University

MIRIAM KATOWITZ

Katowitz Investigators

Young Investigator
Chris Greene, Ph.D.
Trinity College, Dublin

Young Investigator
Jia Guo, Ph.D.
Columbia University

ROSALIE KATZ FAMILY FOUNDATION

Rosalie & Daniel Katz Family Investigators

Young Investigator
Amy Peters, Ph.D.
Massachusetts General Hospital - Harvard University

Young Investigator
Aiste Lengvenyte, M.D.
University of Montpellier

BARBARA, CHRIS & KIMBERLY KENNY

Kenny Family Investigator

Young Investigator
Robert G. Mealer, M.D., Ph.D.
Oregon Health & Science University

LAKESIDE INDUSTRIES/LEE FAMILY

Jeanne Marie Lee Investigators

Young Investigator
Marta Cosin-Tomas, Ph.D.
Barcelona Institute for Global Health

Young Investigator
Michael-John Dolan, Ph.D.
Trinity College, Dublin

Young Investigator
Cassandra M. Eng, Ph.D.
Stanford University

Young Investigator
Joana Ferreira, Ph.D.
Center for Neuroscience and Cell Biology (CNC)

Young Investigator
Alexandra S. Klein, Ph.D.
University of California, San Francisco - The J. David Gladstone Institutes

Young Investigator
Sayan Nandi, Ph.D.
Howard University

Young Investigator
Kirsten E. Schoonover, Ph.D.
University of Alabama at Birmingham

Young Investigator
Johanna Seitz-Holland, M.D., Ph.D.
Brigham and Women's Hospital, Inc. - Harvard University

MOLLY LOU FOUNDATION

Molly Lou Foundation Investigators

Young Investigator
Chinnakkaruppan Adaikkan, Ph.D.
Indian Institute of Science

Young Investigator
Shokouh Arjmand, Pharm.D.
Aarhus University

THE MERJAN FAMILY

Merjan Family Investigator

Young Investigator
Victor M. Luna, Ph.D.
Temple University

P&S FUND

P&S Fund Investigators

Young Investigator
Ryan T. Ash, M.D., Ph.D.
Stanford University

Young Investigator
Samuel William Centanni, Ph.D.
Wake Forest University Health Sciences

Young Investigator
Kenny L. Chan, Ph.D.
Icahn School of Medicine at Mount Sinai

Young Investigator
Ana Paula Costa, Ph.D.
University of Pittsburgh

Young Investigator
Jinye Dai, Ph.D.
Icahn School of Medicine at Mount Sinai

Young Investigator
Livea D. Godoy, Ph.D.
Aarhus University

Young Investigator
Simon B. Goldberg, Ph.D.
University of Wisconsin

Young Investigator
Marito Hayashi, Ph.D.
*Harvard Medical School
Harvard University*

Young Investigator
Frederick L. Hitti, M.D., Ph.D.
*University of Texas Southwestern
Medical Center at Dallas*

Young Investigator
Inge R. Holtman, Ph.D.
University Medical Center, Groningen

Young Investigator
Kyle D. Ketchesin, Ph.D.
University of Pittsburgh

Young Investigator
Sabine Krabbe, Ph.D.
The German Center for Neurodegenerative Diseases, Germany

Research Partners Program

Young Investigator

Nan Li, Ph.D.

University of Texas Southwestern Medical Center at Dallas

Young Investigator

Chiara Maffei, Ph.D.

Massachusetts General Hospital - Harvard University

Young Investigator

Indira Mendez-David, Ph.D.

Paris-Saclay University

Young Investigator

Brittany D. Needham, Ph.D.

Indiana University

Young Investigator

Zachary T. Pennington, Ph.D.

Icahn School of Medicine at Mount Sinai

Young Investigator

Emma K. Stapp, Ph.D.

George Washington University

Young Investigator

Anna Schroeder, Ph.D.

University of Freiburg

Young Investigator

Thomas Steinkellner, Ph.D.

Medical University of Vienna

Young Investigator

Kristin L. Szuhany, Ph.D.

New York University

Young Investigator

Xinzhu Yu, Ph.D.

University of Illinois Chicago

KELLY SEPCIC PFEIL & DAVID PFEIL

The Pfeil Foundation Investigators

Young Investigator

Marjolein E.A. Barendse, Ph.D.

Erasmus Medical Center - University Medical Center Rotterdam

Young Investigator

Daniel S. Barron, M.D., Ph.D.

Brigham and Women's Hospital, Inc. - Harvard University

Young Investigator

Jennifer J. Donegan, Ph.D.

Dell Medical School, University of Texas at Austin

Young Investigator

Anna J. Finley, Ph.D.

North Dakota State University

Young Investigator

Bart N. Ford, Ph.D.

Oklahoma State University Center for Health Sciences

Young Investigator

Patrick R. Sweeney, Ph.D.

University of Illinois at Urbana-Champaign

KATHY AND CURT ROBBINS

Let The Sunshine Run Investigator

Young Investigator

Vineet Augustine, Ph.D.

University of California, San Diego

SUSAN & SARAH SALICE

The Salice Family Investigators

Young Investigator

Rebekah S. Huber, Ph.D.

Oregon Health and Science University

Young Investigator

Debora Masini, Ph.D.

Stockholm University

MEDHAT F. SAMI FOUNDATION, INC

Young Investigator

Judit García-González, Ph.D.

Icahn School of Medicine at Mount Sinai

ELLEN SCHAPIRO & GERALD

AXELBAUM

Ellen Schapiro & Gerald Axelbaum Investigators

Young Investigator

Franco Giarrocco, Ph.D.

National Institute of Mental Health (NIMH/NIH)

Young Investigator

Maryam Hasantash, Ph.D.

Columbia University

Young Investigator

Arielle S. Keller, Ph.D.

University of Connecticut

Young Investigator

Laura Luyten, Ph.D.

Leuven University

Young Investigator

Liming Qiu, M.D.

University of Pennsylvania

Young Investigator

Urszula A. Skupio, Ph.D.

Research Foundation for Mental Hygiene, Inc./NKI

Young Investigator

Michelle E. Stepan, Ph.D.

UPMC - University of Pittsburgh School of Medicine - University of Pittsburgh

Young Investigator

Alex Tang, Ph.D.

University of Western Australia

Young Investigator

Brian Zabolski, Ph.D.

Yale University

SCOTT-GENTLE FOUNDATION

Scott-Gentle Foundation Investigator

Young Investigator

Emilia Favuzzi, Ph.D.

Yale University School of Medicine - Yale University

JOHN & POLLY SPARKS FOUNDATION

John & Polly Sparks Foundation Investigators

Young Investigator

Jessica Lynn Bolton, Ph.D.

Georgia State University

Young Investigator

Sarah M. Clark, Ph.D.

University of Maryland, Baltimore

Young Investigator

Carlos Fernandez-Pena Acuna, Ph.D.

St. Jude Children's Research Hospital

Young Investigator

Antonia N. Kaczurkin, Ph.D.

Vanderbilt University

Research Partners Program

Young Investigator

Nisha Raj, Ph.D.

Emory University

EVELYN TOLL FAMILY FOUNDATION

Evelyn Toll Family Foundation

Investigators

Young Investigator

Harriet R. Feldman, M.D., Ph.D.

The Francis Crick Institute

Young Investigator

Wei-Kai Huang, Ph.D.

Massachusetts General Hospital

Harvard University

Young Investigator

Kevin W. Kelley, M.D., Ph.D.

Stanford University

Young Investigator

Alana I. Mendelsohn, M.D., Ph.D.

Columbia University

Young Investigator

Rik Schalbroeck, Ph.D.

Amsterdam University Medical Centers

W III FOUNDATION

W III Foundation Investigators

Young Investigator

Sean M. Nestor, M.D., Ph.D.

Sunnybrook Health Sciences Centre -

University of Toronto

Young Investigator

Melinda Westlund Schreiner, Ph.D.

The Research Institute at Nationwide

Children's Hospital

Young Investigator

Yun Wang, Ph.D.

Emory University

THE WALDER FAMILY CHARITABLE FUND

The Walder Family Investigators

Young Investigator

Lindsay R. Halladay, Ph.D.

Santa Clara University

Young Investigator

Miles Wischnewski, Ph.D.

University of Minnesota

Young Investigator

Mario Alexander Penzo, Ph.D.

*National Institute of Mental Health
(NIMH/NIH)*

ANONYMOUS

Zorich Family Investigators

Young Investigator

Caroline P. Hoyniak, Ph.D.

Washington University, St. Louis

Young Investigator

Emilia M. Lefevre, Ph.D.

University of Minnesota

Young Investigator

Andrea Reiter, Ph.D.

University Hospital Würzburg

TeamUp

for RESEARCH

With the support of family, friends and your community, you can make a difference in the fight against mental illness. The Brain & Behavior Research Foundation relies on the generosity of our donors to help fund leading brain and behavior research. You fuel the hope and promise of future discoveries that will improve the lives of those living with a mental illness. 100% of all donor contributions for research are invested in research grants. When you hold a fundraiser, you play a key role in helping us fund research toward improved treatments, cures, and methods of prevention for our loved ones.

“Every event brings us that much closer to a day free of mental illness. Thank you for partnering with BBRF.” – Jeffrey Borenstein, M.D.

\$100,000+

DOKIBIRD

Internet Campaign

\$50,000+

BEHAVIOUR INTERACTIVE INC.

Internet Campaign

HIKE FOR MENTAL HEALTH

United States

ANNUAL LET THE SUN SHINE RUN/WALK

Kathy & Curt Robbins

Minnesota

\$10,000+

BE YOUR POSSIBLE RUN

Peter Kirk

New York

PLAY A CHAMPION

William & Richard Noortman

Portugal

GRAY KRUSELL NELSON FAMILY WALK FOR MENTAL ILLNESS CURE

Peggy Krusell & Eric Nelson

Virginia

WILL WOOD, LLC

William J. Colligan

Pennsylvania

\$5,000+

BEN'S MEMORIAL MILE

Jamie & Paul Silver

Arizona & Illinois

CHRISSEY'S WISH

Linda & Mario Rossi

New York

FROYO FOR GOOD WITH NESTOR CANO

Internet Campaign

HOPE FOR LIFE – FRITZLEN & LEAHY MEMORIAL FUND

Internet Campaign

TEAM DANIEL – RUNNING FOR RECOVERY FROM MENTAL ILLNESS

Drs. Ann & Robert Laitman

New York

THAT5K - VICTORIA 'TORI' TRAN COOK MEMORIAL

Tu Anh Tran-Cook & Stephen W. Cook

Indiana

\$1,000+

GANESH CHATURTHI CELEBRATION FUNDRAISER

Yogesh Kulkarni

Texas

2024 RUNNING FOR MENTAL HEALTH

Tyler Couey

Georgia

DAVID E. GREEN MEMORIAL GOLF CLASSIC

Brian Sullivan & John Hagerty

Maryland

GLDN, INC.

Dree Pike

Internet Campaign

HERSHEY CAR SHOW

Kimberly Metz

Pennsylvania

HIZE'NLOWZ, LLC

Dalton Ammerman

Internet Campaign

MANIFOLD CHARITY POKER TOURNAMENT

Manifold Markets, Inc.

California

MARCH COMEDY MADNESS

Josh Filipowski

Massachusetts

MENTAL HEALTH AWARENESS CAMPAIGN

Frank Galante

New York

POKER CHARITY TOURNAMENT

Hunter Kaucky

New York

RPG CROSSING FUNDRAISER

Mark Englehardt

Canada

GREGORY & TYLER STARLING FUND

Dana and Bill Starling

Internet Campaign

TEETURTLE, LLC

Ramy Badie

Internet Campaign

VITAL APPAREL

Hung Dao & Alex Kozub

Internet Campaign

\$500+

FROM ME TO YOU GREETING CARDS

Bryan D'Angelo

Internet Campaign

GIBI ASMR

Gina Lupica

Internet Campaign

BROOKLINE YOUTH TUTORING & ENRICHMENT

Massachusetts

DONORS

Distinguished \$250,000+

Brian Benitz Supplemental Needs Trust
Borrego Foundation, Inc.
Don & Mary Ann Bumbacher Interim Trust
William F. Byerley, M.D.
The Carmel Hill Fund
The Jill L. Davenport Administrative Trust
The Maryann C. Delaney Charitable Remainder Unitrust
The Essel Foundation, Inc.
Mr. and Mrs. Milton Maltz
The Estate of Jean F. Miller P&S Fund
The Estate of Colleen Wald
WoodNext Foundation

Benefactors \$100,000+

Anonymous
Mr. Gerald Axelbaum and Ms. Ellen J. Schapiro
The Peter and Carmen Lucia Buck Foundation (PCLB)
The Clausen Family Foundation
The Katherine W. Cook Trust
Robert and Rita Elmen Foundation
Dr. Judy L. Genshaft and Mr. Steven Greenbaum
Lakeside Industries, Inc./ Lee Family
The Oxley Foundation
Roy H. and Natalie C. Roberts Family Foundation
The San Francisco Foundation
The Gurmukh Sarkaria Family Trust
Dr. and Mrs. Mark Silver
Dennis W. Sobotka, M.D.
Stripe
The Margaret Rose Tascon-Alonso Living Trust
The Maya Tobias Trust
The Evelyn Toll Family Foundation
Vital Projects Fund, Inc.
The Estate of Mary Ann Yahiro

Pacesetters \$50,000+

Anonymous
The Rossella Balint Trust
Behaviour Digital / Interactive, Inc.
The Roderick D. Carroll Trust
Dr. and Mrs. Thomas B. Coles, Jr.
Albert S. Copeland Trust
U/A 1/25/91 FBO Albert D. Copeland
Mr. and Mrs. Robert W. D'Alelio
The Golden Rule Giving Fund
Head Family Charitable Foundation
HIKE for Mental Health, Inc.
Jewish Federation of Metropolitan Chicago
Edward Jones Investments
Miriam E. Katowitz, C.P.A.
The Estate of John Paul LeDoux
The Chris & Melody Malachowsky Family Foundation
The MollyLou Fund
Mr. and Mrs. John R. Osterhaus
The Constance L. Paul Legacy Fund
Mr. and Mrs. Curt Robbins
Ms. Nancy L. Sheehy
Ms. Andrea R. Graham and Mr. Geoffrey A. Simon
Mr. Jason D. Stipanov and Ms. Amy Tisler
Dr. and Mrs. Douglas A. Treco
The Weisman Family Foundation

Leaders \$25,000+

Anonymous (3)
Aramont Charitable Foundation
Mr. and Mrs. Daniel Attias
The Sidney R. Baer, Jr. Foundation
Mr. and Mrs. Michael J. Bass
Becht Engineering Company, Inc.
The Benevity Community Impact Fund d/b/a American Online Giving Foundation (AOGF)
Mr. and Mrs. Barry J. Brandt

Henry J. Carson Revocable Trust
The Case Family
Dauten Family Foundation
Marvin H. Davidson Foundation, Inc.
The Dozen Dimes Foundation, Inc.
Mrs. Mary Ann Ehrlich
Beth and Rob Elliott
Ms. Karin Epstein Kuhns
Mrs. Luisa Francoeur
The Gay Libertarian Fund
The Estate of Dolores L. Gilliam-Barrett
Ms. Gail M. Gouvea
The Peter Gump Endowment Fund
Mr. and Mrs. Alan Hammerschlag
Mr. John K. Harrison II
Jeffrey J. and Mary E. Burdge Charitable Trust
The Kaplen Foundation
The Rosalie Katz Family Foundation, Inc.
Ina Kay Foundation
Dr. Barbara Kenny and Mr. Christopher L. Kenny
Ms. Judith D. Lohaus and Mr. Michael S. Mudd
Ms. Anne Macdonald
The Merjan Family
Morgan Stanley Global Impact Funding Trust, Inc.
Eugene & Bonnie Nugent Foundation
Ms. Riska Platt-Wanago
Mr. and Mrs. Steven P. Rosenmutter
The Roush Family Trust
The Salice Family Foundation
The SandCastle Foundation
Schwab Charitable Fund
The Scott-Gentle Foundation, Inc.
The Estate of Robert N. and Patricia A. Smith
Mrs. Barbara K. Streicker
Mr. and Mrs. William B. Tausig

Patrons \$10,000+

Anonymous (4)
15Five
The 7M Ranch Fund
The Albert Family Fund

Alpine Saxon Woods, LLC
Mrs. Lillian L. Anderson
The Atkinson Family Foundation
The Auslander Family Foundation, Inc.
Ms. Lisa Ball
Be Your Possible
Mr. and Mrs. Thomas M. Bergers
The Adina L. Bernreuter Revocable Trust
Mr. and Mrs. Donald M. Boardman
Ms. Sharon E. Bowyer
Brener International Group, LLC (BIG)
Mr. and Mrs. David E. Brown
The Elise and Andrew Brownstein Charitable Trust
Mr. and Mrs. John B. Carew
Ms. Ashley J. Case
Columbia University
Ms. Judith M. Craig
The Fred Craves Family Foundation
The Estate of Pamela Czaikowski
Mr. Richard E. Dagle
Darden Family Charitable Foundation
Mr. and Mrs. E. Everett Deschner
Ms. Patricia A. Dilanni and Mr. Donald G. Simons
Mr. and Mrs. Samuel E. Eden
Mr. and Mrs. David M. Farren
Fidelity Investments Charitable Gift Fund
Fortis Construction, Inc.
Ms. Patricia R. Fuller-Pratt
Mr. and Mrs. David S. Furman
Mr. and Mrs. David Futterman
Mr. and Mrs. Anil P. Gadre
M. Rameen Ghorieshi, M.D., M.P.H.
Give Lively Foundation, Inc.
Neal and Marlene Goldman Foundation
Dr. and Mrs. John W. Gonzalez
D.W. Gore Family Foundation
Mr. James R. Ingram and Ms. Sheila Grant
Green Foundation
Mrs. Theresa Gunnlaugsson

Patrons (continued)

Mr. and Mrs. John E. Hart
 Mr. and Mrs. Kenneth M. Harvey
 Marilyn G. Harwood Fund
 Mr. and Mrs. Larry J. Hinman
 HMS Manufacturing Company
 Dr. Karen Hobbs
 Independent Charities of America
 Dr. Raj Jeevan
 The Grace Jones Richardson Trust
 Committee for Jackie J. Kiser
 Ms. Ellen Krantz
 Mr. and Mrs. Theodore Larson
 The Lavin Family Foundation, Inc.
 Ms. Sharon Lee
 Ms. Carolyn A. Magee
 Mr. Keith C. Magee
 Carole and Harvey Mallement
 Mr. and Mrs. Wesley McDonald
 Ms. Diane Muccigrosso
 Mr. and Mrs. Eric W. Murchison
 The Naduse Foundation
 New England BioLabs, Inc.
 New York Presbyterian Hospital
 Mark D. Olson, Esq.
 Ms. Alison L. Park
 PayPal Giving Fund
 Mrs. Mary J. Pedrosa
 Mr. Laurence J. Phillips
 Play A Champion Foundation
 Mr. Michael Priven
 Puccia Giving Fund
 Mr. Adam Ratajczak
 Mrs. Hiroko Rawald
 Patrick Engineering, Inc. d/b/a RINA
 Sarah W. and Leonard Y. Safrit Gift Fund
 Mr. and Mrs. Ronald G. Sefried
 Ms. Emily J. Segal and Mr. Andrew D. Ellis
 Ms. Marylou Selo
 The Arnold Simonsen Family Charitable
 Foundation, Inc.
 Supreme Council Benevolent Foundation
 Teapot Foundation
 The Thom Family Foundation, Inc.
 UNIDENTIFIED STOCK OR GIFT
 WCG - MedAvante-ProPhase, Inc.
 Dr. Myrna M. Weissman and
 Dr. James C. Frauenthal
 The Westport Fund
 Willens Family Foundation
 Will Wood, LLC
 The Robert Wood Johnson Foundation
 President's Grant Fund

Sponsors \$5,000+

Anonymous (3)
 Mr. Thomas L. Anderson
 Ms. Pamela J. Andrews
 Barretta Family Foundation
 Mrs. Maureen M. Bartlett
 The Alben F. Bates & Clara G. Bates
 Foundation
 Mary Theresa Becker Special Needs
 Trust
 Ben's Memorial Mile
 Betagole Family Foundation, Inc.
 Mr. and Mrs. Robert T. Blanchard
 Mr. and Mrs. Martin H. Borell
 Dr. and Mrs. Jeffrey Borenstein
 David Broad Fund for Brain Research
 Mrs. Peggy B. Burke
 Ms. Nicole B. Byrd
 Ms. Sally F. Cameron
 Ms. Kathryn A. Cannon and
 Dr. Scott C. Berk
 Charles Schwab
 Mrs. Jane Colman
 Commission Account
 Mary Cooney & Edward Essl Foundation
 Mrs. Joy Davis
 Mr. Nathan Dixon
 Mr. and Mrs. William R. Dodds, Jr.
 Trust Under The Will of Elmer J. Dreher
 Mr. and Mrs. Richard A. Edwards
 Mrs. Shannon Everly
 Dr. Gloria Farber
 Mr. David Feiges
 Mr. Daniel J. Feith
 Ms. Laura Finn
 The Thomas and Jerrice Fritzen Family
 Charitable Fund
 Mrs. Kathleen E. Furness and
 Dr. Gary Furness
 The Joseph and Anna Gartner
 Foundation
 Ms. Jan Gerste
 Ms. Mary T. Gilbert
 Mr. and Mrs. Thomas G. Gillis
 Mr. and Mrs. Timothy H. Gillis
 The Adam Grainawi Fund
 Mr. and Mrs. Kevin M. Greene
 Mr. Leonard L. Gumport and
 Ms. Wendy Munger
 Ms. Maureen Harris
 Mr. Stewart Hatch
 David and Sharon Herzer
 Ms. Jennifer Hinds
 Mr. John J. Hoffman

Ambassador Swanee G. Hunt
 IT Supplies, Inc.
 Ms. Lois Jecklin
 Mr. and Mrs. Mitchell Johnson
 Mr. and Mrs. Patrick L. Johnson
 Mr. and Mrs. Thomas K. Johnson
 Mr. David K. Johnston
 Mr. Charles Jones
 Mr. and Mrs. Steven Jones
 Ms. Ann E. Kenowsky
 The Estate of Daniel Keith Kimbro
 Clemence S. Lieber Foundation, Inc.
 Ms. Linda Lou Lopez
 The Estate of Ruth Lowe Morris
 Mr. and Mrs. L. Alan Lowry
 Ms. Elizabeth A. Maher
 Mr. and Mrs. Lawrence A. Margolis
 Dr. Irving L. Jacobs and
 Ms. Jeanette L. Matye
 Mr. and Mrs. William J. Megowen
 Thomas G. and Andrea Mendell
 Foundation
 The Emil & Toby Meshberg Family
 Foundation, Inc.
 The Minneapolis Foundation
 Dr. Sidney Moon
 NAMI - South Shore, Inc.
 Mr. and Mrs. Claude Nassif
 Mr. Eric H. Nelson and
 Ms. Peggy J. Krusell
 Ron and Joyce Nelson Family Foundation
 Mr. and Mrs. Mark Newell
 Ms. Kristin C. Parsons
 Mr. Daniel Pipinich
 Mr. and Mrs. Brad A. Purifoy
 Rabaut Family Foundation
 Mr. Marc R. Rappaport
 Mr. Rommel Ravanera
 Mr. and Mrs. Matthew L. Renner
 Irene Ritter Foundation
 Mrs. Ellen A. Rosen
 Mr. and Mrs. Robert A. Rowan
 Mrs. Sarah L. Schnarr
 Mr. and Mrs. Brian Sheridan
 Elinor Beidler Siklossy Foundation
 The Clark and Diane Slipper Family
 Giving Fund
 Dr. Kenneth H. Sonnenfeld and
 Dr. Margaret Bolce-Brivanlou
 Mrs. Blanche Speiser
 Dr. Michael L. Stein and
 Ms. Laurie J. Butler
 Ms. Nya Stilwell

Sponsors (continued)

Team Daniel Running for Recovery from
Mental Illness, Inc.
Tulchin Family Foundation
LR Tullius, Inc.
Mr. Jimmy Vogel and
Ms. Melissa James-Vogel
Ms. Josephine Wang
Mr. and Mrs. Louis Weisman
Wellington Shields & Company, LLC
The Westley and Buttercup Fund
Wooley Family Foundation, Inc.
YourCause, LLC
Mr. Marc J. Zwillinger

Associates \$1,000+

Anonymous (12)
Mr. Mario A. Abate
Susan Abbott, M.D.
Mr. and Mrs. Donald D. Abells
Anissa Abi-Dargham, M.D.
Mr. Howard Abramoff and
Dr. Hinda Abramoff
Mr. Joel H. Abrams and
Dr. Robin H. Abrams
Mr. and Mrs. Tim G. Abrams
Mr. and Mrs. Daniel P. Adams
Mr. John Akin
Ms. Amy L. Alexander
Mr. Jeff S. Alexander and
Ms. Jocelyn Bailin
Mrs. Mary D. Alexander
The Alliger Family Charitable Fund
Mr. Alexander Allione
Mr. and Mrs. John W. Allis
Mr. Derek Allwardt
Mr. and Mrs. Kurt Apen
Victoria Arango, Ph.D.
Arkay Foundation
Mr. and Mrs. Bernard J. Armada
Mr. and Mrs. D. Jarrett Arp
Athens Chilesburg Elementary
Mr. Bruce W. Baber
Mr. Matthew D. Baird
Mr. and Mrs. John J. Baldino
Mr. Stephen J. Balek
Ballard Spahr, LLP
Bank of America Charitable Gift Fund
Deanna M. Barch, Ph.D.
Mr. and Mrs. Victor C. Bastron
Mr. Mikel R. Bauer
The William J. Beard and R. Jean Beard
Joint Trust

Mr. and Mrs. James D. Becker
Mr. and Mrs. Michael Becker
Mr. and Mrs. Mitchell Becker
Belmont Books
Ms. Marta J. Bennett
Mrs. Sylvia K. Benzler
Mr. and Mrs. James A. Berch
The Berchin Family Foundation
Mr. Howard G. Berger and
Ms. Jean A. McPhilly
Mr. Isaiah Bergman
Mr. and Mrs. Gene P. Bernardoni
Mr. and Mrs. Nathan Betnun
The Birch Haven Fund
Mr. and Mrs. Michael F. Bishay
Bitly, Inc.
Mr. Gary N. Bjorklund and
Ms. Lorna Renshaw-Bjorklund
Mr. Edward Black
Mrs. Lisa Blazar
Mrs. Jeanne Bloom
Dr. and Mrs. Gregory M. Bolduc
Network For Good d/b/a Bonterra
Mr. Zachary A. Booher
Mrs. Sondra Boone
Dr. and Mrs. Andrew S. Boral
Mr. Andrew K. Boral
Mr. and Mrs. Norman H. Bouton, Jr.
Mrs. Colleen Braa
Mr. Graham Branton
Mr. Thomas J. Brennan
Mr. and Mrs. Robert S. Brewster
The Brickyard Berridge Fund
Dr. Iva L. Bridwell and
Mr. Braughton W. Webb
Mr. and Mrs. Frank J. Brigante
Bright Funds
Mr. and Mrs. Peter M. Briscoe
Bromark Family Foundation
Dr. Marjorie O. Brooks
Ms. Christina Brown
Ms. Paige E. Brown
Robert M. Brown & Thelma Y. Brown
Foundation
Mr. and Mrs. Phillip L. Brown
Dr. and Mrs. William J. Brownstein
Ms. Christine Brozynski
Ms. Margaret R. Brubaker
Mr. Jesse J. Bryant
Peter F. Buckley, M.D.
Mr. and Mrs. Bernard A. Buescher
Ms. Deborah J. Buhro
Mr. and Mrs. George A. Bundschuh
Mr. Michael Burstein

Ms. Mara E. Busby
Ms. Gloria L. Cafeo
Mr. and Mrs. Keith Capasso
Mr. and Mrs. Gerald Capodiec
Mr. and Mrs. Brian O. Caprio
Mr. and Mrs. James P. Carroll
Mr. and Mrs. Tim Carroll
Cameron S. Carter, M.D., M.S.
Mr. and Mrs. Daniel J. Castellani
Mr. Calvin J. Cericola
CH Technologies (USA), Inc.
Ms. Elizaveta Chaikovskaya
Mr. Joseph Chang and Dr. Juliet Siegel
Mr. Gary Chase
Dr. Weiwei Chen
Ms. Elizabeth Childress
Ms. Marilyn Chism-Larkin
Mr. Randolph F. Christen
Mr. Mark W. Chutter and
Ms. Lorna Beth Ellis
CJK Foundation, Inc.
CJR Foundation, Inc.
Mr. David H. Clemens
Mr. and Mrs. Craig W. Clendening
Mrs. Darline Cohen
Dr. Michael M. Cohen and
Ms. Karen L. Cohen
Ms. Susan C. Bourget and
Dr. Peter G. Coles
C&J Collins Family Foundation
Mr. David W. Connelly
Ms. Carolyn M. Connolly
Mr. Stephen W. Cook and
Ms. Tu Anh Tran-Cook
Mr. and Mrs. Angelo J. Correa
Mr. and Mrs. Patrick Consentino
Mr. and Mrs. Robert H. Craft, Jr.
Ms. Katherine M. Crawford
Mr. Jacob Crosmer
The Ed & Shirley Curley Family Fund
Dr. Joanna C. Curran and
Mr. Philip J. Curran
Mr. Thomas D. Curtis and
Dr. Mary A. Curtis
Cybergrants SPV, LLC
Mr. and Mrs. Edward H. D'Alelio
Ms. Enid B. Dalkoff
The Dammann Fund, Inc.
Mr. and Mrs. Aaron Daniels
Mr. and Mrs. Dennis C. Darling
Mr. and Mrs. Paul J. Datta
Mr. and Mrs. C. Marshall Davison
Mr. and Mrs. Gregory P. Dean
Mr. Giuliano Degrassi

Associates (continued)

Mr. and Mrs. Timothy A. DeLapp
Ms. Jessica A. Dembeck
Mr. and Mrs. David Derman
Mr. Philip Desai
Dr. and Mrs. Pedro M. Diaz
Mr. Nicolas DiCiaccio and
Ms. Marquerite Shepard-DiCiaccio
Ms. Nancy G. Dickenson
Dr. Joshua S. Dillon and Ms. Effie Seiberg
Ms. Rachel S. J. Dooley and
Mr. Daniel J. Koevary
Mr. R. Larry Drake and
Ms. Karen L. Erickson Drake
Ms. Bari Dreiband-Burman
Mr. and Mrs. Morris H. Dweck
Mr. and Mrs. Robert S. Earley
Mrs. Miranda C. Echternach
Mr. and Mrs. Eric L. Edelson
Drs. Kurt and Mary Edwards
Einterz & Einterz
Ms. Rosamund M. Else-Mitchell
Mr. and Mrs. Preston C. Everdell
Mr. and Mrs. Michael F. Falkner
Mr. John Ferguson
Mr. Casey Ferris
Mr. and Mrs. John Fidaleo
Ms. Susan J. Finan
Mr. and Mrs. J. Warren Fisher
Rabbi Lyle A. Fishman and
Ms. Debra A. Rosenman
Mr. Adam M. Fletcher
Ms. Carol Flint and Mr. Stephen E. Jones
Mr. Gregory Flood
Ms. Annette Foglino
Judith M. Ford, Ph.D. and
Daniel Mathalon, M.D., Ph.D.
Ms. Betsy Foreman
Mr. John L. Stodola and
Dr. Kathleen T. Frankle
Dr. and Mrs. Robert R. Freedman
Dr. and Mrs. Thomas B. Freeman
Mrs. Susanne Friedel
Ms. Harriet M. Friedland
Ms. Marlene A. Fritz
Mr. and Mrs. Rob Frohwein
Mr. Lawrence S. Frydman
Mr. and Mrs. John C. Frye
The Gaddis Family Foundation, Inc.
Mr. Morgan Gagel
Mr. Frank Galante
Mr. Ronald R. Zellar and
Ms. Susan M. Gallagher
Ms. Catherine B. Gardner
Mr. Alan R. Gartenhaus and
Mr. Rhoady R. Lee III
Mrs. Nancy A. Gecker
Mr. Jeffery L. Gerbitz
Mr. and Mrs. Darryl R. Gerstenecker
Mr. and Mrs. Robert W. Geyer
Mr. and Mrs. Steven A. Gibson
DPR Gilmartin Family Fund
Giving Fund
GLDN, Inc.
Mr. and Mrs. Richard W. Glitz
Ms. Ilana Goldberg
Mr. Robert S. Rosen and
Ms. Marcia H. Golub
Goodwin Procter
Mr. and Mrs. David Gormley
Ms. Diana Graeber
Mr. and Mrs. Bennett G. Grau
Mr. Peter B. Gray and Ms. Pamela Blake
David E. Green Memorial Scholarship
Fund
Mr. and Mrs. Travis D. Green
Mr. Barry K. Greenberg and
Ms. Zoe Friedlander
Mr. and Mrs. Jesse J. Greene, Jr.
Mr. and Mrs. Cary Griffin
Ms. Beth Grossbard
Mr. Matthew Guerra
Mr. Charles Guilamo
Gunn Training Solution (GTS) / Gunn, Inc.
Dr. Suzanne N. Haber and
Mr. William L. Thomson
Ms. Claudia M. Haindl-Ditscher
Ms. Lisa R. Hall
Mr. and Mrs. Stuart D. Halloway
Mr. and Mrs. Roscoe O. Hambric, Jr.
Mr. and Mrs. Gregg Hamerschlag
Mr. Bradley Hamlett
Mrs. Barb Hamor
Mr. Frederick G. Hanselman and
Ms. Talia Hanselman-Shmuel
Mr. and Mrs. Kevin J. Harkenrider
Mr. and Mrs. Norm Harper
Mr. Norman J. Ornstein and
Ms. Judy L. Harris
Haselton Family Foundation, Inc.
Ms. Martha M. Hathaway
Ms. Marian G. Hayes
Mr. Joseph P. Cothrel and
Ms. Linda A. Heban
Mrs. Heidi Heiland
Ms. Susan R. Helsel
Hermann Family Foundation
Mr. Michael T. Hexner
Mr. Stephen Hochbrunn
Mr. Logan M. Hood and
Ms. Apeksha Chauhan
Ms. Ann Hopkins
Ms. Karen E. Hopkinson
Mr. and Mrs. Mark J. Hovis
Mrs. Suzanne C. Hoyt
Ms. Charity Huff
Mr. Daniel Hulsebosch
Human Media Group, LLC
Mr. and Mrs. Scot W. Humphrey
Mrs. Hazel Hundert
Ms. Sarah M. Hunt
Mrs. Gail J. Hurvitz
Mr. and Mrs. Robert Ianni
Mr. and Mrs. John Iber
Mr. Stede Ingram
Mrs. Mary T. Ingriselli
Mervyn Israel, Ph.D.
J Squared Press, Inc.
Mr. Eric M. Jackson
Ms. Mauvareen A. Jackson
Mr. and Mrs. Thomas A. Jacobs
Mr. and Mrs. Sidney S. Jacobson
Mr. Achyut Jajoo
Jama Software
Ms. Ellen E. Jamason
Mr. James P. Jamilkowski
Jonathan A. Javitch, M.D., Ph.D.
Mr. and Mrs. Richard A. Jespersen
Dilip V. Jeste, M.D.
Mr. Samuel I. Johnson and
Ms. Vanessa Howe-Jones
Ryan Joiner Foundation, Inc.
Ms. Elizabeth B. Jones
Ms. Jean Josepho
Mr. and Mrs. Anant S. Joshi
Mr. and Mrs. Robert R. Kain
Mr. and Mrs. David R. Kampf
Mr. and Mrs. Robert N. Kaplan
Mr. Robert Kashtan
Ms. Flora N. Katz and
Mr. Leland C. Ellis, Jr.
Mr. Hunter Kaucky
Mr. Laurance R. Kaufman
Mr. and Mrs. Eugene Keane
Kehl Family Fund
Ms. Elizabeth G. Keller
Mr. and Mrs. Everett Kenerson
Mr. and Mrs. William R. Kennington, Jr.
Mr. and Mrs. Frank S. Kilpatrick
Mr. and Mrs. James P. Kimble, Jr.
Mrs. Margaret F. Knellinger
Mr. and Mrs. Jack L. Knicely

Associates (continued)

Mr. and Mrs. Roger L. Knight
Mr. and Mrs. Warren C. Kocmond, Jr.
Mr. and Mrs. Robert P. Kogod
Kohler Equipment
Ms. Prajakti Kothare
Ms. Ruth B. Kramer
Mr. and Mrs. Michael Kress
Mr. and Mrs. Howard G. Kristol
Dr. and Mrs. Werner Kroll
Drs. John H. Krystal and Bonnie Becker
Mr. Shane D. Kucera
Mr. Yogesh Kulkarni
Dr. Seema Kumar and Dr. Anika Kumar
Mr. and Mrs. Kenneth J. Kunda, Sr.
Mr. and Mrs. J. Wesley Kussmaul
Mr. Sean R. Lahart
Mr. William M. Lam
Ms. Alisa A. Lancaster
Ms. Diane Lane
Dr. and Mrs. George Lantos
Ms. Alice A. Larson
Mr. Brian S. Latell
Mr. Randall Laurence
Mrs. Deirdre Laveran
Mr. and Mrs. Richard A. Lees
Mr. and Mrs. James C. Leichtung
Dr. and Mrs. Robert H. Lenox
Arlene Lerner, Ph.D.
Ms. Elisabeth K. Lescault
Mr. and Mrs. Stephen A. Levis
Ms. Linda K. Levis-Ladd
Mr. and Mrs. Daniel Levy
The Hurwitz Lichtenfeld Family
Charitable Fund
Ms. Kathleen G. Liddy
Robert J. Lieber Charitable Trust
Ms. Rebecca Y. Lieberman and
Mr. George A. Smee
Like 2 Laugh Productions
Mr. and Mrs. Francis J. Lodanosky
Mr. and Mrs. Michael D. Logan
Mr. Brendan L. Lyons, Jr.
M & V Limousines, Ltd.
Dr. and Mrs. Paul J. Macchi
Ms. Cheryl L. MacLachlan and
Mr. Fred S. Gorelick
Ms. Victoria Mah
Mr. and Mrs. Joseph K. Maiuro
John & Marlene Major Foundation, Inc.
Dolores Malaspina, M.D., M.S., M.S.P.H.
Ms. Emily Malison
Manifold Markets, Inc.
Dr. Angelica Marer and
Mr. Stephen W. Marer
Frederick Joseph Martens Trust
Mr. and Mrs. Lowell F. Martin
Mr. Brandon Martinelli
Dr. and Mrs. Sanjay Mathew
Mr. and Mrs. Bayard R. Maybank
Mr. and Mrs. Chuck Mayo
Mr. Brian T. McCarthy
Dr. Rosemary C. McCoy
Dr. and Mrs. John Z. McDonald
Ms. JoLynne McDonald
Ms. Suzanne McGill
Mr. and Mrs. Richard F. McInerney
Mr. Jonathan B. McMillan
Ms. Katherine H. McNabb
Ms. Ellen C. Meadows
Mr. Dennis R. Ladick and
Ms. Karen L. Meadows
Ms. Gwendolyn Medrano-Pratts
Ms. Seema Mehta
Mr. and Mrs. Alan Meier
Ms. Julie Menin
Mr. and Mrs. David B. Merchant
Mrs. Sharon A. Messmer
Mr. and Mrs. Todd W. Metz
Mr. Nicholas J. Meyer
Mr. Anton J. Michelich
Mr. and Mrs. Scott D. Michelich
Middaugh Giving Fund
Mr. Gary R. Mikula and
Ms. Holly Burnet-Mikula
Mr. Cameron Miles
Mr. James Miller
Mr. and Mrs. Michael E. Miller
Mr. and Mrs. Paul D. Miller
Ms. Maida Milone
Dr. and Mrs. William J. Mitchell
Ms. Yasaman Molavi Vassei
Mr. Benjamin Montgomery
MRC Full Circle Foundation
MSSC, Inc.
Mrs. Joyce Mullan
Mrs. Meaghan E. Mullgardt
Mr. Roger C. Murphey III
Mr. Daniel Murphy
The Nacchio Foundation, Inc.
Mr. John Nachbar
Ms. Grace Nagaur
Mr. and Mrs. Joseph J. Nahas
NAMI - Newton Wellesley Eastern
Massachusetts, Inc.
National Charities Services
National Philanthropic Trust
Navient Community Fund
Mr. Patrick D. Navin
Mr. Carl Nelson
Ms. Rachel Nelson
Newbury Animal Hospital
Thomas C. Neylan, M.D.
NF Forward Payment
Mr. Quan Nguyen and Ms. Diana Feng
Dr. Nicole A. Nichols and
Dr. Jeffrey C. Nichols
Ms. Mary M. Nicol
The Gerald Norton Foundation
Patricio O'Donnell, M.D., Ph.D.
Mr. Brian Oldenburg
Mr. and Mrs. John A. O'Malley
OneStream, LLC
Mr. Ellis M. Oppenheim and
Dr. Lois L. Oppenheim
Mr. Jamison Orten
Mr. and Mrs. Bob Osterhaus
Ms. Jane T. Osterhaus and
Mr. Raymond J. Townsend
Dr. and Mrs. Robert J. Osterhaus
Ms. Debra A. Outlaw
Mr. Steven P. Paar
Ms. Francesca Painter
Ms. Lynn Panciera-Fraser
Mrs. Bonnie A. Parker
The Grayson Parker Memorial
Foundation
Mr. and Mrs. Robert L. Parks
Ms. Jeanne Pastore
Mr. Douglas W. Pastrich
Ms. Megan P. Patel
Mr. and Mrs. Leland R. Payton
Henry Safford Peacock Foundation
Mr. Jeffrey R. Peterson
Mr. Scott Peterson
Mr. Niels Peyls
Mrs. Marilyn M. Phillips-Bever
Mr. and Mrs. Joshua W. Pickus
Mr. Alan G. Pierce
Pledgeling Foundation
Ms. Pamela R. Polak-Collins
Dr. and Mrs. Robert M. Post
Ms. Hillary J. Powers
Mr. and Mrs. Robert Prieve
Mr. Roger Prior and Dr. Barbara A. Page
Mrs. Holly Pruett
Ms. Linda J. Purdy-Ohland
Mrs. Betsy V. Quinn
Dr. and Mrs. Mohammad E. Qureshi

Associates (continued)

Mr. and Mrs. Derek K. Rapp
Mrs. Margot E. Razziano
Mr. Jodd Readick
Cynthia M. Reed Heart & Solle
Foundation
Ms. Nancy Reeve
Mr. Michael E. Reeves
Mrs. Edith J. Rein
Mr. Ronald J. Remillard
Ms. Carol Reyes
Mr. and Mrs. Joseph J. Ricci
Mr. and Mrs. Stephen Rice
Mr. Gage M. Richert
Ms. Margaret Ann Ricketts
Ms. Victoria A. Riddell
Mr. and Mrs. Donald Rigoni
Mr. Brian A. Riley
Mr. Frederic W. Ripley and
Ms. Sharon Kirby
Ms. Min S. Ro
Max Robinowitz, M.D. and
Carolyn B. Robinowitz, M.D.
Mr. and Mrs. Daniel G. Rodgers
Dr. Rosalyn L. Roesel
Rogers Behavioral Health
Mr. Christopher P. Romaine
Dr. Jeffrey Rosen
Mr. and Mrs. Michael A. Ross
Mr. and Mrs. Mario J. Rossi
Mr. and Mrs. Michael R. Rothman
George A. Rozanski, Ph.D.
Dr. Guillermo J. Rozas and
Ms. Ariane L. Pannell
Mr. Rob Ruenes
Mr. and Mrs. James W. Rutherford
Mr. and Mrs. Jeffery L. Rutherford
The Petros K. & Marina T. Sabatacakis
Foundation
Gerard A. Sanacora, M.D., Ph.D.
Dr. Judith K. Hall and
Mr. Donald S. Sargent
Pankaj Sarin, M.D.
Mr. and Mrs. Jay Sarles
Mr. and Mrs. Phillip Satow
Dr. and Mrs. Adam J. Savitz
Mr. William Scanlan, Jr.
Ms. Sheila Scharfman
Dr. and Mrs. Alan F. Schatzberg
Mrs. Arlene Schemm
Anthony Schmidt Family Foundation
Mr. E. James Morton and
Ms. Matthild C. Schneider
Mr. and Mrs. Edward J. Schoenecker
Nina R. Schooler, Ph.D.
Ms. Mary L. Schoolman and
Mr. Jim Hinrichs
Mr. Daniel J. Schreiber
Mr. and Mrs. Richard Schuckle
Mr. and Mrs. Wayne H. Schut
Mrs. Susan K. Schwab
Mrs. Joann W. Schwentker
Mr. and Mrs. Stephen Segal
The Pearl and Alan Seidman Charitable
Fund
Mr. and Mrs. Dennis M. Seremet
Mr. and Mrs. Thomas W. Servas
The Wilson Sexton Foundation
Mr. and Mrs. Timothy O. Shally
The Carrie Shapiro Foundation
Ms. Elizabeth A. Shapland and
Mr. Mark A. Box
Mr. and Mrs. Gerry A. Shear
Mr. and Mrs. L. Michael Sheehy
Mr. and Mrs. Andrew Sheinman
Shell Oil Company Foundation Matching
Gifts
Mr. Hansen Shi
Mr. and Mrs. John Shields
Dr. and Mrs. Jonathan L. Shurberg
Mrs. Lilian Sicular
Mr. and Mrs. Robert M. Simon
Ms. Catherine H. Sisson
Ms. Barbara R. Smith
Mr. and Mrs. Craig F. Smith
Mr. and Mrs. David Smoley
Mr. Glenn Snodgrass
Mr. and Mrs. Jon A. Sobotka
Ms. Sallian Song
Mr. Jordan Sorensen
Mr. William H. Soskin and
Ms. Marian Penn
The Spangler Family Fund
Mr. Herrick Spencer
Mr. and Mrs. Paul Sprague
Mr. Mike Sramek
Ms. Amanda N. Sramek
Mr. and Mrs. William N. Starling, Jr.
Ms. Elizabeth Steele
Mrs. Faye Steiner
Ms. Johanna Steinmetz-Cummings
Mr. and Mrs. John P. Stenbit
Mr. and Mrs. Thomas F. Stephenson
Ms. Grace Stetson
Mr. and Mrs. Brent Stewart
Mr. Robert C. Stewart
Mr. Robert Stocks
Mr. Benjamin D. Strange
Mr. Joseph A. Svozil
Ms. Lauren Swift-Brokaw
Talon Communications, Inc.
Mr. and Mrs. Geoffrey Tate
TeeTurtle, LLC
Mr. and Mrs. Edward J. Terrell
Mr. Jorgen Thelin
Mr. and Mrs. Alan C. Thomas
Mr. and Mrs. Carlos A. Tizon
Mr. and Mrs. Lawrence M. Tolchin
Ms. Barbara Toll
Ms. Lupe S. Tortorella
Ms. Linda D. Tosti
Mr. Scott Touzinsky
Mrs. Esther F. Trachtman
Mr. and Mrs. Timothy C. Tuff
Mr. and Mrs. Paul Ulland
Vanguard Charitable Endowment
Program
Vital Apparel, LLC
Mrs. Marion Walsh
Dr. and Mrs. Robert L. Waterhouse, Jr.
Mr. and Mrs. Thomas Watson
Ms. Letitia Weber-Ford
Mr. Halbert S. Washburn and
Ms. Allison A. Weber-Washburn
Mr. Steven J. Wein
Mrs. Marilyn A. Weintraub
Mr. and Mrs. Jay Weisbrod
Ms. Constance Wells-Schnuck
Mr. and Mrs. Mark Welsh
Ms. Elizabeth West
The David & Sara Weston Fund
The Harold Wetterberg Foundation
Mr. and Mrs. Thomas C. White
Whitehall Family Foundation
Mr. and Mrs. James H. Wilbur
Mr. Paul C. Williams and
Ms. Leslie Berger
Mr. and Mrs. Steven C. Wills
Mr. and Mrs. John Winter
Mr. and Mrs. Robert E. Witt III
Mr. and Mrs. Craig S. Woelfel
E. Judson Wolfe, C.P.A.
Mr. David Wong
Mr. Morgan R. Dallman and
Ms. Carolyn Woodruff
Ms. Amy K. Wu Casler and
Mr. David A. Casler
Ximorsi
Mr. Daniel Zabloutney
Mr. and Mrs. Thomas Zambrano
Mr. James N. Zartman
Ms. Yaeko A. Zeigler

Associates (continued)

Mr. David S. Zelman
Mr. and Mrs. Jon Zeschin
Mr. William Zhou
Edward N. and Gladys P. Ziegler
Private Foundation, Inc.
Ms. Karen Zimmer
Mr. Charles L. Zody and Mr. Michael Zody
Dr. Alba Lucia Zuniga

Supporters \$500+

Anonymous (7)
Mr. and Mrs. Michael D. Abel
Ted Abel, Ph.D.
Mr. and Mrs. Celso C. Aberin
Dr. Charlene Abernethy
Mr. and Mrs. Wilson Aboudi
Ms. Wesal Abualkhair
Mr. Samy Achour
Ms. Tamara D. Alairys
Mr. and Mrs. Mark H. Alcott
Mr. and Mrs. Oscar Alerhand
Mr. John S. Miner and
Ms. C. Nelle Alexander
Ms. Ann T. Allen
Dr. Lauren B. Alloy
America's Charities
Ms. Ruth A. Rydstedt and
Mr. Ted T. Amsden
Ms. Kristina E. Andersson
Dr. A. Ballard Andrews
Arbor Assays, Inc.
Mr. Richard J. Arellano
Ms. Linda M. Awn
Dr. Mark Axelrode
Mr. Orhan Ayasli
Mr. Brian W. Baker
Ms. Ann Banchoff
Mr. and Mrs. Michael A. Barrett
Mr. Jeffrey Bartunek
Mr. and Mrs. Steven A. Baskin
Ms. Jennifer Baum
Mr. and Mrs. James P. Becker
Dr. and Mrs. Alfred D. Bell
Mr. and Mrs. Roger J. Berdusco
Ms. Lisa Berg
Mr. and Mrs. Herbert M. Bernard
Ms. Susan K. Berry
Mr. D. Max Bichunsky
Ms. Phyllis Bilus
Mr. and Mrs. John C. Binder
Mrs. Anne L. Bird
Ms. Melissa Bloch
Mr. Jacek Blonski
Mr. Michael A. Bobal, Jr.
Mr. David D. Boes and
Ms. Martha Mayes-Boes
Mrs. Marnie L. Bohr
Mr. and Mrs. William Borer
Mr. Brian Bosak
Mr. Joshua Box
Bracken Engineering, Inc.
Ms. Maria Branco
Mr. Brendan Brasel
Mr. and Mrs. Brad Brian
Mr. Daniel D. Broockmann
Mr. James Brook and
Ms. Isabelle Pinzler-Brook
Mr. Lawrence Brown
Mr. and Mrs. Bobby D. Brown
Mr. and Mrs. Jeff Brown
Ms. Rebecca Buntrock
Mr. and Mrs. Leslie F. Burd
Ms. Mary Ellen Burke
Dr. Rosemary Burke
Mr. and Mrs. Alan P. Burton
Ms. Ada M. Cardona
Mr. David Carlson
Mr. Jeffrey W. Carlson
Mr. Michael T. Carlson and
Dr. Traci M. Carlson
Cars Commerce
Chalmers / Gladieux Family Fund
Ms. Jill M. Chapman and
Mr. Richard K. Allen
Charities Aid Foundation of America
(CAF America)
Ms. Brooke Chaudhri
Ms. Alison Cherry Marer
Mr. and Mrs. Brian T. Chinn
Mr. Raymond P. Chlan and
Dr. Eleanor Chlan
Ms. Jill Choate
Ms. Paula A. Chomis
Ms. Barbara L. Chuko
Ms. Ingrid B. Chung
Mrs. Meghan Cioffi
Ms. Lillian Clagett
Clean Air Group Trucking Corporation
Dr. Charles Cleeland and
Dr. Xin Shelley Wang
Dr. John Connolly
Cooper Family Foundation
Ms. Patricia C. Corbett
Mr. Alexander N. Cory
Mr. Daniel V. Coyne

Mr. and Mrs. Brian S. Craig
Mrs. Mary Jo R. Crane
Ms. Melissa A. Crawford
John J. Creedon Foundation
Ms. Jaquelin Crew
Mr. and Mrs. Daniel E. Cromie
Mr. Scott R. Croy
Mr. and Mrs. Peter Dalglish
Mrs. Marilyn Daniel
Mr. and Mrs. Joe D'Augustine
Mr. Derek R. Davis
Dr. José DeLeon and
Ms. Victoria Martinez
Ms. Kimberly Denbow-Renegar
Mr. Stephen W. DeVinney
Mr. and Mrs. Michael Dickler
Ms. Genevieve L. Dimmitt
Mr. John M. Dimor
Lisa Beth Dixon, M.D., M.P.H.
Mr. Thomas K. Dockery
Ms. Diane Dondershine
Mr. and Mrs. Michael H. Donoghue
Ms. Sherry Draper
Mr. Matthew J. Drinkwater and
Dr. Adrienne S. Drinkwater
Dulinski Family Foundation
Ms. Kathleen M. Duncan
Ms. Amy Durr
Dr. and Mrs. Bennett Edelman
Mr. David Einhorn
Mr. and Mrs. Michael G. Eller
Employees of the Penn's Way Campaign
Mr. Sean R. Enck
Dr. and Mrs. Bulent Ender
Mr. and Mrs. Marc L. English
Ms. Jean L. Enloe
Ms. Nancy Eskenazi
Kathy and Jason Evans Philanthropic
Fund
Ms. Kate S. Ezra
Mr. Kenneth F. Fankhauser
Mr. and Mrs. Randy Ferguson
Ms. Patricia Fernandez
Mr. Johannes Fickert
Dr. and Mrs. Raymond S. Field
Findlay Galleries
Mr. and Mrs. William H. Fleser
Dr. Corinne N. Foley
Ms. Christine Forkner
Mr. and Mrs. Harvey Fox
Mr. Harvey Fox
Dr. and Mrs. Alan Frazer
Ms. Katherine French

Supporters (continued)

Ms. Marjorie Friedlander
The Friedman / Wiegand Giving Fund
Full Potential Fund
Mr. Jonathan S. Furay and
Ms. Erin M. Hawker-Furay
Mr. and Mrs. Donald L. Gardner
Mr. Paul Gardner
Mr. William Gatgens
Dr. and Mrs. Grant E. Gauger
The Ghosh Foster Family
Mr. David J. Glowny
Michael and Lola Goodstein Charitable
Foundation Trust
Dr. and Mrs. Harvey A. Gould
Ms. Gwendolyn M. Grant
Mr. and Mrs. Edward A. Gray
Mr. and Mrs. William R. Graybeal
Ms. Joy Griffin
Ms. Lynn Griffin
Dr. and Mrs. Alan B. Griffith
Mr. Michael Griswold
Dr. Michael Grunebaum and
Ms. Ruth Graver
Mr. and Mrs. William R. Hacker
Dr. and Mrs. William H. Hague
Ms. Patricia S. Haldeman
Mr. Abraham-David Hall
Dr. Justin Han
Mr. and Mrs. David M. Harlow
Mr. and Mrs. Matthew S. Harrison
Ms. Susan A. Hatch
Mr. and Dr. Lonnie G. Hazlitt
Mr. John J.H. Phillips and
Ms. Carolyn Healy
Ms. Melvina M. Heap
Mr. Jonathan Heigel
Dr. Aude I. Henin
Hentschel Giving Fund
Mr. and Mrs. Marvin L. Higgins
Ms. Elizabeth Hilla
Mr. John Hiltenbrand
Mr. and Mrs. Tom Hipp
Ms. Ruth A. Hodges and
Mr. John A. LeClaire
Mr. and Mrs. Justin W. Hoffman
Mr. Timothy A. Hood
Ms. Isabella G. Hortick
Mr. Mark Housman
Mr. and Mrs. Greg Howard
Ms. Sheryl L. Howe
Ms. Mary Ellen Huckabee
Mr. and Mrs. John A. Hurvitz
Mr. Gordon G. Hof and
Ms. Melissa L. Huther
Mr. Jonathan Imperiosi
Mr. and Mrs. Louis Innamorato
Mr. and Mrs. Jeffrey A. Jackson
Ms. Susan J. Jansen
Mr. and Mrs. Schuyler W. Johnson
Ms. Mary M. Johnston
Mrs. Mary Ellen Jones
Dr. Cecile B. Jordan
Mr. Matthew D. Kalos
Ms. Meagan J. Kalpokis
The John Lee Eichman and
Jaque (Janice Louise) Karnowski-
Eichman Charitable Fund
Mr. and Mrs. Jeffrey Karp
Dr. and Mrs. Richard T. Kasbeer
Ms. Claire Kayacik
Mr. John A. Keda
Dr. and Mrs. Hale M. Kell
Mr. Faroque A. Khan and Dr. Arfa Khan
Dr. and Mrs. Camille Y. Khawand
Mr. Kevin Kielbasa
Mr. Eric H. King
Mr. William H. Kirby and
Dr. Lenore S. Kirby
Mr. Melvin J. Klein
Mr. Nash Klinger
Mr. and Mrs. Kevin D. Knussmann
Mr. Wesley A. Kohler
Mr. Ivan Koon
Mr. Vincent Korts
Mr. Joseph Krizmanich
Mr. and Mrs. Thomas M. Lade, Jr.
Ms. Anne G. Landis
Mr. and Mrs. Fred M. Lara
Mr. and Mrs. Gary C. Lathrop
Dr. James F. Leckman and
Dr. Hannah H. Leckman
Mr. John Lee
Ms. Elizabeth LeFauve and
Mr. Mark W. Roe
Leichtag Foundation
Mr. and Mrs. Robert A. Lenicheck
Mr. John B. Leonard, Jr.
Dr. Edward D. Levin and Ms. Risa E. Hiller
Mr. Jason Levin
Ms. Karen Levine
Mr. Wei Pan and Ms. Shelby Y. Li
Ms. Mingkai Lian
Mr. Bentley Lim
Ms. Meghan Lindt
Mr. and Mrs. Samuel A. Livingston
LogRocket, Inc.
Lomanco, Inc.
Mrs. Barbara A. Lorber
Ms. Katherine Love
Ms. Ann Lowry
Mrs. Samantha Lucas
Mr. and Mrs. Richard A. Lynch
Mr. and Mrs. Mark L. Lynne
Mrs. Gretchen Mack
Mrs. Kelsey C. Maki
Mr. and Mrs. Andrew W. Marcoux
Mr. and Mrs. Paul N. Marcus
Mr. Jeffrey N. Marcus and
Ms. Susan Nitkin
Mrs. Joanne L. Marian
Mr. Stephen M. Marshall
Mr. Michael Martin
Ms. Carol A. May
Helen S. Mayberg, M.D.
Mr. and Mrs. Kevin McGlynn
Dr. Sean P. McKenna
Mr. and Mrs. David McMahon
Mr. David Melvin
Mr. Gilbert Menna
Mr. Steven M. Miller and
Ms. Ilene Meyers-Miller
Mr. and Mrs. Michael Miller
Enrique H. Monsanto, M.D.
Ms. Elizabeth Monteleone
Mr. and Mrs. John Montgomery
Ms. Liz Morgan
Mr. and Mrs. Loren J. Morris
Mr. Matthew Moskowitz
Mr. Spencer Mulligan
Mr. and Mrs. Kenneth N. Musen
Mr. and Mrs. Richard K. Nakamura
Mr. Timothy M. Nedom
Mr. Zachary Neill
Ms. Carol A. Nelson
Mr. Elmer J. Nelson
Dr. and Mrs. Eric J. Nestler
New Era Family Foundation
Mr. Peter W. Newell
Mrs. Suzanne L. Newman
Mr. Christopher A. Nichols
Mr. Daniel Nielsen
Dr. Andrew A. Nierenberg and
Ms. Karen Blumenfeld
Mr. Wesley Nisbett
Michael Obuchowski, Ph.D.
Mr. Tim O'Donnell
Mr. and Mrs. Paul H. Olsavsky
Mr. and Mrs. Richard J. Orr
Mr. and Mrs. Vincent Paragano

Supporters (continued)

Mr. and Mrs. Anthony Pardo
Mrs. Patsy S. Parker
Mr. and Mrs. Russell V. Parrish
Mr. Thomas E. Krisa and
Ms. Corinne E. Pearson
Mr. Jesse M. Abraham and
Ms. Amy Peck-Abraham
Dr. Robert J. Perlmutter and
Mrs. Rachel M. Perlmutter
Mr. and Mrs. Jacques R. Perreault
Mr. Eric Nilles and Ms. Susan L. Peters
Darlene A. Peterson Charitable Fund
Mr. Xander Peterson
Pictura, Inc.
Dr. Daniel S. Pine and Ms. Judith Brazen
Poet Grain, LLC
Mr. and Mrs. Eugene M. Poluha
Ms. Marybeth Pomeroy
Mrs. Anne Potter-McWilliams
Mr. Ryan Poulson
Ms. Tina M. Pruetz
PsychoGenics, Inc.
Mr. Harish Pudukodu
Mr. and Mrs. Stuart Rabner
Mr. Fadi Rached
Ms. Carrol L. Rafferty
Pasko Rakic, M.D., Ph.D.
Ms. Sowmya Ram
Mr. and Mrs. Dale A. Ramsden
Mr. Joshua Randall
Mr. Marcel Ratajzak
Dr. Rebecca M. Reese
Mr. and Mrs. Benjamin L. Regnier
Ms. Susan Reilly
Mr. David Rennwald
Mr. Trevor Rice
Mr. Brian A. Robbins
Mr. Lee M. Rodgers
Ms. Heather M. Roessler
Ms. Erin Rogers
Mr. Steven C. Rogers, Sr.
Mr. Mitchell Rosen
Mrs. Laura D. Rosenwald
Ms. Jane S. Ross
Mr. John Roth
Dr. and Mrs. Gasper F. Ruffino
Mr. Ram Tamir and Ms. Lisa M. Rzepka
Mr. John Sabella
The Salon Family Foundation, Inc.
Ms. Cheryl D. Sandler
Dr. Mark D. Santello
Mrs. Kathleen Schafer
Mr. Scott D. Schauer
Mr. Nico Schnarr
Mr. and Mrs. Richard A. Schneider
Mr. Oliver Schubert
Mr. Howard Schusterman
Mr. and Mrs. Kevin M. Schwab
Mr. Marc A. Schwartz
Mr. and Mrs. James Segelstein
Mr. and Mrs. Barry S. Seidel
Mrs. Anne G. Sennott
Mr. and Mrs. John L. Sheldon
Shell Oil HERO
Dr. Miriam Shenfeld
Dr. and Mrs. Kenneth C. Shestak
Mrs. Betsy Sihner
Mr. and Mrs. Kenneth L. Simon
Joseph T. & Helen M. Simpson
Foundation
Mr. Pao Sinkan
Mr. and Mrs. Jeffrey Sisco
Mr. Michael Skeate
Mr. Eric Sload
Mr. and Mrs. Hugh A. Smith
Ms. Julie Smith
Ms. Jolene Sobotka
Ms. Denise A. Soltis
Mr. and Mrs. Steven Sonet
Mr. Gary O. Stankiewicz
Ms. Cullen Stanley
Mr. Thomas Stanton
Mr. Noah Steele
Dr. Melvin J. Stern and
Ms. Merna Wagshal-Stern
Dr. Claudia C. Stewart
Ms. Laura Stokley
Mr. Michael S. Strauss and
Ms. Robin B. Klein-Strauss
Ms. Alexandra E. Sutlief
Mr. and Mrs. W. Mark Swingle
Dr. Kevin S. Tait
Mrs. Carol J. Tallman
Mr. and Mrs. Bryce G. Tanner
Mrs. Elizabeth J. Taylor
Mr. and Mrs. Robert Tekiela
Ms. Lori A. Teller
Ms. Beena Thattil
Mr. Rob Thomas and Ms. Sue Reichert
Mr. William T. Scherkey and
Ms. Melinda M. Thompson
Ms. Marjorie Thompson Duck
Mr. and Mrs. Bradley W. Tomlinson
Mr. Edward F. Toomey
Ms. Maria Tovar-Hopper
Ms. Suzanne G. Towey-Pelkaus
Mr. Edward L. Trageser
Mr. Robert W. Turner
The U.S. Charitable Gift Trust
Ms. Clara M. Ueland and
Mr. Walter McCarthy
Mr. and Mrs. Samuel Ulcak
United Way of the Greater Lehigh Valley,
Inc.
Mr. Darien Valdes
Mrs. Elizabeth A. Van Dyke
Mr. Alexander F. van Geen
Mr. Brian Vassallo
Jeremy M. Veenstra-VanderWeele,
M.D., Ph.D.
Vegari Foundation, Inc.
Mr. Timothy Venters
Mrs. Valerie L. Vergara
Vericast
Mr. Duane F. Vermazen
Visa Giving Station / FrontStream, Inc.
Ms. Shirley A. Voelker
Mrs. Martha J. von Boeselager
Mr. and Mrs. Gregory von Briel
Mrs. Karen A. Wadams
Mr. and Mrs. Steven R. Wagner
Ms. Shirley M. Waldron
Ms. Aja D. Walker
Mr. David Zell and
Ms. Diane L. Walker-Zell
Allen C. Waltman, M.D.
Mr. Robert L. Waring and
Ms. Elizabeth J. Miles-Waring
Dr. Douglas J. Warsett and
Ms. Susan Warsett
The Kirk and Angela Watson Educational
Foundation
Mr. Cody Weible
Ms. Patti J. Welch
Dr. Lisa J. Whitfield
Mr. Jeffrey A. Whitley
The Alex and Karen Widiger Fund
Mr. and Mrs. John Wiegmann
Mr. and Mrs. Jay K. Wiggins
Ms. Charla A. Willian
Mrs. Nancy A. Willick
Mr. and Mrs. Jeffrey J. Wilson
Mr. Dean L. Windgassen
Mr. and Mrs. Jacob Wirth
Mrs. Tracy Wise
Mr. and Mrs. Michael R. Witt
Dr. Edwin M. Wolf
Dr. Kenneth M. Woodson, Jr.
Ms. Allie Workman

Supporters (continued)

Amy J. Worrell, VMD
Mr. and Mrs. Charles R.B. Wright
Mr. Tom M. Javins and
Ms. Beverly A. Young
Mr. Kenneth Young and
Ms. Julie B. Landau
Mr. and Mrs. Stephen A. Zastrow
Ms. Judith J. Zawojewski
Dr. Maxwell B. Zeigler

MATCHING GIFT COMPANIES

American Endowment Foundation
American Online Giving Foundation
(AOGF)
AOGF
The Bank of America Charitable
Foundation
Bank of America Charitable Gift Fund
Bank of America Corporation
The Benevity Community Impact Fund
Benevity Social Ventures, Inc.
CAF
CAF America
Charities Aid Foundation of America
Charities Aid Foundation of America
(CAF America)
Citizens Charitable Foundation
Cybergrants
Cybergrants SPV, LLC
Edwards Lifesciences Foundation
Fortis Construction, Inc.
JMT Charitable Foundation
JPMC
JPMorgan Chase Foundation
Lawrence Livermore National Laboratory
The Merck Foundation
Pivotal Enterprises, LLC
RRF
RRF Foundation for Aging
Shell Oil Company Foundation
Matching Gifts
Jeffrey M. Talpins Foundation
The Progressive Insurance Foundation
– Giving Station
The UK Online Giving Foundation
(UKOGF)
UKOGF
Viking Global Foundation, Inc.
YourCause, LLC

TRIBUTES

Honor Tributes

(4n_or) Retired T.A.R.P. Twitch Streamer
A friend's birthday
A loved one
Milanga K. Abeyesuriya and Lee D. Poston
Dylan Abraham
Anne and Ron Abramson
Jeremy T. Addison
Michael Adelman
Alina's 60th birthday
All in need
John Allison
Marissa Alonso
Mark Anastasi
Elizabeth Anderson
Matthew Anderson
Andre
Sebastian B. Andrews
Dr. Miriam (Mimi) C. Arnold
Sophia M. Aschieris
Jameson T. Ashley
FrivolousFox ASMR
Gibi ASMR
Axolotl Arms
L Ba
Ju Bao
Hannah Barnes
Sadie L. Barnes
Jennifer Batra
John C. Bayat
Esther L. Beardsley
Brian and Laura Becker
Dr. Klaus Bensch and
Mrs. Barbara Bensch
Kate Benzler
Christopher Betagole
Tyler Bolton
Martin H. Borell
Jeffrey Borenstein, M.D.
Phoebe Bouleh
Steve Bowers
Dr. Christine Bradley
Brenda's birthday
Brookfield Academy Unity Club
James E. Brown, Jr.
Andi Burd
Andrea Burd
The Butler Families
Catherine Campbell
Patricia (Patty) R. Cashour
Dennis S. Charney, M.D.
Sho Tin Chen
Natalie Cizik

Jill Cochran
Alison P. Cohen
Dr. Thomas B. Coles, Jr. and
Mrs. Nancy A. Coles
Kellie I. Cook
Cookie
Shawna Copeland
Courtney S. Crane
Colin J. Crawford
Andrew M. Curry
Joe D.
DEAD RKGK
Stephen P. Dean
Jeffrey DeBono
Zac Deckard
Burak Deniz
Amit Desai
Bill DeSiena, LCSW
Dokibird
Patrick Doncov
William Duffy
Quan Duong
Lauren R. Duran
Eastside Management
Dr. Christopher Eginton and
Mrs. Lindsay Eginton
EJ Eisenberg
JR Eisenberg
Lee Eisenberg
Chris Ellis
Hande Erçel
Matt Festa
Kristi A. Fitz
Judith Fleschner
Lajpat R. Gandhi, M.D., MB, BS
Emilie J. Gannon
Irving Getz
Joseph and Sarah Goodman
Darlene Graham
Thomas D. Green
Bryan M. Greene
Sarina Gwartzman
The Hagen Family
Layla Hamedi
Bruce Harlow, Sr. and his unconditional
love for his three children
John Kennedy Harrison II
Eric and Madeline Hauser
Zachary Hendricks
Hize'NLowz, LLC
Natalie Hoague
Dr. David P. Hoffman and
Mrs. Susan M. Hoffman
Jacob Hoffman
Mark Holloway

Honor Tributes (continued)

Nicola and Erin Holloway
Keith Hopkinson
Paul Horelick
Samuel Hurley
Angela Hurtado
Kenneth Hyacinthe
Louis Innamorato, C.P.A.
Bob Jackson
Julia and Chris
Mariel Kagan
David Kahl
Jared W. Kaplan
Karen's birthday
Joe Karner
Robert Karner and Mary Chung
Miriam E. Katowitz, C.P.A.
Joel and Elinor Katz
Ken
Kerry
Christopher Kilbourne
Peter Kirk
Brian Kirkpatrick, M.D.
Nicholas Kirkpatrick
The Kirsics: Michael, Lisa, King Khaya and
Chloe Superstar
Elisabeth D. Kline's beloved children
Jack Lee Knicely
Alexander Kocinsky
Karl F. Korpela
Howard and Shelley Kristol
John H. Krystal, M.D.
Jaren M. Kuester
Mr. and Mrs. Moon Kwok Kwong
Danielle D. Ladensack
Ian Laidlaw, LCSW-R
The Laitman Family
Skylar Lake
Martin Langer
Sarah Leonard-James
Jill D. Lewis-Spector, Ed.D.
Lisa
Lisa's birthday
Kelsey Loughlin
Daniel Maahs
Jeff Macdonald
Maci's birthday
William Maier
Robert Malone
The Winner of the Manifold Charity
Poker Tournament
J. John Mann, M.D.
John D. Marangiello
Jared and Carley Margolis

The Maybank Family
Ian M. McElheny
Teresa McInerney
Jeffrey McKnight
Patrick McWilliams
Ingrid Mesa-Gibbons
Michael
Timothy Miller
The Morisi Family
Andrew L. Morrison, M.D.
Melissa Mortensen
Anne K. Muellerleile
Grace Nagaur
The Recipients of the Navient Team
Leadership Award
Natalie Newcamp
Tiffany Nguyen
Nita's birthday
Diane M. Novellino
Paul O'Connell
Ella Orloff
Nieves A. Ortiz
Mary Pat and John Osterhaus
The Osterhaus Family
Gloria Palma-Olsavsky
Patrick W. Parker
Sallie M. Parker
The Patient
Dr. David Penn-Soskin
Eleanor Perry-White
John and Brittney Pfafflin
Alberto Piazza and Ada Ruata
Patricia H. Porter
Robert M. Post, M.D.
James and Donna Potter
Paul Pozniak
Stephen Quentzel, M.D.
Ryan T. Rauscher
Katherine (Kat) R. Raveling
Madeline Reed-Johnston
Andy Reynolds
Min J. Ro
Kimberly A. Rock
Harry Rollings
Faith Rothblatt
Michael R. Rothman
Ann Royall-Bolton
Tyler J. Rutherford
Mary C. Salpukas
Mark A. Satterthwaite, M.D.
Sawyer
Charles Scharfman
Dr. Brett Shurman
Dr. and Mrs. Mark Silver

Geoffrey A. Simon and
Andrea R. Graham
Helen B. Simpson, M.D., Ph.D.
Arron N. Smith and Sean D.O. Smith
Eugene (Gene) Smith
Grace Smith
Richard and Sue Smith
Kathryn A. Snow, LCSW
Kenneth H. Sonnenfeld, Ph.D., J.D.
Alan J. Spandorf
Kathy Stephens
Fiona Stewart, Ph.D.
Greg Stickel
Jean L. Stone
Gregory Strauss, Ph.D.
Dr. Darcy Strobel
Sarah Stroh
Peter J. Tarr, Ph.D.
Taylor
The King
James C. Thies
Kristen Tizon
Arlene Tracy
Alex Tramiel and Sonia Miller
John Tyler and Caroline Kelly
Unexplainable (the podcast)
Jasmine S. Van Regenmortel
Juliana Venegas and Brent McBride
Michael Vollmar, M.D.
Les Wallin
Jennifer Ward
The Wei Family
Robert and Frances Weisman
The Wells Family
Dr. Austin J. Wertheimer and
Ms. Caryl I. Goodman
The White Family
Brooke Wilken
Mike Yamanaka
Michael Yelenosky
Young Basic Science Researchers
Alex Zeigler
Stuart Zeigler
Zachary Zelman
Howard L. Zenker
Raleigh Zimmerman

Memorial Tributes

A loved one
Kathleen (Kathy) M. Abaray
Sue Abiad
John (Jed) B. Abrams
William F. Abrams
Alexis (Lexi) N. Adams

Memorial Tributes (continued)

Cecilia J. Adamski
Joyce Adelman
Aria N. Albertelli
Allison J. (Smith) Alfonso
Michael Alice
Darryl Allen
Janice M. Allison
Adrienne L. Anderson
Susan (Sue) K. Anderson
Angel
Edward Arvey
Zerqa Atiq
Christopher J. Awn
John J. Awn, Jr.
Arthur Aylem
Margaret R. Bachman
Gregory T. Bak
Kiara Baker
Anna Balek
Scott Balgemann
James (Jim) F. Balistreri
Mary Jane (Hauersperger) Banta
Cynthia L. Barazowski-Kassel
Neil Gregory (The Warrior) Barber
Richard (Ricky) B. Barfuss
Rebecca Bartlett's beloved family
Scott R. Bartlett
Stephen D. Bartusiak
Judith A. Baskin
Brian A. Bass
Leroy Baumgartner
David Beckel
Patricia (Pat) A. Bell
Jim Bennefield
John Bennefield
Chester Charles Bennington (Linkin Park)
Benny
Angelique N. Benrahou
Timothy J. Berchin
Dr. Deepak Bhasin
Stephen J. Binder
Victor Biondo
Dorothy F. Birdwell Maughan
Phyllis J. (Kratovil) Birk
Heather A. Bleick
John H. Blomquist
Kirk D. Boise
Oliver R. Bolger
Dennis L. Bond
Joanne M. Borkowicz
Betty Jane Boydstun
Dustin (Bo / Dbo) W. Bozarth
Michael C. Bragg
Robert Branch
Amy J. Brandl's beloved brother
Randall Brandt Smith
David Breuer
Elise Bridwell
Catherine (Cathie) A. Brodie
Reina Brody
Joan Y. Brooks
Daniel S. Brown
Elyce A. Brown
Beverly Brownlee
Bruce Brownlee
Corey A. Brunk
Elaine C. Bryant
James C. Bryant
Walter W. Bundschuh
Peter R. Bunning
Dorothy L. Burgess
Colleen M. Burke
Evan P. Busbey
The Butler Families
Patrick M. Caires
Brent M. Cameron
Tyler J. Cannon
Susana Cardenas
Dennis J. Carlton
Jeffrey T. Carlton
Em (Scout) Marie Carr
Tara L. Carrilli-Johnson
Richard M. Casey
Suzanne L. Castellani
Cynthia (Cindy) M. Cates
Catherine
Victoria E. Catral
Mary T. Cavanaugh
Adam R. Cavender, M.D.
Cynthia L. Chabay-Rosen
Patrick J. Chaloux
Dale R. Cherney
Matthew Cherney
Vizia Chinthala
Allison A. Chlan-Fellner
John A. Chomis
Andrew S. Christie
Kevin A. Christoffers
Heather Christopher
Kristina Cicoria, M.D.
Anthony (Tony) Cifelli
Jenna Clemenz
Justin W. Cline
Valerie L. Collar
Alexander B. Conley
Cynthia Cook
Ryan J. Cook
Grace Cook-Blasingame
David Cooper-Claire
Jordan Cooper-Halpern
Cara E. Corin
Cameron M. Cosentino
Christopher M. Cowan
Prudence Cox
John R. Craig
Jacob W. Crowder
Joan (Joanie) M. Curtin
Cynthia Dalao Bagatelas
Colter Dallman
Richard D. Daly
Cynthia (Cindy) A. Dankberg
Ross M. DaPrato
Sarah N. Darby
Dan M. David
James (Jim) L. Davidson III
Greg Davis
Terrence (King Terry) A. Davis
Decker J. Davison
Dr. Margarida Magalhães Dederick
Joseph Dell
Tyson J. Dent
Henry (Hank) J. Deutschendorf II
Nathaniel J. Dickinson
John Dilanni
Brandon Dixon
Nicholas (Nick) A. Dobbert
Una G. Donnelly
John Donovan
Stephen G. Doochin
August (Gus) E. Doskey
Loraine (Lory) J. Dryden
Michael Ducate
Michael A. Ducate
Jack E. Duffy
Dylan J. Edwards
Mark D. Edwards
Ronald (Ronnie) O. Edwards
Major Lawrence J. Elliott (USAF Retired)
Paula J. Erdelyi
Erica
Catherine (Catie) A. Etier
Marian (Molly) P. Everdell
Terri Everett's Home
Erik S. Fallahi
Garrett R. Farr
Alex D. Farren
Jan A. Fawcett, M.D.
Nathan Feinstein
Dorothy B. Feit
Hettie Feldman
James (Alec) A. Fentum

Memorial Tributes (continued)

Catherine Finn
Helga Fischbach
Nicholas D. Fischer
Ruth H. Flick
Raymond J. Flood, Jr.
Edwin (Ted) H. Flowers
Kathleen Foglino
Helen C. Fontana
Jacob J. Fox
Frank
Astral (Andrew) B. Freeman
Gail W. French
Robert (Bob) O. Friedel, M.D.
H. Bruce Friedrich
Rose Marie Friedrich
Jason C. Frisco
Jerrice A. Fritzen
David Fuller-Cowles
Carl Fulmer
Stanton E. Gagel
Diane N. Galba
Mary Gallagher
Daniel (Danny) L. Gallegos
Ines Garcia
Erika N. Garlich
Richard V. Garrett
Olive (Lehmer) Garrett Frye
Susan Getz
Steven H. Gibson
Erin M. Gilmer
Wendy A. Giurleo
Daniel J. Glorioso
Isabella (Izzy) Glorioso
Brian D. Go
George Goldman
Rochelle B. Goldman
Dr. Patricia Goldman-Rakic
Zachary Golub-Rosen
Ethel G. Gordon
Francey Gordon
Ted A. Gorman
Ellen Gottfried
Grace
Adam J. Grainawi
William F. Grant, Sr.
Andrew N. Gray, Ph.D.
Jacob A. Gray
Norma Gray
Susan J. Gray
Michael (Mike) J. Gredlein
David E. Green
Rose K. Greenberg
Andrew J. Greenfield
Mark J. Greenlee
Mark Greenwood
Matthew J. Gregory
Noah J. Grimes
Joshua E. Grossman
Wilfred L. Guerin
Viola M. Gugliuzza
Thomas S. Gumport
Amanda G. Gurley
John B. Haldeman
Matthew A. Hall
Stephen B. Ham
Kuang-Hwa Han
Ruth Handleman
James (Jim / Jamie) V. Hanna II
John P. Hanus
Matthew (Matt) J. Hardin
Jason R. Hargarten
Andrew Harrison
Dr. William L. Harrison
Cynthia (Cindy) M. Harwell-Paar
Deborah Hawkins
Norma (Levenson) Haynes
Larry Hays
Kevin J. Heald
John A. Heather, M.D.
Bradley R. Heilman
Gary E. Heussler, Ph.D.
Margaret C. Hibbitts
John Hickey
John J. Hoffman V
David J. Holien
Corinne H. Holt
Dr. Philip S. Holzman
Mark J. Hovis' best friend
Rong Huang
Edelgard Hubbauer
Rennie E. Hughes
William (Billy) W. Humphrey
Alan N. Hundert
Richard (Rich) W. Hungate
Darrell K. Hutchins
Irene (Renie) Hutt
Bessie L. Iglehart
Naveed A. Iqball
Sandra J. Israel
Vivian B. Jackson
Marie Jana's beloved nephew, Brandon
Leslie (Les) W. Janski
Maria C. (Basdekian) Jarusinsky
Jimmy
Michael D. Johnson
Ryan P. Johnson
Ryan B. Joiner
Herbert (Skip) R. Jones, Jr.
Savit Joshi
Allison Judd's beloved grandma
Andreas (Dre) P. Kahan
Leif Kamara
Mehul Kamble
Michael D. Kamp
Albert W. Kaplan
Gary A. Kaplan's departed grandparents,
aunts, uncles, cousins and friends
Jeannette Kaplan
John R. Karatheodoris
Steven M. Karp
Melissa N. Karpf
Kevin J. Kassel
Claude R. Kaufman
Phyllis Kazik
Brian J. Kelly
Tyler S. Kelly
Michael F. Kenigsberg
Kenneth
Patrick (Stacy) W. Kenny
Marc Kerben
James (Jim) J. Kerrigan, Jr., M.D.
Lucas R. Ketelsen
Kevin
Gary D. Kiefer
Paul Killea
Jonathan S. Kinsley
Jill A. Kirby
Brian Kirschner
Steve Knitzer
William F. Koch
Allison (Alli) S. Kohl
Robert Kolozsvary
Steven Korn
Julie A. Kounce
John B. Kramer, Jr.
Olivia L. Kresach
Joseph J. Kroepil, Jr.
Rebecca J. Kruger
Scott Kruse
Michael Krusell Nelson
Kendal (Ken) A. Kucera
Ivan A. Kurcsinka
Gary Kushman
Murray (Murry) Kusmin
Keith Kussman
Shirley A. Kussman's beloved son
Morris Laitman, Ph.D.
Carole Jean Laping
Mary Ann Lapinskas
Misty D. LaRue
Jenna R. Laubach

Memorial Tributes (continued)

Brendan L. Lauderdale
Robert E. Lauer
Paul T. Laun
Henry R. Laveran
Alexander (Alex) P. Lawlor
Edward J. Leahy
Harry R. Leeds
Linda G. Leeds
Thomas (Tommy) J. Leonard
Allison Leong
Jorie Lester-Mark
Stephen (Steve) E. Librizzi
Jacob Lichtenstein
Constance E. Lieber
Samuel A. Lieber
Stephen A. Lieber
Anna Y. Li-Harezlak
Lance Lipton
Frank J. Lodanosky
John (Jack) S. Logue II
Danielle M. Lorenz
Victor G. Lottmann
Betty (Splawn) Lowder
James (Jim) E. Lowder
Joanna Lowry
Thomas A. Luby, Jr.
Gavin Lundin's beloved mother
Barbara Lyons
Matthew C. Lyons
Marissa N. MacLaughlin
Ann Marie Madigan, M.D.
Roman Makuch
Earl P. Malarchick, Ph.D.
Robert T. Malison, M.D.
Merrill M. Manning III
Marco
Alan G. Marer
Dr. Peter Marks
Matthew Marshall
Tara L. Martabano
Elizabeth (Beth) A. Martino
Martyred Jews and those Jews that died
in the Holocaust
Dolores Massey-Healy
Michael D. Mattoon
Thomas Matye
Travis Matye
John K. Maxwell, Jr.
Kate McAllister Neely
Michael P. McClain
June E. McDonald
Mark McDonald
Kevin M. McLaughlin
John (Mr. Mc) P. McManus
William Cody Meeks
Abigale O. Merrifield
Daniel Michaels
Apphia Michelich
Ronald Michelich
Mary Ruth Middlebrook
Christopher F. Miehlisch
Andrew (AJ) J. Miller
Lori Miller-Levine
Duncan N. Mitchell
Neil Molberger
Gregory A. Monk
Juan (Joji) Maniquis Montelibano
Jeffrey D. Moon
Irene Moran
Richard Moran
Christa M. Mordino
Frank Morgan
Matthew P. Morgan
Isabelle Moua
Patrick Rory Muldoon
Ronald P. Mullan
Ronald (Ronnie) Mullan
Wyatt L. Murchison
Barbara Nachbar
Martin Nachbar
Paul Nachbar
Lori A. Nahas
Narayan K. Nannaware
Adam Neely
Dale Neilson
Barry J. Nelson
Karen S. Nelson
Paul Nelson
Christopher (Chris) J. Neubecker
Douglas A. Newman
David Nicholas
Emma (Emmie) Kajsa Marie Nicholas
Richard (Toby) W. Nichols, Jr.
Andrew Niskala
Richard (Dick) A. Nunis
Kelly O'Malley-Coogan
Greg Ochs
Emily Odle
Katherine (Katie) R. Olin
Cameron R. Orr
Barbara W. Page
James D. Palmer III
Albert L. Pan
Jennifer Y. Paragano
Herbert Pardes, M.D.
David W. Park
Grayson M. Parker
Josiah E. Parker III
Mark Parr
Georgiana A. (Thorpe) Pasela
William (Billy) F. Paul III
Arthur Peck, M.D.
Randy A. Perdon
Judith Pestronk
Seymour Pestronk
M. Hunter Phillips
Nan E. Phillips
Parker E. Phillips II
William Brodie Phillips
Reed Pickus
Sybil Pierce
Jessica A. Piesman
James (Jim) Piskule III
Aaron R. Pixley
Genesis Pool
Dr. Alex Porter
Brad Powers
Sean P. Pryor
Peppino Puleo
Matthew P. Purcell
Joel M. Purrington
Dylan Quast
Ramez E. Qureshi
Andrew Radcliffe-Watts
Luca Rader
Arthur J. Radin, C.P.A.
Evelyn R. Rafferty
James P. Rafferty, Sr.
Jane (Janie) E. Ragel
Sidharth Ramakrishnan
Christine M. Rancatore
Steve Ratner
Cassandra (Cassie) N. Ray
Anthony M. Razziano
Russell J. Razziano
John Reason
Steven (Stevie) R. Reid II
Vito Rella
Jesse I. Remez
Samuel (Sam) D. Rendall
Michael Reschke
Chris Reuter
Dr. Ernie Rhamstine
John J. Rice, M.D.
Paul F. Richards
Caasi A. Rich-Vogel
Christopher Ricker
William L. Ricketts
Priscilla Riddick-Trotter
Dorrit L. Rippchen
David A. Rock

Memorial Tributes (continued)

David P. Rogers
Brian Rorick
Thomas Rorick
Alan G. Ross
Christina (Chrissy) Rossi
Matthew S. Rothman
Kevin Rubinstein
Irwin Rutland
John G. Ryan
Patricia (Patty) L. Ryan
Edward (Eddie) M. Saenz
Edward Salvucci
Carol Sanchez
Anton E. Schanz
Terry Scheffler
Delbert (Del) J. Scheid
David L. Schmidlap
Lee R. Schoolmeesters
Karen L. Schuetz
Nora E. Schuster
Ellen Schusterman
Jeffrey A. Schwartz
Judith Schwartz
Norma Schweitzer
David J. Scott
Kelly M. Scruggs
Michael Seeds
Ezra L. Seegull
Kerry W. Self
Kenneth F. Selig
Timothy B. Sennott
Gary S. Sevitsky
Ratilal C. Shah
William D. Shannon
Daniel Sharkey Esrick
Megan L. Sharp
Conor F. Sharpe
Harriet Shetler
Sylvia Shick
Benjamin L. Silver
Rochelle (Shelly) Simms
Marcia Simon-Kaplan
Kurt Simpson
John T. Sinnott
Helen Siporin
Marianthi (Bavas) Skiadas
Patrick D. Skosnik, Ph.D.
Lilia Slodownik-Dalkoff
Edmund Smith
Edward J. Smith
Jeff C. Smith
Robert (Bob) H. Smith
William H. Smith II

Ann Smith-Sovey
James (Bert) Snider
Candace Snyder
Donald E. Snyder
Joseph (Drew) A. Sobotka
Marilyn (Lynn) J. Sobotka
Sierra Soler
Betty Jean Sonny
Michael J. Sonny
Chris E. Sorensen
Kelly L. Sorensen
Nathan A. Soukup
Gena Spaulding
Brad M. Speiser
Jeffrey T. Sramek
Doretha St. Clair
Ian J. Stancato
Brian A. Stapleton
John (Jack) A. Stapleton
Gregory L. Starling
Tyler R. Starling
Nathan B. Steinbach
Edward G. Steinmetz, Jr.
Robert Steinpreis
Marlene H. Steiskal
Kolne M. Stella
Florence Stern Weisman
Amy M. Strahan
Alfred F. Strakshus
Steven (Scott) Stripling
Mary J. Strub-Caulkins
Ruth S. Sweeney
Andrew Taddy
Cheryl J. Tallant
Melanie D. Tannenbaum
Dino B. Taraschi
H. Vonn Taylor
Lyle Taylor
Nancy Teas-Hardie
William Theos
Thomas
Camilla (Cammie) L. Thompson
Susan Thorpe
Yolanda E. Thorpe
Patrick C. Tierney
Zachary (Zach) Tolchin
Troy Torres, Jr.
Leanne Townsend
Mario A. Tozzi, Jr.
Victoria (Tori) Trang Cook
Jeffrey S. Trott
Virgina Trunzo
Donald Trybula
Alexandros Tsaoussis-Maddock

Amanda E. Tucci
Robert (Bob) T. Tucker
Mackenzie E. Tynan
Logan Upton
Maple Valiente
Brett A. Van Vort
Corey R. Varga
Charles Varkoly
John M. Vergo
Alysia P. Vesley
Harriet Vicente
James (Jim) E. Vlach
Kurt J. von Boeselager
Gregory Von Burg
Paul Von Burg
Wm. F. Wagner, Jr.
Capt. Anders (Andy) G. Wallin II
Tordis Wallin
John (Jack) Wallisch
Catherine (Katie) R. Walsh
Thomas Walsh
Sharon Wang
Robert (Bob) L. Waterhouse, Sr.
Susan Weems
Sifei Wei
Colleen E. Westbrook
Robert M. Wetzel
Michael G. Wieman
Jon K. Wilbur
Judith (Judy) Wildfeuer
Gertrude Wildgruber
Robert (Bob) L. Wildt
Mark Williams
Wesley Willis
Betty J. Winberg
Barbara A. Winkler-Monsanto, M.D.
Douglas Wistner
Farrell J. Wolfson
Ryan M. Woodland
Robert T. Woods
Surekha Yadawad
April A. Yahiro
Mary Ann Yahiro
Catherine (Kitty) L. Yelenosky
Kenneth L. Yocom
Anna Zarski
Mary Katherine Zartman
Peter W. Zartman
Jieru Zhao
Edward N. Ziegler
Gladys P. Ziegler
Barry L. Zimmerman
Joseph (Joe) J. Zito
Stan Ziubrzynski

Financial Summary*

Consolidated Statement of Financial Position

	DECEMBER 31, 2024	DECEMBER 31, 2023
ASSETS		
Current Assets		
Cash and cash equivalents	\$38,084,529	\$26,905,317
Investments, at fair value, current portion	11,991,311	14,629,688
Contributions receivable	96,425	415,480
Pledges receivable, current portion	4,895	7,470
Prepaid expenses and other assets	302,557	230,236
Total Current Assets	50,479,717	42,188,191
Pledges receivable, net, less current portion	9,738	9,738
Assets held in charitable remainder trust	2,300,206	1,885,836
Fixed assets, net	8,085	9,684
Investments, at fair value, less current portion	8,947,449	8,947,449
Right-of-Use Asset	716,139	125,457
Total Assets	\$62,461,334	\$53,166,355
LIABILITIES AND NET ASSETS		
Current Liabilities		
Accounts payable and accrued expenses	\$52,931	\$75,069
Grants payable	15,014,698	14,887,604
Operating lease liability, current portion	342,373	148,179
Accrued compensation	71,023	48,077
Annuities payable	970,084	826,641
Charitable gift annuities payable	12,780	13,599
Total Current Liabilities	16,463,889	15,999,169
Operating lease liability, net, less current portion	528,260	—
Total Liabilities	16,992,149	15,999,169
Net Assets		
Without donor restrictions	34,274,112	26,492,489
With donor restrictions	11,195,073	10,674,697
Total Net Assets	45,469,185	37,167,186
Total Liabilities and Net Assets	\$62,461,334	\$53,166,355

* The Foundation's complete audited financial statements are available on our website.

Consolidated Statement of Activities

	YEAR ENDED DECEMBER 31, 2024	YEAR ENDED DECEMBER 31, 2023
SUPPORT AND REVENUE		
Contributions	\$15,589,932	\$14,613,749
Special events, net	42,878	89,157
In-kind contribution of services	2,054,955	2,048,285
Bequests	3,472,060	5,022,129
Net realized and unrealized gains on investments	3,698,514	3,929,558
Net appreciation of assets held in charitable remainder trusts	414,370	184,399
Dividend and interest income	1,462,573	908,154
Total Support and Revenue	26,735,282	26,795,431
EXPENSES		
Program Services		
Research grants and awards	10,772,382	9,232,426
Scientific advancement	2,397,371	2,309,627
Program support	2,513,497	2,352,532
Total Program Services	15,633,250	13,894,585
Supporting Services		
Fundraising**	989,718	897,389
Administration**	1,810,315	1,629,752
Total Supporting Services	2,800,033	2,527,141
Total Expenses	18,433,283	16,421,726
Change in Net Assets	8,301,999	10,373,705
Net Assets, beginning of year	37,167,186	26,793,481
Net Assets, end of year	\$45,469,185	\$37,167,186

** All fundraising and administration expenses are funded by specially designated grants.



Awarding **NARSAD** Grants

747 Third Avenue, 33rd Floor
New York, NY 10017

646.681.4888 | 800.829.8289
info@bbrfoundation.org
bbrfoundation.org

President & CEO

Jeffrey Borenstein, M.D.

**President,
Scientific Council**

Judith M. Ford, Ph.D.

**Vice President,
Scientific Council**

John H. Krystal, M.D.

OFFICERS

Chairman

Geoffrey A. Simon

Vice President

John Osterhaus

Secretary

Judy Genshaft, Ph.D.

Treasurer

Miriam E. Katowitz

DIRECTORS

Carol A. Atkinson
J. Anthony Boeckh
Martin H. Borell
John Kennedy Harrison II
John B. Hollister
Carole H. Mallement
Milton Maltz
Jeffrey R. Peterson
Marc R. Rappaport
Mary Rubin
Virginia M. Silver
Ken Sonnenfeld, Ph.D., J.D.
Barbara Toll
Robert Weisman, Esq.

PUBLICATION CREDITS

Writers

Lauren Duran
Peter Tarr, Ph.D.

Editor

Lauren Duran

Designer

Eugene Smith

Sign up for eNews at bbrfoundation.org/signup.



100% OF EVERY DOLLAR
DONATED FOR RESEARCH
GOES TO RESEARCH